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Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These
Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of
PlumX Metrics
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improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb
ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical
syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower
limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All
patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb
threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of
Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the
preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent
axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by
estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System
(GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP),
resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the
availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data,
pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb
threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high
patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical
therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as
counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is
advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids,
and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI
should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study
designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence
for amputation prevention is stressed as a key health system initiative.
Keywords:
Chronic limb-threatening ischemia, Critical limb ischemia, Peripheral artery disease, Diabetes, Foot ulcer, Endovascular
intervention, Bypass surgery, Practice guideline, Evidence-based medicine
GVG Guideline writing group conflict of interest policy: industry relationships
I Introduction
The organizations participating in the Global Vascular Guidelines are committed to the precept of developing trustworthy
clinical practice guidelines through transparency and full disclosure by those participating in the process of guideline
development.
The tenets of the policy as set forth are reflective of the desire to maintain a balanced approach in the guidelines
development process. Ensuring that industry will have no direct influence on the clinical content and recommendations
of the clinical guideline is fundamental to a trustworthy and independent document. Conversely, it is acknowledged that
a healthy relationship between content experts and industry, when properly managed and transparent, may bring value to
the process and the final document.
II Scope
All Co-Editors, Steering Committee members, and authors are required to disclose relationships with industry and other
relevant entities as defined in Section IV.
III Disclosure Categories
The required categories for disclosure and their respective examples are as follows:
•
Industry income—Monies received from biomedical companies, device manufacturers, pharmaceutical companies,
or other companies producing products related to the field.
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•
Industry relationships
-
Serve as an officer, board member, trustee, owner, or employee of a company;
-
Direct owner of stock, stock options, or bonds of a company (excludes diversified mutual funds);
-
Consultancy, scientific advisory committee membership, or lecturer for a company (required to disclose
regardless of income; if income, must disclose amount; please note that disclosure is not required for an
honorarium paid by a university, hospital, or medical society for a lecture that has received an unrestricted
funding);
-
Investigator for a company, including holding research grants from the company (disclosure of research
funding paid directly to your institution is not required as it does not constitute industry income);
-
Personal income from patents (intellectual property).
IV Reporting Time Frame and Disclosure Timing
Disclosure is required from all members of the writing group for the past 12 months. Authors are discouraged from
adding new relationships during the guideline development process; if relevant relationships are added, they must be
disclosed immediately to the co-chairs and verbally disclosed during any conference calls or meeting and added to the
author disclosure grid. In the event that the required balance is not met, additional members may be added or removed to
achieve balance.
Disclosures are made in writing or online before the writing initiative to determine eligibility of members to serve and
throughout the guideline development process to ensure transparency.
V Conflict of Interest Requirements by Role
The Co-Editors of the Global Vascular Guidelines should have less than $10,000 USD in industry income in aggregate
during their work on the guidelines or subsequent revisions.
The majority (>50%) of the steering committee members and guideline authors should have less than $10,000 USD in
industry income in aggregate during their work on the guidelines or subsequent revisions.
The minority of steering committee members and authors allowed additional industry income may have no more than
$50,000 per annum (USD) in aggregate during their work on the guidelines or subsequent revisions.
Guideline reviewers are required to adhere to the same criteria for conflict of interest as the steering committee members
and guideline authors.
VI Review of Disclosures
The Conflict of Interest Committee for each sponsoring organization will review disclosures for relevant conflicts of
interest. A member of the steering committee will be appointed to ensure ongoing compliance by committee members
and authors.
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VII Industry Involvement
Industry involvement in the development and review process is not permitted.
•
Direct industry funding will not be accepted by participating societies to support the Global Vascular Guidelines
initiative.
•
Part-time, full-time, and paid industry consultants (ie, advocacy, government affairs, and lobbyists) are prohibited
from serving as members of the guidelines writing group and as document reviewers.
Contributing authors
Table of abbreviations and acronyms
Introduction
Rationale and goals
Chronic limb-threatening ischemia (CLTI) represents the end stage of peripheral artery disease (PAD), a problem of
growing prevalence and increased health care costs around the globe.1 CLTI is a highly morbid disease, incurring
significant mortality, limb loss, pain, and diminished health-related quality of life (HRQL) among those afflicted.
Multiple health care specialists are involved in the management of CLTI, yet lack of public awareness and the frequent
failure to make an early diagnosis continue to be major obstacles to effective treatment. Variability in practice patterns is
high, contributing to a broad disparity in the use of treatments and clinical outcomes. For example, a study from the
United States suggested that many patients do not even receive angiography in the year before major limb amputation.2
These data also demonstrate a broad variation in the use of open or endovascular interventions by region of the country
and hospital referral center.2 More expensive (and more invasive) care is not associated with better outcomes.3 Instead,
what is lacking is a uniform definition of clinical stages of disease and key patient-focused outcomes, contributing to an
incomplete picture of the epidemiology of CLTI and a limited evidence base to guide daily practice.
At the same time, rapidly evolving technologies in diagnostics, devices, drugs, and biologics offer new opportunities to
improve treatment and to address unmet needs in this vulnerable population. A PubMed search of the term “critical limb
ischemia” revealed >5000 citations, with a clear inflection point at the turn of the millennium, demonstrating an
explosion of interest. A new framework is urgently needed to establish evidence-based medical practices in this changing
field. The rationale for this global guideline on the management of CLTI was based on this nexus of factors and the
recognition of its growing impact on public health across all nations and socioeconomic strata. Vascular specialists play a
dominant role in the treatment of CLTI. Accordingly, in 2013, when several leading vascular societies determined to
launch the Global Vascular Guidelines (GVG) initiative, CLTI was considered the first priority disease area of focus. The
primary goal of this practice guideline on CLTI is to improve the quality of care for all patients with CLTI as well as for
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
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those at risk for CLTI. An important secondary goal is to identify key research priorities in need of further basic,
translational, clinical, and health services investigation to advance those aims.
GVG structure
The three major global vascular surgical societies, the European Society for Vascular Surgery (ESVS), the Society for
Vascular Surgery (SVS), and the World Federation of Vascular Societies (WFVS), joined efforts to launch the GVG
initiative. In this process, the ESVS represents national vascular societies from Europe and the SVS represents national,
regional, and local vascular societies in North America. The WFVS represents a large number of non-European, non-
North American vascular surgical societies from across the world. These include the Australian and New Zealand
Society for Vascular Surgery, the Japanese Society for Vascular Surgery, the Vascular Society of India, the Vascular
Society of Southern Africa, the Asian Society for Vascular Surgery, and the Latin American Society of Vascular Surgery
and Angiology (this list is not exhaustive). As the primary sponsors, the ESVS, SVS, and WFVS developed the
organizational structure, policies on conflict of interest, and committed financial support for the GVG program. All
financial support for the GVG was derived directly from the sponsoring societies and without the direct involvement of
industry or other external stakeholders. Representatives from the three leading societies were asked to serve as Co-
Editors as well as members of the Steering Committee to oversee all aspects of the project and its subsequent
communications. Oversight from the societies was limited to budgetary and administrative aspects, including their
respective document review policies before public dissemination of the final guideline. The Steering Committee
recruited a large and diversified writing group; developed the scope and section briefs for the guideline; identified
priority questions for commissioned evidence reviews; and participated in all stages of writing, consensus debate, and
editing of the manuscript.
Conflict of interest policy
A primary consideration on inception of the GVG was to create a robust yet practical approach to conflict of interest to
enable an unbiased effort at guideline development by experts in the field. A central element to this, in concert with the
exclusion of direct commercial funding sources, was full disclosure and specific limits on relevant financial relationships
for members of the writing group, Steering Committee, and Co-Editors. A full description of the GVG Conflict of
Interest policy is provided at the beginning of this supplement. Financial disclosures for all contributing authors were
collected and updated by the Steering Committee. They are detailed in the table of Contributing Authors listed at the
beginning of the guideline.
Leadership and writing group
The Co-Editors and Steering Committee were selected by the three major sponsoring societies and were tasked with the
recruitment of a multidisciplinary, international writing group of recognized experts. In total, the final writing group
comprised 58 individuals from 24 countries across 6 continents. This group represents specialists in vascular surgery,
vascular medicine, interventional cardiology and radiology, angiology, epidemiology, podiatry, and orthopedics as well
as a methodologist with expertise in guideline development. Authors were assigned to individual sections of the
guideline, and all authors reviewed the complete final document before societal review.
Methodology
The Steering Committee drafted a Table of Contents that was divided into distinct sections. Briefs were created to outline
the scope and content of each section. Potential authors were then solicited and vetted, and two authors were chosen to
co-lead the writing effort for each section. The co-lead authors communicated directly with the Steering Committee on
their progress and on iterative cycles of revision as needed. All of the authors of each section reviewed and approved
their final versions before compilation of the full document.
The Steering Committee examined the state of recent evidence reviews in the field, including those commissioned by the
participating societies, and determined the need for additional evidence reviews and updating. These were commissioned
to an external group (Mayo Clinic Evidence-Based Practice Research Program) who performed four systematic reviews
that summarized evidence from randomized and nonrandomized studies.4-7 These systematic reviews underwent peer
review and were published in the Journal of Vascular Surgery, one of which is published as an accompaniment to the
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
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guideline document in this supplement.7
Consensus development during the process occurred through confidential electronic communications, teleconferences,
and multiple in-person meetings of the Steering Committee and members of the writing group. The Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to determine the quality of
evidence and strength of recommendations.8 A strong (Grade 1) recommendation implies that the guideline developers
are confident as to the balance of benefits and harm and that this recommendation should apply to the majority of
patients. A conditional recommendation (Grade 2) implies less certainty and indicates that a different course of action is
reasonable. The guideline developers used an imperative verb to denote strong recommendations and used the term
“consider” to denote a conditional recommendation. The level of evidence for each recommendation is considered high
quality (A), moderate quality (B), or low quality (C). The guideline also includes good practice recommendations. These
ungraded good practice recommendations are supported by a wealth of indirect evidence but no direct evidence, and the
benefit of pursuing the recommended actions is considered to outweigh any plausible harm. The intention of these good
practice recommendations was to draw attention to and remind providers of known and noncontroversial surgical
principles or principles about general medical care. For example, there are good practice statements about performing a
comprehensive history and physical examination in patients with CLTI.9
The final grading of all guideline recommendations was determined by the guideline developers and the methodologist.
After approval by the full writing group, the sections were compiled into one document and reviewed concurrently by the
document oversight bodies of each of the three sponsoring societies. An open comment period was subsequently enabled
on a secure website (http://vsweb.org/GlobalVascularGuidelines) to provide an opportunity for external stakeholders to
review the document. The Co-Editors collated all reviews and made final revisions to the document, which was then
approved by the sponsoring societies before publication and dissemination.
Target population
The target population of patients includes adults with CLTI, defined as a patient with objectively documented PAD and
any of the following clinical symptoms or signs:
•
Ischemic rest pain with confirmatory hemodynamic studies
•
Diabetic foot ulcer (DFU) or any lower limb ulceration present for at least 2 weeks
•
Gangrene involving any portion of the lower limb or foot
Specifically excluded are patients with pure venous ulcers, pure traumatic wounds, acute limb ischemia (symptoms
present for 2 weeks or less), embolic disease, and nonatherosclerotic chronic vascular conditions of the lower extremity
(eg, vasculitis, Buerger disease, radiation arteritis).
Target audience
The primary target audience for this guideline includes all clinicians who are directly involved in the management of
patients with CLTI, to include surgeons (vascular, general, plastic, and orthopedic), interventionalists (radiologists,
cardiologists), podiatrists, wound care providers, rehabilitation medicine specialists, orthotists and physical therapists,
and trainees in these disciplines.
Secondary audiences include referring providers, such as primary care physicians, medical specialists, nurses, and other
allied health providers, who may care for the at-risk population and who are critical for awareness and timely specialist
referral of patients with suspected CLTI. Other key targets for this guideline are third parties with influence over the
current and future treatment of CLTI, including government agencies, payers (funders), industry stakeholders,
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
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investigators, and research organizations.
CLTI: A new paradigm for treatment and research
This clinical practice guideline (CPG) intentionally seeks to create a new conceptual framework for the treatment of
CLTI. It encompasses nomenclature, disease staging, and a platform for evidence-based revascularization (EBR) that will
allow future evolution and quality improvement in the field. A brief introduction to the key elements introduced in this
document is provided here.
Nomenclature
Consistent and meaningful nomenclature is of fundamental importance for assessing the state of evidence and guiding
future research efforts. To this end, the GVG promotes the use of the term CLTI, defined by the target population, to
denote the universe of patients with advanced lower limb ischemia, wounds, neuropathy, and infection who are
commonly referred to vascular specialists for evaluation and management. Prior terms, such as “critical” and “severe”
limb ischemia, connote specific hemodynamic thresholds and fail to recognize the full spectrum and inter-relatedness of
components beyond ischemia that contribute to major limb amputation and long-term disability. This is addressed fully
in Section 1 of the guideline.
Disease staging in CLTI
Improved disease staging is mandatory for designing clinical trials, conducting comparative effectiveness research,
identifying critical gaps in knowledge, and developing effective algorithms for treatment. CLTI represents a broad range
of clinical severity (limb threat) and anatomic complexity of disease. The GVG incorporates the SVS Lower Extremity
Threatened Limb Classification System10 as a preferred staging system for CLTI, which is discussed more fully in
Section 1 and other related areas of the document.
EBR and the PLAN concept
The GVG espouses a goal of EBR for CLTI to improve the quality of vascular care and to reduce disparities in treatment
and outcomes. However, the existing database to support EBR is found to be lacking in many domains. There have been
few high-quality randomized controlled trials (RCT) or comparative effectiveness studies in the field. This remains a
major unmet need requiring broad support from national health agencies, payers, industry, professional organizations,
and research foundations. The writing group sought the best available evidence to generate consensus recommendations
while also providing a foundation for future iterations based on a patient- and limb-centric approach to treatment rather
than on the prevailing lesion-focused lexicon in the field.
The PLAN concept of EBR (Section 6) stresses a structured management approach based on Patient risk, Limb severity,
and ANatomic pattern of disease, in that order of priority. The authors believe that adequate stratification along these
three independent axes is clinically relevant and of fundamental importance to improve evidence quality and to achieve
EBR for patients with CLTI. Further development of this approach requires prospective validation and refinement of
tools to accurately stage patient risk, limb threat, and anatomic patterns of disease, as discussed in detail in the document.
Global Limb Anatomic Staging System (GLASS)
A new anatomic scheme for the threatened limb is proposed. Commonly used anatomic classification schemes for PAD
are lesion or segment focused11 or aim to quantify the overall burden of disease,12 rather than integrating the complex
patterns of disease found in most patients with CLTI. Successful revascularization in CLTI, particularly in patients with
tissue loss, nearly always requires restoration of in-line (pulsatile) flow to the foot. Moreover, there is a general lack of
understanding of the relationships between patterns of disease, hemodynamic improvement after treatment, anatomic
durability, clinical stage, and outcomes that continues to plague the field. With this in mind, a new approach was
developed to facilitate clinical decision-making in CLTI—the GLASS (Section 5). To be most useful, GLASS
incorporates a set of baseline assumptions to avoid overcomplexity and to permit its ready utility in everyday clinical
practice and in future research.
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GLASS incorporates two novel and important concepts, the target arterial path (TAP) and estimated limb-based patency
(LBP). Based on appropriate angiographic imaging, the TAP is defined by the treating surgeon or interventionalist as the
optimal arterial pathway to restore in-line (pulsatile) flow to the ankle and foot. It may incorporate either the least
diseased or an angiosome-preferred path, as chosen by the treating clinician. LBP is defined as maintenance of in-line
flow throughout the TAP, from groin to ankle. LBP allows more direct comparison of anatomic outcomes across
revascularization strategies in CLTI. The complexity of disease traversed by the TAP is integrated in the GLASS.
Femoropopliteal (FP) and infrapopliteal (IP) arterial segments are individually graded on a scale of 0 to 4. Using a
consensus-based matrix, these segmental grades are combined into three overall GLASS (I-III) stages for the limb.
GLASS includes a simplified approach to inflow (aortoiliac [AI]) disease, a dichotomous stratification for severe
calcification within segment, and a simple modifier for pedal (inframalleolar [IM]) disease. GLASS stages (I-III) were
defined on the basis of expected technical success and anatomic durability for infrainguinal endovascular intervention
and reflect the overall complexity of disease within the TAP. The consensus process for developing and assigning
GLASS stages was informed by an updated systematic review of revascularization outcomes in CLTI.7 Thus, GLASS
stages I to III correlate with low-, intermediate-, or high-complexity infrainguinal disease patterns, with expected
correlation to immediate technical success and 1-year LBP for endovascular intervention. The relevance of these GLASS
anatomic stages in different clinical scenarios is integrated within the PLAN framework for decision-making. GLASS is
designed for subsequent refinement, reclassification, and validation based on data from prospective studies that employ
the scheme and report appropriate outcome measures. A mobile app to quickly derive GLASS stage from angiographic
imaging in real time will be released in proximity to the guideline publication.
End points and trial designs
Existing limitations of the evidence base in CLTI were obvious and broadly acknowledged during the GVG development
process. The importance of developing consensus around key outcome measures, with a focus on patient-oriented end
points, is critical to advancing the field. It is anticipated that currently enrolling RCTs, including Bypass vs Angioplasty
in Severe Ischaemia of the Leg (BASIL-2) trial, Balloon vs Stenting in Severe Ischaemia of the Leg (BASIL-3) trial, and
Best Endovascular vs Best Surgical Therapy for Patients with Critical Limb Ischemia (BEST-CLI), will allow important
advances in the management of CLTI, with significant overlap among these efforts.13-15 In Section 11 of the guideline, a
full consideration of this important topic is provided as a framework, with specific recommendations for study and RCT
designs going forward.
Interdisciplinary team in CLTI
There has been growing recognition of the value of multidisciplinary and interdisciplinary team-based care to optimize
the outcomes for patients with CLTI. The components of such teams vary considerably across centers and regions of
practice, but certain critical skill sets, expertise, facilities, and resources are required to create a Center of Excellence for
CLTI management. Consideration of this important topic is addressed in Section 12 of the guideline.
Dissemination, translation to practice, and future revisions of the guideline
Translation of expert guidelines into clinical practice is known to be a major obstacle to evidence-based medicine.
Reasons are multifactorial and include limited provider and patient engagement, lack of consensus, economic conflicts,
and resource constraints. The international scope of the GVG mandated an attempt to survey differences in practice
patterns, resources, and potential hurdles to implementation around the globe (Section 13). Dissemination of the
guideline by the sponsoring societies is planned to include an array of print media, web and social media, mobile apps,
and communications at multiple national and regional meetings to facilitate discussion. The incorporation of suggested
staging systems and end points into national and multinational registries will greatly facilitate use and future refinement
of this effort. It is anticipated that the GVG will be translated into the other major world languages.
To remain current and evidence based, practice guidelines must be periodically reviewed and updated. Ongoing RCTs
and prospective cohort studies will provide critical new evidence in the management of CLTI during the next several
years. The sponsoring societies of the GVG recognize the importance of stewardship of this practice guideline, both as
new key evidence arises and as a planned interval exercise.
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Supporting materials
Evidence-based recommendations made in this guideline are supported by key references listed in the text. A summary
of the relevant findings from the studies used to support each recommendation is provided as a Supplementary
Table (online only) to the guideline.
A scientific manuscript summarizing a commissioned evidence review on the outcomes of revascularization in CLTI is
also published within the guidelines supplement.7 This manuscript underwent independent peer review by the Journal of
Vascular Surgery. The Supplementary Tables of that document summarizing the individual source studies and the various
outcomes analyzed by time interval are also available online (https://www.jvascsurg.org/article/S0741-5214(18)30854-
1/fulltext).
Summary of recommendations
1 Definitions and nomenclature
Defining and describing the severity of PAD
The term “critical limb ischemia” (CLI) is outdated and fails to encompass the full spectrum of patients who are
evaluated and treated for limb-threatening ischemia in modern practice. Instead, the new term CLTI is proposed to
include a broader and more heterogeneous group of patients with varying degrees of ischemia that can often delay wound
healing and increase amputation risk.
For development of a clearer concept of CLTI, the following are excluded from the population as defined in this
guidelines document: patients with purely venous ulcers, acute limb ischemia, acute trash foot, ischemia due to emboli,
acute trauma, or mangled extremity and those with wounds related to nonatherosclerotic conditions. These include
vasculitides, collagen vascular disease, Buerger's disease, neoplastic disease, dermatoses, and radiation arteritis.
Previous leg ischemia definition and classification systems
CLI
In 1982, a working group of vascular surgeons defined CLI as ischemic rest pain with an ankle pressure (AP) <40 mm
Hg, or tissue necrosis with an AP <60 mm Hg, in patients without diabetes.144 Patients with diabetes were specifically
excluded because of the confounding effects of neuropathy and susceptibility to infection. This definition has long been
debated because it failed to capture a large group of patients who were at risk for amputation from a broader range of
ischemia.145,146 To address this limitation, multiple and disparate lower limb ischemia and wound/DFU classification
systems have been developed and promulgated during the past 5 decades, many of which remain in use today. These and
other commonly used classifications and their associated components and grades of severity are summarized in
Table 1.1.10,147-158 Among vascular surgeons, the Fontaine and Rutherford classifications have been the most widely
adopted, whereas orthopedists, podiatric surgeons, and diabetic foot specialists traditionally applied the Wagner and
University of Texas classifications. The strengths and limitations of each have been widely discussed in previous key
publications.10,150,159-161 Although each of these systems has advantages, the use of multiple classification systems has
hindered the development of optimal treatment algorithms. It has also contributed to the fragmentation and variability of
care provided for patients with DFUs as well as for nondiabetic patients across the spectrum of CLTI.
Table 1.1
Classification schemes used for chronic limb ischemia and ulceration
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
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Table 1.2
One-year major limb amputation rate by Society for Vascular Surgery (SVS) Wound, Ischemia, and foot Infection (WIfI)
clinical stage
Lower extremity threatened limb classification system
The definitions summarized in Table 1.1 were developed primarily to describe patients suffering from pure ischemia due
to atherosclerosis. This was when the predominant risk factor was tobacco smoking and before the global epidemic of
diabetes mellitus (DM). As such, these definitions were ischemia-dominant models of limb threat. However, because
patients with DM now make up the majority of patients with CLTI, absolute perfusion now needs to be considered in the
context of neuropathy, wound characteristics, and infection. To address this unmet need, the SVS Lower Extremity
Guidelines Committee created the SVS Lower Extremity Threatened Limb Classification System. This system stratifies
amputation risk according to wound extent, degree of ischemia, and presence and severity of foot infection (Wound,
Ischemia, and foot Infection [WIfI]).10 Although it may require some adjustments, WIfI appears to correlate strongly
with important clinical outcomes. This includes those set forth in the SVS objective performance goals (OPGs) that focus
on limb amputation, 1-year amputation-free survival (AFS), and wound healing time (Table 1.2).10,68-72,162-167
The WIfI classification system is currently being evaluated in multicenter trials including the U.S. National Institutes of
Health-funded BEST-CLI trial13 and the UK National Institute for Health Research Health Technology Assessment-
funded BASIL-2 and BASIL-3 trials.14,15 WIfI is also being incorporated into the U.S. SVS Vascular Quality Initiative
registry of lower extremity interventions.
Hemodynamic criteria
Although previous guidelines have suggested a range of AP and toe pressure (TP) thresholds for defining limb-
threatening ischemia, such thresholds must be used with great caution and considered in the clinical context because of
multiple confounding factors and the lack of a clear and reliable relationship to outcomes. Patients with limb-threatening
ischemia should be defined primarily in terms of their clinical presentation, supplemented by physiologic studies that
demonstrate a degree of ischemia sufficient to cause pain, to impair wound healing, and to increase amputation risk.
In addition to patients who meet the proposed new definition of CLTI, there are a significant number of patients whose
PAD is so severe that they are likely to be at increased risk for development of CLTI in the foreseeable future.168
Although data are lacking, it is logical to suggest that such individuals should be monitored closely for clinical disease
progression.
CLTI
We propose that CLTI be defined to include a broader and more heterogeneous group of patients with varying degrees of
ischemia that may delay wound healing and increase amputation risk. A diagnosis of CLTI requires objectively
documented atherosclerotic PAD in association with ischemic rest pain or tissue loss (ulceration or gangrene).
Ischemic rest pain is typically described as affecting the forefoot and is often made worse with recumbency while being
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relieved by dependency. It should be present for >2 weeks and be associated with one or more abnormal hemodynamic
parameters. These parameters include an ankle-brachial index (ABI) <0.4 (using higher of the dorsalis pedis [DP] and
posterior tibial [PT] arteries), absolute highest AP <50 mm Hg, absolute TP <30 mm Hg, transcutaneous partial pressure
of oxygen (TcPo2) <30 mm Hg, and flat or minimally pulsatile pulse volume recording (PVR) waveforms (equivalent to
WIfI ischemia grade 3). Pressure measurements should be correlated with Doppler arterial waveforms, keeping in mind
that AP and ABI are frequently falsely elevated because of medial calcinosis, especially in people with DM and end-
stage renal disease (ESRD). For this reason, a combination of tests may be needed. In patients with DM or ESRD, toe
waveforms and systolic pressures are preferred. One study demonstrated that AP alone failed to identify 42% of patients
with CLTI. TP and TcPo2 measurements were more accurate than AP and also were more predictive of 1-year
amputation risk (TP <30 mm Hg or TcPo2 <10 mm Hg).169
Tissue loss related to CLTI includes gangrene of any part of the foot or nonhealing ulceration present for at least 2
weeks. It should be accompanied by objective evidence of significant PAD (eg, WIfI ischemia grade ≥1). This definition
excludes purely neuropathic, traumatic, or venous ulcers lacking any ischemic component. However, the WIfI scheme
recognizes that a wide range of ischemic deficit may be limb threatening when it coexists with varying degrees of wound
complexity and superimposed infection. CLTI is present if either ischemic rest pain or tissue loss with appropriate
hemodynamics is present.
Some patients may have relatively normal hemodynamics when the limb or foot is considered as a whole but
nevertheless suffer ulceration as a result of diminished local perfusion (ie, angiosomal or regional ischemia without
adequate collateral flow). It is recognized that such ulcers may contribute to limb threat, and current tools to assess
regional ischemia require further development to better define such circumstances and their treatment. The relationship
between regional ischemia and patterns of IP and pedal disease also requires more in-depth study.12,170
The GVG recommends use of the SVS WIfI classification (Section 3) in a manner analogous to the TNM system of
cancer staging to stage the limb in patients with CLTI. The WIfI classification is intuitive and has been made user-
friendly by the availability of free online application software provided by the SVS (SVS Interactive Practice Guidelines;
https://itunes.apple.com/app/id1014644425).
Data accrued in nearly 3000 patients to date and summarized in Table 1.2 suggest that the four WIfI clinical stages of
limb threat correlate with the risk of major limb amputation and time to wound healing. It has also been suggested that
novel WIfI composite and mean scores may predict other clinically significant events as well.164 The WIfI system
appears to contain the key limb status elements needed to gauge the severity of limb threat at presentation.
In addition, recent data suggest that WIfI can assist in predicting which patients might fare better with open surgical
bypass compared with endovascular therapy.171,172 One study reported that when endovascular therapy alone was
applied to WIfI stage 4 patients, results were worse than in lower clinical stage patients.172 Specifically, the wound
healing rate was only 44%, the major limb amputation rate was 20%, and 46% of patients required multiple, repetitive
endovascular procedures. In a nonrandomized, single-center comparison of WIfI stage 4 patients, researchers found that
freedom from major limb amputation was superior in patients who underwent bypass compared with those who
underwent endovascular therapy.171 If these results can be confirmed, WIfI may prove to be a useful tool in deciding
whether to offer endovascular therapy or bypass.
Another study used WIfI in a fashion analogous to TNM staging for cancer and reassigned patients to stages after 1
month of therapy. The investigators found that at 1 month and 6 months, wound, ischemia, and infection grades
correlated with AFS, whereas baseline ischemia grade did not.173 These data suggest that restaging with WIfI at 1 month
and 6 months after intervention may help identify a cohort of patients undergoing therapy for CLTI that remains at higher
risk for major limb amputation and may merit targeted reintervention.
Ultimately, the optimal staging system for CLTI is expected to evolve with additional clinical application and larger
scale, multicenter, and multinational data analysis.
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
Page 13 of 203
2 Global epidemiology and risk factors for CLTI
In 2010, estimates suggested that >200 million people worldwide were living with PAD. This represented a 23.5%
increase since 2000, an increase that is believed to be largely attributable to aging populations and the growing
prevalence of risk factors, in particular DM.1 These figures are thought to almost certainly underestimate the true burden
of disease as they are largely based on community-based studies that define PAD on the basis of reduced ABI. Although
CLTI is widely believed to be a growing global health care problem, reliable epidemiologic data are extremely limited.
Men have been reported to have a higher prevalence of PAD in high-income countries (HICs; Fig 2.1), whereas women
seem to have a higher prevalence of PAD in low- and middle-income countries (LMICs).1 As life expectancy increases,
the burden of PAD seems likely to rise in LMIC. However, in certain geographic regions, notably in the western Pacific
and Southeast Asia, most PAD cases are reported in people younger than 55 years.1
Fig 2.1
Prevalence of peripheral artery disease (PAD; ankle-brachial index [ABI] <0.9) by age and sex in high-income countries
(HICs) and in low- and middle-income countries (LMICs).1
Fig 2.2
Odds ratios (ORs) for peripheral artery disease (PAD) in high-income countries (HICs) and low- and middle-income
countries (LMICs). BMI, Body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; HDL, high-density
lipoprotein.
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Fig 2.3
Association of risk factors with the level of atherosclerotic target lesions. The red overlay on the anatomic cartoon
illustrates the association of risk factor with patterns of atherosclerotic disease.217
Fig 3.1
Flow diagram for the investigation of patients presenting with suspected chronic limb-threatening ischemia (CLTI). ABI,
Ankle-brachial index; PAD, peripheral artery disease; TBI, toe-brachial index; WIfI, Wound, Ischemia, and foot Infection.
In a meta-analysis from the United States, the prevalence of PAD in men ranged from 6.5% (aged 60-69 years) to 11.6%
(aged 70-79 years) to 29.4% (>80 years).174 There were similar age-related increases in PAD prevalence in women
(5.3%, 11.5%, and 24.7% in these age categories, respectively).174 Given that the life expectancy of women still exceeds
that of men, the overall burden of PAD (total number of individuals affected) is likely to be greater in women than in
men. The epidemiology of PAD is likely to be similar in other developed countries, such as the United Kingdom, and
regions, such as the European Union.175,176 However, as these populations become more multicultural, differences in
disease burden between different communities within these nations seem likely to become apparent, further complicating
the epidemiology of the condition.177
Data on the epidemiology of PAD and in particular of CLTI in other parts of the world are even more limited. In one
Japanese community study of people older than 40 years, the prevalence of ABI <0.9 was very low (1.4%).178 In a
population-based cohort of 4055 Chinese men and women older than 60 years, the prevalence of PAD (ABI <0.9) was
2.9% and 2.8%, respectively.179 Another population-based cohort of 1871 individuals younger than 65 years in two
countries from Central Africa showed that the overall prevalence of PAD was 14.8%.180
There is a considerable body of evidence showing that PAD is more common among black individuals than among
whites.181-184 There is also evidence that Asians and Hispanics have a lower prevalence of PAD than whites do.184 It is
not clear whether these differences have a genetic basis or simply reflect differential exposure to traditional risk factors.
However, disease risk profiles appear to change as populations migrate, suggesting that environment is more important
than genetic makeup. Another explanation may be that ABI is intrinsically lower in black individuals, resulting in a
falsely high prevalence of PAD.185
There are far more international data on the epidemiology of intermittent claudication (IC) than of CLTI. The annual
incidence of IC in 60-year-old men has been shown to range from 0.2% in Iceland to 1.0% in Israel.186 A study using
data from a large, insured U.S. population estimated the annual incidence of PAD, defined by the presence of a diagnosis
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or procedure insurance claim, to be 2.4% in a cohort of adults older than 40 years.187 Studies reporting on the
epidemiology of PAD based on ABI rather than on the presence of symptomatic disease suggest that the prevalence of
asymptomatic PAD may be similar in men and women, although IC appears to be more prevalent in men.188,189
Differences in presentation between men and women with IC may influence the accuracy of prevalence estimates.190
Risk factors for PAD
Modifiable risk factors for PAD have been comprehensively studied in HICs and include smoking, DM, hypertension,
hypercholesterolemia, and air pollution. A global study suggested that although these risk factors may be equally
applicable to LMICs, for most, the strength of the association was greater in HICs. This may be because HIC studies
often include a larger number of older patients and because the exposure time tends to be shorter in LMICs.1
Smoking is unarguably a significant risk factor in the development and progression of PAD. Nevertheless, whereas
smoking rates are falling in most HICs, this is not the case in LMICs (Fig 2.2). DM is also strongly associated with the
development of PAD, and risk increases with the duration of DM in affected individuals. Patients with DM are widely
recognized to be at markedly higher risk of amputation.191,192 The rapidly increasing worldwide prevalence of type 2
DM is concerning and likely to have a significant impact on the future incidence and prevalence of PAD and CLTI as
well as their morbid end points.
The link between obesity and PAD is inconsistent. Many studies have suggested the existence of an “obesity paradox,”
with lower rates of PAD being observed in patients with a higher body mass index (BMI).186 By contrast, other studies
that have adjusted for smoking, which is associated with a generally lower BMI,193 reported a positive correlation
between BMI and PAD. Hypertension is associated with the development of PAD and is another common risk factor in
the adult population.
The association between dyslipidemia and the development and progression of atherosclerosis has been extensively
studied. Whereas elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) are widely
accepted as risk factors for PAD, reduced high-density lipoprotein cholesterol levels also appear to be associated with
increased mortality in PAD patients.194 A ratio of the two may also be a useful predictor of PAD.195 Whereas
hypertriglyceridemia appears to be atherogenic,196 its role in the development and progression of PAD remains
incompletely defined.
Chronic kidney disease (CKD), particularly ESRD, is a strong risk factor for PAD and limb loss, especially in association
with DM. Affected patients frequently have heavily calcified arteries and a distal pattern of arterial disease.186
The association between alcohol consumption and PAD is inconsistent, making it difficult to draw any firm
conclusions.197 However, heavy alcohol consumption is often associated with other risk factors for PAD, such as
smoking, and as with DM, the presence of alcoholic neuropathy increases the risk of tissue loss for any given perfusion
deficit.
Recent data suggest that air pollution from sources such as motor vehicles, power plants, wood burning, and some
industrial processes may be associated with increased cardiovascular morbidity and mortality.198 Likewise, chronic
inflammation, characterized by elevated levels of C-reactive protein and other biomarkers, has been shown to be
associated with PAD.186 Homocysteine levels are higher in several case-control PAD cohort studies, although the
benefits of folate supplementation appear to be negligible.186,199
The significance of family history and genetic makeup is uncertain.200,201 Studies have yielded varying results, with
some identifying a small number of candidate genes or even single-nucleotide polymorphisms and others failing to
identify any association at all.
Finally, people of lower socioeconomic status and educational attainment tend to have a higher prevalence of IC and
probably also of CLTI, although the association is not always strong and can often be explained in part by their increased
exposure to other risk factors, such as smoking.180,183,202 However, there is increasing evidence that chronic mental and
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psychosocial stress may have direct effects on cardiovascular health.203
Incidence and prevalence of CLTI
As noted before, high-quality data on the epidemiology of CLTI are lacking, especially from LMICs, with many
estimates being extrapolated from the incidence and prevalence of IC, amputation, and DM. Unfortunately, such
estimates can be highly misleading for a number of reasons. First, IC does not progress to CLTI in a predictable manner.
Second, CLTI probably represents <10% of all PAD patients, and those undergoing amputation for CLTI are at very high
risk of premature death (and so more likely to be absent from population-based studies). Third, the clinical and
hemodynamic data required to reliably diagnose CLTI are difficult to obtain in large populations. This is particularly true
in patients with DM, who often have incompressible vessels. Thus, although it is estimated that approximately half of all
patients with a DFU in western Europe and North America also have significant PAD, the disease may often appear
relatively mild (not fulfilling the criteria for CLTI) on hemodynamic assessment.204
For many years, the annual incidence of what has typically been termed CLI was estimated at 500 to 1000 new cases per
million individuals in Western countries.205 Unfortunately, there are no reliable contemporary epidemiologic data that
take into account recent changes in lifestyle (such as reduced smoking rates), identification and medical management of
cardiovascular risk factors, prevalence of obesity and diabetes, and overall increasing life expectancy around the world.
In 2013, a meta-analysis involving 6 studies and close to 83,000 patients showed the overall prevalence of severe chronic
limb ischemia (defined by Fontaine stage, AP <70 mm Hg, and ABI <0.60) to be 0.74% (95% confidence interval [CI],
0.26-1.46), with marked heterogeneity between studies (prevalence, 0.11%-1.59%).206
In an analysis of the U.S. MarketScan database (Truven Health Analytics, Ann Arbor, Mich), composed of
approximately 12 million Americans aged 40 years and older receiving care from Medicare and Medicaid between 2003
and 2008, the prevalence and annual incidence of CLTI were estimated at 1.33% and 0.35%, respectively. This equates to
around 3500 new cases per million individuals per year.187 The study defined primary CLTI as patients with no prior
PAD or subsequent PAD diagnostic code >30 days after a CLTI diagnostic code. Secondary CLTI included patients with
prior PAD (or subsequent PAD diagnostic codes within 30 days of a CLTI diagnostic code). The annual incidence rate of
primary and secondary CLTI was 0.19% and 0.16%. CLTI patients represented 11.08% (95% CI, 11.03%-11.13%) of
total PAD patients annually. As noted before, although one might expect similar rates of CLTI in other developed nations
and regions, data from LMICs are lacking. Even within HICs, the epidemiology of CLTI is likely to be complex and
evolving.
Amputation and CLTI
A number of studies have used major lower limb amputation as a surrogate for CLTI on the basis that most (>80%) are
due to CLTI. However, it can be difficult to distinguish reliably between minor (below the ankle) and major (above the
ankle) amputations in some administrative data. Furthermore, the number of amputations that are performed for trauma,
tumor, or infection, including patients with DM and neuropathy (but without PAD), is likely to vary considerably from
country to country, particularly in comparing HICs and LMICs.
In the United States in 2015, an estimated 504,000 individuals (of a total estimated population of 295.5 million) were
living with a major amputation due to PAD, a number that was projected to more than double by 2050.207 In Minnesota,
a state with low overall rates of cardiovascular disease (CVD), one study showed that between 2005 and 2008, the age-
adjusted annual incidence of ischemic lower limb amputation (amputations not due to trauma or cancer) remained
unchanged at 20 per 100,000.208
A systematic review found that the rate of major amputation varied considerably (3.6 to 68.4 per 100,000 per year)
across the world, probably because of differences in ethnicity, social deprivation, and, in particular, the prevalence of
DM.209 In some countries, including England, the incidence of amputations unrelated to DM appears to be
decreasing.210 However, in most parts of the world, the incidence of DM-related limb amputations is increasing.211
Natural history of untreated CLTI
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A meta-analysis (13 studies and 1527 patients) of the natural history of untreated CLTI found that during a median
follow-up of 12 months, both the mortality rate and the per-patient amputation rate were 22%, although there was
marked heterogeneity between studies.5 With regard to disease progression, one study estimated that only 5% to 10% of
patients with either asymptomatic PAD or IC went on the develop CLTI during a 5-year period.212 However, another
meta-analysis suggested that this progression rate may be significantly higher at 21% (range, 12%-29%) during 5
years.213 Approximately 50% of patients presenting with CLTI have no prior history of PAD.214,215
Patients with CLTI present with a wide spectrum of clinical, hemodynamic, and anatomic disease. Outcomes depend on
the availability and quality of primary and secondary care and may be further influenced by factors such as social
stigmatization and cultural and religious beliefs. Those living in regions with poor access to health care often present late
with advanced disease and unsalvageable limbs. Indeed, it has been estimated that approximately half of all patients with
CLTI do not undergo revascularization.216 Even in HICs with advanced health care systems, such as Germany and the
United States, many patients with suspected CLTI do not receive angiography or any attempt at revascularization.217
This may be because patients are too sick or frail, are thought to have no revascularization option, or present too late.
Unfortunately, whereas reasonable data are available on amputation rates, data on processes of care that can help explain
the shortfall and differences in revascularization and amputation are lacking.
The recently published VASCUNET report showed large (almost sixfold) differences but an overall decline in major
amputation rates in 12 European and Australasian countries between 2010 and 2014.218 DM prevalence, age distribution,
and mortality rates were also found to vary between countries. Despite limitations inherent to the use of registry data,
these findings are important and may indicate disparities in access to vascular surgical intervention across the countries
studied. Further research is clearly required to improve limb salvage in different demographic and geographic
settings.218
In patients with known PAD, the risk for development of CLTI appears to be greater in men, in patients who have had a
stroke or are in heart failure, and in patients with DM.187 Patients who present de novo with CLTI (no prior diagnosis of
PAD) seem more likely to be older and male and to have pre-existing CVD (including hypertension, myocardial
infarction, heart failure, or stroke) and renal failure.187 Not surprisingly, because of the associated high prevalence of
neuropathy, DM had the strongest association with a new presentation of CLTI (odds ratio [OR], 7.45; 95% CI, 7.19-
7.72). The medical management of patients who have or are at risk of having CLTI is covered elsewhere in the guideline
(Section 4). Still, there is growing evidence that aggressive medical management of risk factors can significantly
improve the overall prognosis for patients with PAD. This may in part explain the decline in mortality observed in
patients with IC and CLTI in The Netherlands between 1998 and 2010.219
The risk of amputation is high in CLTI patients, even in those undergoing a successful revascularization.220
Unsurprisingly, patients who present late and with the greatest degree of tissue loss are at highest risk. In one analysis,
the rates of amputation at 4 years were 12.1%, 35.3%, and 67.3% for Rutherford class 4, class 5, and class 6,
respectively.217
Anatomic patterns of disease
CLTI is usually the result of multilevel arterial occlusive disease. Involvement of parallel vascular beds, such as the
superficial femoral artery (SFA) and profunda femoris artery (PFA), is also common. Below-knee arteries typically
become increasingly involved as the overall severity of disease worsens. However, FP and IP disease does not always
progress in parallel. The general requirement is that there needs to be two levels of arterial occlusive disease to cause
CLTI. However, an increasingly observed exception is diffuse disease involving the IP and pedal arteries in patients with
DM or CKD. In patients with CLTI and IP disease, the PT artery tends to be the most diseased, often with relative
sparing of the peroneal artery. In patients with DM, there may also be sparing of the DP artery. A number of specific
factors appear to drive the distribution of lower limb PAD (Fig 2.3). Thus, women may be more prone to development of
FP disease, whereas elderly male patients and those with diabetes are more likely to develop IP disease.221 There is also
some evidence that black people and Asians are more likely to develop distal disease.222,223
CVD and mortality risk
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Despite some evidence of recent improvements in HICs, patients who develop PAD and CLTI remain at high risk of
premature death. Thus, in a German study, 4-year mortality was 18.9% in Rutherford class 1 to class 3, 37.7% in class 4,
52.2% in class 5, and 63.5% in class 6.217 However, interestingly, up to 40% of the deaths were not cardiovascular,
perhaps because better medical therapy and management of risk factors have improved overall survival from
CVD.224,225
In 2014, the Global Burden of Disease (2010) database was used to estimate PAD deaths, disability-adjusted life-years,
and years of life lost in 21 regions worldwide between 1990 and 2010. In 1990, the age-specific PAD death rate per
100,000 population ranged from 0.05 among those aged 40 to 44 years to 16.63 among those aged 80 years or older. In
2010, the corresponding estimates were 0.07 and 28.71. Death rates increased consistently with age in 1990 and 2010,
and the rates in 2010 were higher than they were in 1990 in all age categories.
The overall relative change in median disability-adjusted life-years was greater for men and women in developing than in
developed nations. The overall relative change in the median years of life lost rate in developed countries was larger in
women than in men. Researchers concluded that disability and mortality associated with PAD increased during the 20
years of the study and that this increase in burden was greater among women than men. In addition, the burden of PAD is
no longer confined to the elderly population and now includes young adults. Finally, the relative increase in PAD burden
in developing regions of the world is striking and exceeds the increases in developed nations.226
Management strategies in CLTI
A study based in South Carolina identified patients who underwent revascularization for CLTI in 1996 and 2005 and
examined the requirement for subsequent amputations and further revascularizations. Although revascularization
procedures increased by 33%, the 1-year and 3-year amputation rates did not change significantly between 1996 (34%
and 43%) and 2005 (34% and 40%). However, the percentage of patients who required further revascularization in the
same calendar year increased from 8% to 19%. Investigators concluded that the shift to endovascular interventions
increased the number of secondary procedures required to maintain limb salvage rates. Although the absolute number of
amputations appeared to decrease despite the increasing population at risk, they concluded that it could be misleading to
suggest a direct relationship to the increase in revascularization rates. Thus, whereas the number of amputations fell by
approximately 500, the number of revascularization procedures rose by only 187.227 As noted before, improved risk
factor management and use of best medical therapy are likely to have been important factors. The increased number of
revascularization procedures may also be due to the increasing availability of endovascular technology and techniques.
Indeed, there is some suggestion that practitioners have become more liberal with the use of all revascularization
techniques, including bypass and angioplasty.228 Data from the United Kingdom suggest that an increasing number of
patients are undergoing attempts at revascularization.228
Undoubtedly, there is an increase in the number and proportion of revascularization procedures performed using an
endovascular approach. In the South Carolina study, the endovascular approach was used in 26% of CLTI
revascularization procedures performed in 1996 compared with 51% in 2005.227 It is difficult to establish whether this
change in management strategy has resulted in the salvage of more limbs and prevention of premature deaths. Such
questions can only be answered by RCTs. There are, however, consistent data to suggest that more modern vascular
strategies (including a more widespread adoption of endovascular techniques as first- or second-line therapies) are
associated with an increased number of patients requiring repeated revascularization (increasing from 8% to 19% in the
South Carolina study).227 Alternative explanations may be that vascular surgeons are becoming more aggressive at
retreating patients or that patients are living longer.
Summary
PAD is an increasingly common condition worldwide. Most patients remain asymptomatic, but it is estimated that up to
10% will progress to or present de novo with CLTI (although that figure appears to vary widely). The number of women
with PAD continues to increase, and women may be more likely to develop symptomatic disease. Modifiable risk factors
include DM, smoking, hypertension, dyslipidemia, CKD, obesity, and sedentary lifestyle.
Despite advances in risk factor management and best medical therapy, PAD and especially CLTI are associated with
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
Page 19 of 203
markedly increased cardiovascular morbidity and mortality, especially in LMICs. Left untreated, the overall risk of limb
loss in CLTI is estimated at approximately 25% at 1 year.5 However, it will probably be much higher than that for some
groups, such as those with extensive tissue loss at presentation. The key to preventing limb loss is aggressive risk factor
management and best medical therapy together with timely EBR. There are major differences in amputation rates
between and within countries. An increasing number of patients appear to be undergoing revascularization (both
endovascular and bypass surgery) in HICs, and at least in part, this may account for a reduction in amputation. However,
improvements in cardiovascular risk management, processes of care, and vascular and endovascular technology may be
equally important.
3 Diagnosis and limb staging in CLTI
Diagnosis and evaluation
The diagnostic evaluation, staging, and imaging of patients with suspected CLTI, leading to EBR, is an integral part of
successful treatment. Beyond history and examination, an important new tool is the SVS Threatened Limb Classification
System (WIfI), which correlates with the probability of limb salvage and wound healing after revascularization. Fig 3.1
summarizes the recommended evaluation pathway for patients presenting with CLTI that should be followed whenever
possible. In patients who are appropriate candidates for revascularization (Section 6), the GLASS (Section 5) anatomic
scheme can be used to help define the optimal revascularization strategy.
Recent technologic advances have made the diagnosis and imaging of CLTI more accurate, which in turn allows better
selection of patients and planning of revascularization. However, the authors are well aware that access to sophisticated
diagnostic modalities and vascular imaging varies considerably around the globe, and as expected, this leads to a wide
range of different approaches being employed in different health care settings.229 As such, it would not be possible or
indeed desirable to make firm, proscriptive recommendations in this section. Rather, the aim is to set out broad principles
and considerations that can reasonably be used to guide patient evaluation, diagnosis, limb staging, and imaging in most
health care environments.
History
Ischemic rest pain usually affects the forefoot, is frequently worse at night, and often requires opiate analgesia for
management. If present for >2 weeks and combined with hemodynamic evidence of severely impaired perfusion (eg,
absolute AP <50 mm Hg, absolute TP <30 mm Hg), it is diagnostic of CLTI.230
Ischemic ulceration is frequently located on the toes and forefoot, but other areas may be affected in patients with
diabetic neuropathy, altered biomechanics, or foot deformity. Gangrene usually occurs on the forefoot. A range of
perfusion deficits may be limb threatening in different scenarios of tissue loss and concomitant infection (Section 1).
Thus, all patients presenting with signs or symptoms of suspected CLTI should undergo a complete vascular assessment.
In addition to a carefully documented history of presenting limb complaints, it is important to record details of
cardiovascular risk factors, drug history, and previous vascular and endovascular revascularization procedures and
amputations.230,231 Assessment of frailty, functional status, and HRQL is also important.232,233
Physical examination
All patients with suspected CLTI should undergo a complete physical examination.234,235 Palpation of lower limb pulses
can help determine the likely presence and distribution of arterial disease.236-240 Although they can be nonspecific,
features such as coolness, dry skin, muscle atrophy, hair loss, and dystrophic toenails are frequently observed in patients
with PAD. Buerger sign, pallor of the foot on elevation and rubor (so-called sunset foot) on dependency, is usually
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present in CLTI. The capillary refill time will usually exceed 5 seconds, especially when the patient is lying supine or the
leg is elevated.239 It is important not to examine the patient with suspected CLTI sitting in a chair with the leg hanging
down as that may lead to false reassurance regarding the perfusion of the foot.
Many patients with CLTI, especially those with DM, have “glove and stocking”239 sensory, motor, and autonomic
neuropathy that may be asymptomatic or be associated with tingling, numbness, weakness, and burning pain in the feet
and ankles. The presence of such neuropathy is a major risk factor for tissue loss and should be carefully sought and
evaluated using monofilaments and, if available, a tuning fork (loss of vibration sense is an early feature).241-244
Neuropathy often leads to abnormal foot biomechanics and deformity, and neuropathic (neuroischemic) ulcers often
occur at sites of abnormal pressure (load bearing). In patients with suspected CLTI who have a foot ulcer, a probe-to-
bone test should be performed to assess depth and the probability of underlying osteomyelitis.245,246
Noninvasive hemodynamic tests
AP and ABI
Measurement of AP and calculation of ABI (highest AP divided by highest brachial systolic pressure) is recommended as
the first-line noninvasive hemodynamic test in all patients with suspected CLTI (Fig 3.1).19 Although many patients with
CLTI will have an AP <50 mm Hg or a markedly reduced ABI (typically <0.4), an increasing proportion will not,
especially those with DM and CKD, who may have incompressible crural arteries. ABI results should be reported as
noncompressible if the value is >1.4. However, it is important to be aware that incompressibility can lead to artifactually
elevated readings between 0.4 and 1.4.247-249 This should be suspected when the ABI falls in or near the normal range
but is associated with dampened, monophasic waveforms (recognized acoustically or visually on a screen).23 These
falsely normal APs and ABI values have been reported to be an independent predictor of major amputation.250 In such
patients, TP and toe-brachial index (TBI) or other hemodynamic measurements, as described next, should always be
obtained.251
TP and TBI
TP is measured using an appropriately sized mini-cuff typically placed around the base of the great toe and attached to a
standard manometer. A photoplethysmographic or continuous-wave Doppler flow detector is then used to determine
when flow returns while the inflated cuff is slowly deflated. Various automated systems can be purchased. TPs are less
often affected by incompressibility and, if possible, should be measured whenever falsely elevated APs or ABIs are
detected or suspected, particularly when such values are nonconcordant with acoustic or visual waveform analysis.
Studies have suggested that TP is more sensitive than AP in the diagnosis of CLTI and more predictive of amputation
risk.21,22 Systolic TPs are generally 20 to 40 mm Hg lower than APs. TBIs <0.7 are considered abnormal and TPs <30
mm Hg are typically associated with advanced ischemia.22,230,252
Other methods for noninvasive diagnosis of CLTI
Alternative noninvasive testing methods can also be used to assist in the diagnosis of CLTI (Table 3.1). Whereas each
method has its own advantages and limitations, depending on local availability and expertise, they can be used to
augment APs and TPs and indices. Segmental pressures can provide information on anatomic localization of lower
limb vascular disease in patients with CLTI but are used infrequently today, at least in HICs. Several other noninvasive
tests, including laser Doppler flowmetry, TcPo2, skin perfusion pressure, and plethysmography, have been used to
evaluate limb perfusion.16,253 However, these tests can be influenced by a variety of confounding factors and are not
used routinely in most vascular laboratories around the world.
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Table 3.1
Comparison of methods of noninvasive testing in patients with chronic limb-threatening ischemia (CLTI)
Wound and tissue loss classification systems
A number of limb and wound classification systems have been developed to try to improve clinical decision-making and
clinical outcomes.254-256 The WIfI system10 is based on three key factors: wound, ischemia, and foot infection
(Tables 3.2-3.5). WIfI correlates with limb salvage, amputation risk, and wound healing and can identify patients who
are likely to benefit from revascularization.68,69
Table 3.2
Wound grading in Wound, Ischemia, and foot Infection (WIfI) classification
Table 3.3
Ischemia grading in Wound, Ischemia, and foot Infection (WIfI) classification
Table 3.4
Foot infection grading in Wound, Ischemia, and foot Infection (WIfI) classification
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Table 3.5
Clinical stages of major limb amputation risk based on Wound, Ischemia, and foot Infection (WIfI) classification
A limb-staging classification system, such as WIfI, should be used in all patients presenting with suspected CLTI
(Tables 3.2-3.5). Limb staging should be repeated after vascular intervention, foot surgery, or treatment of infection and
whenever there is suspected clinical deterioration.
Imaging of vascular anatomy
Vascular imaging should be performed in all patients with suspected CLTI (Table 3.6) to determine the presence, extent,
and severity of arterial disease and to help inform decisions about revascularization. Although there have been huge
advances in imaging techniques in recent years, access to these latest modalities, and so practice, varies considerably
between and even within countries.
Table 3.6
Comparison of different imaging modalities for patients with chronic limb-threatening ischemia (CLTI)
In patients with CLTI who are candidates for revascularization (Section 6), imaging should allow complete anatomic
staging using, for example, GLASS (Section 5). Adequate imaging of the tibial and pedal vessels is of critical
importance, particularly in planning intervention in patients with tissue loss. History and physical examination often help
guide the optimal imaging approach. For those with tibial disease, particularly in the setting of tissue loss, computed
tomography angiography (CTA) and magnetic resonance angiography (MRA) may offer useful information but may fail
to completely image the ankle and foot vessels with sufficient resolution for procedural planning. Many vascular
specialists believe that digital subtraction angiography (DSA) remains the “gold standard.” CTA offers more precise
quantification of arterial calcification compared with MRA and DSA. Selective intra-arterial dual-energy CTA combines
the low contrast material dose of conventional angiography with computed tomography; if it is available, it may allow
crural artery visualization in patients with renal insufficiency.257 This technology is in evolution and not routinely
available.
Duplex ultrasound imaging (DUS)
DUS imaging is usually the first imaging modality of choice and in some health care settings may be the only modality
available. DUS provides information on the anatomic location and extent of disease as well as information about flow
volume and velocity.258,259 There may be difficulty in directly imaging the AI segments because of body habitus, bowel
gas, and movement. However, the presence of “inflow” disease can often be inferred from common femoral artery (CFA)
waveforms. In the IP arterial segments, assessment can be technically challenging, particularly when vessel calcification
and overlying tissue loss are present. Some vascular specialists advocate the use of ultrasound contrast agents to improve
visualization; however, clinical studies to date are limited.260 Although multiple studies have shown DUS to be inferior
to other imaging techniques, such as DSA, it offers many advantages as a first-line imaging modality, including its
noninvasive nature, low cost, no iodinated contrast media, no ionizing radiation, and no fixed installation
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(mobility).25,261,262 The main disadvantages of DUS are that it is time-consuming and highly operator dependent, and it
does not produce a continuous lesion map. DUS is also poor at estimating collateral blood supply and reserve.
Furthermore, the stored images can be difficult to interpret at a later point in time.
CTA
In recent years, CTA has advanced considerably in terms of accuracy and acquisition times. Modern CTA quickly
generates high-resolution, contrast-enhanced images that can be viewed in multiple planes or as three-dimensional
reconstructions.26,263-265 In a meta-analysis comparing CTA with DSA that predominantly included patients with IC,
CTA was found to have high sensitivity and specificity in the AI (95% and 96%, respectively) and FP (97% and 94%)
segments but was somewhat inferior in the IP segment (95% and 91%).29 The researchers highlighted the difficulties
encountered with blooming artifact in calcified arteries (where motion-related artifact causes calcium deposits to appear
larger than they truly are), which would probably result in lowered accuracy of this modality in the CLTI population,
particularly in the IP segment. As such, in many centers, CTA is primarily used to image and plan intervention in AI and
FP segments.266
Contrast-induced nephropathy can be a significant problem,57,267,268 and patients with pre-existing renal insufficiency
are at particular risk.269 Various guidelines have been written,270,271 and many hospitals have local operating policies to
try to mitigate the risks. Unfortunately, practices vary considerably, making it impossible to identify firm
recommendations, outside of recognizing the risk. Finally, CTA is associated with significant doses of ionizing
radiation.26,272
MRA
MRA has the potential to produce images that are comparable in quality to DSA images but without exposure to ionizing
radiation or iodinated contrast material, making contrast-induced nephropathy extremely rare.27-29,57,263-269,272-276
Time-resolved techniques can accurately image flow patterns, which can be helpful in assessing IP runoff. In a meta-
analysis, MRA also showed improved specificity and sensitivity over CTA and DUS.276 Whereas conventional time-of-
flight MRA sequences may overestimate the degree of arterial stenosis, newer techniques suggest that noncontrast-
enhanced MRA remains an excellent imaging modality for patients with CLTI, accurately assessing distal lower
extremity vessels.277 However, failure of MRA to visualize vessel wall calcification may underestimate the difficulty of
surgical and endovascular revascularization. Contrast-enhanced MRA (CE-MRA) using gadolinium-based contrast
agents is generally preferred because of the high contrast to noise ratio, better spatial resolution, more rapid acquisition,
and less artifact. Time-resolved MRA is particularly useful in imaging of IP disease.274 Finally, MRA produces a three-
dimensional map of the overall arterial tree, with the possibility of additional accurate mapping of the IP and foot vessels
in more specialized centers. Other challenges of MRA include the potential overestimation of stenoses, problems
visualizing in-stent restenosis, compatibility with implanted devices such as pacemakers and defibrillators, longer image
acquisition times, and image artifact. Patients often have a lower tolerance for MRA than for CTA because of
claustrophobia. Accurate interpretation of the images by a dedicated subspecialist, such as a vascular radiologist, is
essential in aiding revascularization strategies. MRA equipment is expensive, although it can be used for other
nonvascular magnetic resonance-based investigations. Thus, in some developing and developed countries, access to
MRA and to dedicated subspecialists who are available to interpret the images is scarce.229 Finally, gadolinium contrast
enhancement has been associated with cases of nephrogenic systemic fibrosis, primarily in individuals with an estimated
glomerular filtration rate of <30 mL/min/1.73 m2.278
Foot MRA
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CLTI patients have a high incidence of IP and pedal artery disease. The precise location, length, and severity of disease
as well as the patency of runoff vessels should ideally be delineated before revascularization planning. In highly
specialized centers, compared with DSA, foot CE-MRA yielded a sensitivity of 92% for the detection of significant
disease in IP and pedal vessels.279 Magnetic resonance perfusion imaging may have a role in assessing overall foot
perfusion before and after intervention.280,281 As for limitations of foot CE-MRA, in slow-flow states, there may be
significant venous overlay obscuring arterial anatomy, and the availability of the modality is limited.
In summary, MRA is still an evolving technology with new contrast-enhanced and noncontrast-enhanced sequences
being reported in the literature. Time will tell whether these advances will overcome some of the current limitations.
However, access to the most modern imaging techniques is highly variable around the world.
Catheter DSA
With the advent of DUS, CTA, and MRA, diagnostic DSA is probably performed less commonly now, but many vascular
specialists still consider it the gold standard imaging modality in patients with suspected CLTI, particularly when IP
disease is likely to be present.282 Enthusiasts for DSA will also point out that it allows intervention at the same setting.
Other vascular specialists, however, argue that diagnostic DSA is outdated. The DSA technique should minimize the
amount of iodinated contrast material and the dose of ionizing radiation used while maximizing imaging of the distal
vasculature.268,283-285 In general, diagnostic DSA is widely available, and the complication rate is low.283,286
CO2 angiography
CO2 angiography can be used in patients with an allergy to contrast material or in individuals with severe CKD;
unfortunately, it frequently causes significant discomfort of the patient. CO2 angiography is generally considered inferior
to iodinated angiography but can still provide useful diagnostic images. There is a general trend of imaging performance
progressively degrading down the leg.287 Power injectors may improve safety and quality.
Perfusion angiography
This is a new technique performed with use of a dedicated imaging suite and workstation to provide time-resolved
perfusion imaging of the foot to aid in the diagnosis and impact of revascularization techniques. Perfusion angiography
provides quantifiable information of the functional status of foot perfusion and is a positive step toward functional
imaging of the foot.288
Summary
All patients presenting with CLTI should have a full history and physical examination followed by noninvasive
hemodynamic testing. These studies can be easily performed in most centers around the world. The authors recommend
that all patients undergo limb staging by a classification system, such as WIfI, that integrates multiple key elements (eg,
wound, ischemia, infection) and correlates with the risk of amputation and the likelihood of wound healing. The next
step in appropriate candidates (Section 6) is to obtain high-quality diagnostic images to guide revascularization. This will
depend heavily on the availability of equipment and local expertise (Fig 3.2). Where it is available, DUS is the preferred
first noninvasive imaging modality. However, for more complete noninvasive anatomic imaging, either MRA or CTA can
be considered.
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Fig 3.2
Suggested algorithm for anatomic imaging in patients with chronic limb-threatening ischemia (CLTI) who are candidates
for revascularization. In some cases, it may be appropriate to proceed directly to angiographic imaging (computed
tomography angiography [CTA], magnetic resonance angiography [MRA], or catheter) rather than to duplex ultrasound
(DUS) imaging.
Catheter DSA represents the gold standard imaging technique, especially below the knee. In many centers, however,
DSA is typically used only when MRA or CTA is not available, when MRA or CTA imaging is suboptimal and fails to
adequately define the arterial anatomy, or for those patients expected to proceed to endovascular intervention. No patient
with suspected CLTI who is a suitable candidate for limb salvage should be denied revascularization without first
undergoing complete diagnostic angiography that includes the ankle and foot.
4 Medical management
CLTI is an end-stage manifestation of systemic atherosclerosis. It is frequently accompanied by clinically significant
CVD, resulting in exceedingly high mortality from stroke and myocardial infarction. In the absence of aggressive
identification and treatment of risk factors and associated comorbid conditions, the prognosis of CLTI is usually poor,
with a mortality rate of 20% to 26% within 1 year of diagnosis.5,30,154,213,219,220,230,289
In a study of 574 patients with CLTI who did not undergo revascularization after 2 years, 31.6% had died, primarily of
CVD, and 23% required major amputation.290
The goal of treatment of patients with CLTI is not only to salvage a functional limb but to reduce cardiovascular
morbidity and mortality through aggressive risk factor modification and best medical therapy.31,32,224 Whereas certain
risk factors, such as age and sex, cannot be modified, others can, including hyperlipidemia, hypertension, diabetes,
smoking, and sedentary lifestyle.
Antithrombotic therapy
Antiplatelet agents are strongly recommended for all patients with symptomatic PAD to reduce the risk of major adverse
cardiovascular events (MACE).33,34,291 The Antithrombotic Trialists’ Collaboration performed a meta-analysis of
antiplatelet agent trials before 1997.33 It included 135,000 patients with cerebrovascular disease, coronary disease, or
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PAD (IC) who were treated with antiplatelet agents and 77,000 control patients. The antiplatelet therapy group had a
22% reduction in MACEs, and 75 to 150 mg of aspirin per day was as effective as higher doses but with a lower risk of
bleeding.33 A more recent meta-analysis studied the specific benefit of aspirin in 16 secondary prevention trials
comprising 17,000 patients.34 This study confirmed the benefit of antiplatelet agents with an 18.2% reduction in MACEs
in both men and women. The Critical Leg Ischaemia Prevention Study (CLIPS) group compared the benefit of 100 mg of
aspirin per day in 185 patients with symptoms of PAD and an ABI <0.85 or a TBI <0.6 with placebo and reported a 64%
risk reduction in vascular events compared with a 24% reduction in the placebo group.291
However, there is a growing body of literature indicating that alternatives to aspirin, such as ticlopidine, dipyridamole,
and clopidogrel, may be more effective.35,292-294 The Clopidogrel versus Aspirin in Patients at Risk for Ischaemic
Events (CAPRIE) trial, although not specifically designed to address CLTI, compared 75 mg of clopidogrel per day with
325 mg of aspirin per day in patients with PAD. Researchers noted an 8.7% decrease in MACEs with clopidogrel
compared with aspirin. There was no significant difference in bleeding risks between the two agents.35
Other antiplatelet agents, such as ticagrelor and vorapaxar, have also been shown to reduce MACEs in patients with
PAD.292-294 However, benefit over clopidogrel has not been demonstrated.36,294-298 The Examining Use of Ticagrelor in
Peripheral Artery Disease (EUCLID) trial compared ticagrelor with clopidogrel in 13,885 patients with symptomatic
PAD and an ABI ≤0.8.36 Although both drugs had a similar safety profile, ticagrelor was not superior to clopidogrel. The
Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients with Atherosclerosis-
Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50) examined the effects of the protease-activated receptor 1
antagonist vorapaxar on secondary prevention of ischemia events in patients with stable atherosclerosis, including
symptomatic PAD.295 Acute limb ischemia, a prespecified study end point, was reduced by 41% among the PAD
cohort.298 However, vorapaxar has been associated with an increase in intracranial hemorrhage in patients who have had
a prior stroke or transient ischemic attack.296 In a meta-analysis, vorapaxar added to aspirin yielded little improvement in
the reduction of MACEs in patients with atherosclerosis and was associated with a slightly higher incidence of
intracranial hemorrhage.294 Finally, a meta-analysis that reviewed the use of ticagrelor, ticlopidine, aspirin, cilostazol,
picotamide, vorapaxar, and clopidogrel as single antiplatelet therapy or dual antiplatelet therapy (DAPT) in patients with
PAD found that clopidogrel monotherapy resulted in the best overall safety and efficacy (reduction of MACEs).297
The long-term use of DAPT or systemic anticoagulation with vitamin K antagonists is not indicated for PAD.299,300 The
role of direct oral anticoagulants is currently the subject of intense investigation. The Cardiovascular Outcomes for
People Using Anticoagulation Strategies (COMPASS) trial, a multicenter randomized trial of 7470 individuals with
stable, mild to moderate PAD, found that low-dose rivaroxaban (an oral factor Xa inhibitor) in combination with aspirin
reduced MACEs (death, myocardial infarction, or stroke) and major adverse limb events (MALEs) compared with
aspirin alone.37 Patients who had previous lower extremity revascularization, amputation, or history of IC and ABI
of <0.9 and documented peripheral stenosis of >50% or carotid stenosis of >50% were included in the study. Overall,
8.5% of study patients had an ABI of <0.7. In this population, there was a significant reduction in MALEs, major
amputation, and acute limb ischemia compared with aspirin alone.301 This drug combination was associated with a small
but statistically significant increase in clinically relevant bleeding. Whereas the study results are promising, the benefits
and risks of the low-dose rivaroxaban and low-dose aspirin combination in patients with CLTI have not yet been
adequately defined. In addition, this drug combination is not globally available at this time.
The ongoing VOYAGER trial (ClinicalTrials.gov identifier NCT02504216) is comparing the same two antithrombotic
regimens in PAD patients undergoing peripheral revascularization.302
Lipid-lowering therapy
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The Heart Protection Study (HPS) evaluated the effect of blood lipid lowering on cardiovascular events in PAD and
included patients with CLTI.40 Other studies, although similar, limited inclusion to patients with IC.41 The HPS included
20,536 high-risk individuals with a total cholesterol concentration of at least 135 mg/dL (3.5 mmol/L). The participants
were randomized to 40 mg/d of simvastatin or a placebo. In the simvastatin group, there was a 25% (95% CI, 16%-33%)
relative risk (RR) reduction in the first major vascular event among patients who had no history of a coronary event at
baseline.40 In addition, lipid lowering was shown to be most effective in patients with a blood cholesterol concentration
>135 mg/dL (> 3.5 mmol/L). There was also a significant reduction in cardiovascular events (P < .0001) among a
subgroup of individuals with PAD.
A Cochrane review evaluated 18 lipid-lowering trials comprising 10,049 PAD patients.39,42 Whereas the majority had IC
and only some trials included CLTI, the results appear relevant to the CLTI population. Only one study showed a
negative effect of lipid lowering. When this study was excluded, analysis showed that lipid-lowering therapy
significantly reduced the risk of total cardiovascular events in PAD (OR, 0.74; CI, 0.55-0.98).42 This was primarily due
to a positive effect on total coronary events (OR, 0.76; CI, 0.67-0.87).
The impact of statin agents may extend beyond their lipid-lowering effect by reducing inflammation in patients with
PAD.303,304 An individual-patient data meta-analysis of 54 prospective cohort studies demonstrated that inflammatory
biomarkers independently predict vascular risk with a magnitude of effect at least as large as that of blood pressure or
cholesterol.305 Even after adjustment for age, sex, and traditional risk factors, patients with PAD are known to have
increased levels of inflammatory cytokines, acute phase reactants, and soluble adhesion molecules.306 However,
although the attributable vascular risk associated with inflammation is large and animal models using targeted anti-
inflammatory therapies have shown promise, it remains unknown whether inhibiting inflammation alone will lower
vascular event rates.
The landmark Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) examined the use of intensive statin therapy (rosuvastatin 20 mg daily vs placebo) in a primary prevention
trial.307,308 In total, there were 17,802 individuals who had low levels of LDL-C but an elevated vascular risk based on a
proinflammatory biomarker (high levels of high-sensitivity C-reactive protein). Investigators demonstrated a 44%
reduction in major vascular events, including a 54% reduction in myocardial infarction, a 48% reduction in stroke, a 46%
reduction in arterial revascularization, a 43% reduction in deep venous thrombosis or pulmonary embolism, and a 20%
reduction in mortality. The greatest absolute risk and the greatest absolute risk reduction were observed among those
with the highest levels of high-sensitivity C-reactive protein. There are now multiple studies showing a decrease in
cardiovascular events in patients with established atherosclerosis treated with intensive statin therapy.43,224,309,310 A
large retrospective cohort study from the U.S. Veterans Affairs population demonstrated reduced mortality and major
amputation rates among patients with established PAD receiving intensive-dose statins.311 Statin therapy can be
associated with muscle aching, the most common adverse effect limiting its use. In the setting of this complication, statin
dose can be lowered to the maximum tolerated dose, and a second nonstatin cholesterol-lowering drug can be added to
reduce cholesterol levels even further.
Recent (2013, 2018) American College of Cardiology/American Heart Association guidelines on treatment of blood
cholesterol recommend the use of moderate- to high-intensity statins for all individuals with established atherosclerotic
CVD including PAD.312,313 Both rosuvastatin (20-40 mg) and atorvastatin (40-80 mg) have been shown to be
effective.310 The 2018 guideline describes “very high risk” individuals to include those with symptomatic PAD and at
least one other high-risk condition (age ≥65 years, familial hypercholesterolemia, history of coronary revascularization,
DM, hypertension, CKD, current smoking, congestive heart failure)—a categorization that applies to the overwhelming
majority of patients with CLTI. For this population, high-intensity/maximally tolerated statin dosing is recommended,
and if on-treatment LDL-C levels remain ≥70 mg/dL (1.8 mmol/L), the addition of ezetimibe is considered
reasonable.313
New lipid-lowering agents have entered the armamentarium. Proprotein convertase subtilisin/kexin type 9 (PCSK9)
directs the degradation of LDL receptors in the liver and has become a drug target. The Further Cardiovascular Outcomes
Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) RCT demonstrated an additional benefit of
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evolocumab (a PCSK9 inhibitor) in reducing MACEs in PAD patients already receiving statin therapy.314 The composite
end point of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina, or coronary
revascularization was statistically reduced in PAD patients treated with the PCSK9 inhibitor evolocumab (hazard ratio
[HR], 0.79; P = .0040). There was also a reduction in the risk of MALEs, including acute limb ischemia and major
amputation. Further studies will be needed in PAD subpopulations including CLTI.
Further studies of these agents are desirable in high-risk PAD subpopulations including CLTI.
Management of hypertension
It is universally accepted that control of hypertension reduces MACEs in patients with PAD. The International
Verapamil-SR/Trandolapril Study (INVEST) analyzed the impact of control of hypertension on all-cause death, nonfatal
myocardial infarction, and nonfatal stroke in 22,576 hypertensive patients with stable coronary artery disease (CAD), of
whom 2699 also had PAD.46 PAD patients had a significantly higher incidence of sustaining a primary end point MACE
compared with those without PAD (16.3% vs 9.2%). In addition, among those with PAD, a MACE was less likely to
occur in patients with systolic blood pressure <145 mm Hg and diastolic pressures <90 mm Hg. Further reduction of
blood pressure to below 130 mm Hg systolic and 80 mm Hg diastolic provides even greater protection from
cardiovascular events.48 The Systolic Blood Pressure Intervention Trial (SPRINT) compared blood pressure control with
a systolic pressure of 120 mm Hg (intensive control) or 140 mm Hg (standard control) in 2510 patients with a mean age
of 79.9 years observed for a mean of 3.14 years.315 The study documented a significantly lower incidence of composite
cardiovascular events of death with intensive control. However, intensive blood pressure control may result in greater
morbidity associated with periods of clinically significant hypotension.45,47 Optimal blood pressure control for patients
with CLTI has not been established, and although maintaining systolic pressure <140 mm Hg and diastolic pressure <90
mm Hg is important, lower pressures may be beneficial to further reduce MACEs.
The first-line category of oral antihypertensive does not appear to be of significance. Angiotensin-converting enzyme
inhibitors (ACEIs), calcium channel blockers, and diuretics, when successful in lowering blood pressure to target, reduce
cardiovascular events to a similar extent.316,317 Although the Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET) and Heart Outcomes Prevention Evaluation (HOPE) study suggested that
in the absence of heart failure, monotherapy with an ACEI (ramipril) reduces the rate of MACEs in high-risk patients,
there is recent evidence to suggest that this class of drug may result in a higher amputation rate for patients with CLTI.318
In an analysis of the Medicare database for 2007 to 2008, there were 22,954 patients who underwent lower extremity
revascularization. Of these, 64.6% were treated for CLTI. Compared with those not taking an ACEI, patients who
presented with rest pain and were taking an ACEI after the index procedure had a higher risk of amputation. Other
studies have not noted an increased risk of amputation associated with ACEIs but have suggested an increased rate of
reintervention. A propensity score-matched cohort study of 17,495 Danish patients compared those receiving ACEIs with
those who were not after vascular reconstruction. Observed for a mean of 1.6 years, the patients treated with ACEIs had
a lower all-cause mortality (20.4% vs 24.9%) but underwent more reintervention (24% vs 23.1%).319 Using the same
general methodology, these investigators found that the use of beta blockers after primary vascular reconstruction was
associated with a decrease in the incidence of major amputation but a higher rate of myocardial infarction and stroke
without an increase in all-cause mortality.320
Globally, adequate control of hypertension remains a significant challenge. In LMICs, the availability of oral
antihypertensives is limited and costs are high, resulting in poor overall blood pressure control. Strategies are urgently
required to improve availability and affordability of drugs so that vascular specialists can treat their patients to target.321
There have been concerns that drugs reducing heart rate and blood pressure will worsen ischemia in patients with PAD.
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
Page 29 of 203
Although beta blockade has not been directly evaluated in CLTI, it has been the subject of several clinical trials in IC and
has been shown to be effective in lowering blood pressure without worsening symptoms.322,323
Management of diabetes
Type 2 DM is a significant risk factor for PAD,324,325 and the extent of vascular disease appears related to the duration
and severity of hyperglycemia. Glycemic control is therefore essential in all diabetic patients with PAD. Metformin
monotherapy is generally recognized as the best initial oral hypoglycemic agent. When additional therapy is needed, any
other class of oral hypoglycemic agent, including sulfonylurea, thiazolidinedione, dipeptidyl peptidase 4 inhibitor, or α-
glucosidase, can be added with equal effectiveness.54
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a newer class of agents that have been associated with
beneficial effects on cardiovascular complications, renal disease, and mortality in type 2 diabetics. However, one large
trial (10,142 subjects) demonstrated an approximately 2-fold increased risk of lower limb amputations associated with
the use of canaglifozin, an SGLT-2 inhibitor, prompting a “black-box” warning.326-328 The mechanism is unclear and
may be generically related to diuretic actions in this population.329 Caution is advised in the use of this agent in diabetic
patients with advanced PAD and/or CLTI.
Whereas there are some data to suggest that the dipeptidyl peptidase 4 inhibitors may reduce the risks of myocardial
infarction and stroke, the impact on PAD in patients with CLTI has not yet been defined.330 The goal for most adults
with DM is to maintain a glycosylated hemoglobin A1c level of <7% (equivalent to International Federation of Clinical
Chemistry units of 53 mmol/mol).49-52 However, less stringent goals (eg, hemoglobin A1c level <8%) may be
appropriate for individuals with advanced vascular complications or limited life expectancy.53
Type 2 DM patients with abnormal renal function treated with metformin may be at higher risk for contrast-induced
nephropathy and lactic acidosis. Whereas the matter is the subject of continued debate, it is reasonable to withhold
metformin for 24 to 48 hours after the administration of an iodinated contrast agent.55-57,270,271
Lifestyle modifications
In addition to controlling risk factors as discussed, it is important to encourage CLTI patients to adopt a healthier
lifestyle. Stopping smoking (tobacco and other recreational drugs) completely and permanently, adopting a healthy diet
and weight control, and regular exercise must be stressed as extremely important for both life and limb.331,332
Tobacco
The adverse impact of tobacco use on cardiovascular health has been well established. Despite the use of best medical
therapy, male and female smokers (even those smoking 1-10 cigarettes per day) have a significantly higher rate of
disease progression and MACEs.58-60 Thus, all patients presenting with CLTI should be asked about smoking and
referred to a smoking cessation program if they are still smoking. To encourage compliance with advice to stop smoking,
patients should be challenged about smoking at every medical encounter.61,62 The safety of electronic cigarettes has not
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been established, including for patients with PAD, and until more evidence becomes available should not be considered
in patients with CLTI.333
Diet and exercise
Although diet and exercise have not been specifically evaluated in CLTI, there is compelling evidence that they affect the
progression of atherosclerosis. Diets that are high in carbohydrates and saturated fats are associated with a higher risk of
MACEs.334 A diet that reduces the intake of saturated fats and increases the intake of monounsaturated fats, omega-3
fatty acids, antioxidants, and other natural plant sterols and stanols is associated with a reduction in plaque burden and
MACEs.335-337 Patients should be encouraged to adopt a low-fat or Mediterranean diet.338 Unfortunately, fruits and
vegetables are not always available or affordable, especially in LMICs.339
Although CLTI studies are not available, numerous trials have confirmed the benefits of supervised exercise in IC.340
Exercise-based cardiac rehabilitation reduces the risk of subsequent myocardial infarction and cardiovascular
mortality.341 It therefore seems reasonable to suggest that a postrevascularization walking-based exercise program would
also benefit CLTI patients who are cleared for full weight-bearing.
Management of pain
Although pain is an important issue for most CLTI patients, it is often poorly managed. Poor pain control can reduce
HRQL levels to those seen in patients with terminal cancer and has a major adverse impact on functional capacity.
As no RCTs have been conducted in CLTI, good practice recommendations have to be extrapolated from other
conditions in which severe pain is a major factor. The management of ischemic pain in CLTI is often complicated by the
coexisting neuropathic pain, particularly in patients with DM. However, the management of neuropathic pain is not
covered here.
Guidelines usually recommend a tiered approach to pain management, with a “tradeoff” between benefits and harms (eg,
constipation, drowsiness).342,343 Patients should be offered paracetamol (acetaminophen) in combination with opioids
and in proportion to the severity of pain. All patients receiving opioids should also be offered laxatives and antinausea
medication. If the maximum tolerated analgesic dose does not produce adequate pain relief, alternative approaches
should be considered. These include tricyclic antidepressants, gabapentin, and pregabalin, all of which are used
effectively for neuropathic pain. However, if the clinician is unfamiliar with the use of these compounds, early referral to
a pain management service for patients with pain not controlled by opioids is required.
5 The Global Limb Anatomic Staging System (GLASS)
Rationale
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An accurate assessment of limb threat and stratification of the anatomic pattern of disease are the foundations of EBR.
This is true not only in everyday practice but also in outcomes assessment and research. The authors propose a new,
clinically oriented framework for classifying the pattern of arterial disease in CLTI. The GLASS is a fundamental
departure from current approaches used in PAD and more analogous to the SYNTAX system for CAD.344,345
Current PAD anatomic classification schemes either describe the location and severity of individual arterial lesions11,156
or quantify the overall burden and morphology of disease.12,151,170 Lesion- or segment-based grading systems are useful
for comparing endovascular device performance in well-defined clinical situations. They are not, however, useful for
defining EBR strategies in CLTI, especially given the complex, multilevel, and increasingly distal disease patterns
typically seen in current clinical practice.
Successful revascularization in CLTI, particularly in patients with tissue loss, nearly always requires restoration of
pulsatile in-line flow to the foot. Because individual lesion-based schemes correlate poorly with effective
revascularization in CLTI, vascular specialists must integrate approaches for arterial segments into a management
strategy for the whole limb. Factors that determine a successful anatomic outcome are intrinsically different for bypass
grafting and endovascular intervention. Bypass surgery requires adequate inflow and outflow and, perhaps most
important, a suitable autologous conduit. By contrast, the success of endovascular intervention is largely defined by the
complexity of atherosclerosis within the anticipated target arterial path (TAP) that provides in-line flow to the foot. When
the TAP includes multiple lesions in series, technical success and sustained patency for the limb as a whole must be
estimated as a product function of each lesion traversed.
GLASS is based on defining the TAP in each individual patient by high-quality imaging and requires selection of a
preferred infrapopliteal (IP) artery. The TAP is generally selected on the basis of the least diseased crural artery providing
runoff to the foot. It can also be selected on the basis of other relevant factors, such as angiosome preference or
avoidance of a previously instrumented vessel. Whereas the relationship between the pattern of occlusive disease,
patency of the chosen intervention, and clinical success in CLTI is a complex one, an integrated limb-based anatomic
staging system like GLASS is critical to define it. The preferred TAP for endovascular intervention and the preferred
target artery for open bypass surgery may not always be the same; clinical decision-making thus hinges on a comparative
estimate of risk and success for each. Like SYNTAX, GLASS stage is designed to correlate primarily with endovascular
outcomes. As such, it does not incorporate factors like venous conduit quality or distal runoff that are more directly
relevant for bypass grafting.
GLASS provides a basis for clinical practice and supports future research in CLTI. When it is combined with tools for
stratification of patient risk and severity of limb threat (Sections 1 and 3), GLASS facilitates the development of specific
evidence-based revascularization (EBR) guidelines in CLTI (Section 6). In developing GLASS, the writing group was
informed by a commissioned systematic review of revascularization outcomes in CLTI and expert opinion. Still, the
authors acknowledge that the new grading system requires prospective validation in a variety of patient populations and
health care environments. The system is expected to undergo revisions as outcomes are reported. Important factors for
refinement include the current state of limited high-quality evidence in the field, ongoing changes in both epidemiology
and technology, and differences in disease patterns and practice around the world.
Assumptions and approach
As CLTI is usually the result of complex multilevel occlusive disease, certain simplifying assumptions are required to
develop a usable anatomic staging system (Table 5.1). First, because existing schemes for AI disease appear adequate,
the focus of GLASS is on infrainguinal disease (a simplified inflow disease scheme is presented in Table 5.2). In
GLASS, the CFA and PFA are seen as inflow arteries, and the infrainguinal system begins at the origin of the SFA. This
is justified by the distinct approaches used in the treatment of CFA and PFA disease (Section 6) and long-term results that
are similar to those for AI interventions.
Table 5.1
Key definitions and assumptions in the Global Limb Anatomic Staging System (GLASS)
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Table 5.2
Aorto-iliac (inflow) disease staging in GLASS
For GLASS to be useful in everyday clinical practice and to form the basis of practice-changing research, it is important
that it does not rely on complex methods of lesion characterization. With regard to vessel calcification, GLASS adopts a
dichotomous subjective scale in which severe calcification (eg, >50% of circumference; diffuse, bulky, or “coral reef”
plaques) increases the within-segment grade by one numeric level. This is a subjective determination made by the
treating physician that the severity of calcification significantly increases technical complexity (and expected technical
failure rates) for endovascular intervention. Alternative approaches for quantifying arterial calcification in PAD have
been suggested but are more complex, and none of these has been validated for discriminating clinical outcomes.346,347
With regard to IM disease, GLASS employs a three-level modifier (Fig 5.1) to describe the status of arteries crossing the
ankle (including the terminal divisions of the peroneal artery) and the pedal arch. Currently, the IM disease modifier is
not considered within the primary assignment of limb stages in GLASS, given the absence of strong evidence on how it
affects treatment outcomes. It should, however, be captured in future studies to better define how to incorporate pedal
outflow disease into anatomic staging in CLTI.
Fig 5.1
Inframalleolar (IM)/pedal disease descriptor in Global Limb Anatomic Staging System (GLASS).
GLASS also makes the following assumptions:
•
Restoring durable (pulsatile) in-line flow to the affected part, particularly in patients with tissue loss, is a primary
goal of revascularization in CLTI.
•
Using high-quality imaging (Section 3), the vascular specialist chooses and defines a TAP that is most likely to
achieve that in-line flow.
•
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The TAP will usually involve the least diseased IP artery.
•
Other IP arteries (not selected for the TAP) are equally diseased or more so.
In addition, although it is an important research question, the current version of GLASS does not consider multivessel IP
revascularization because evidence of its role is still lacking. Where the clinician is considering such revascularization,
GLASS staging is based on the primary IP target, as defined by the clinician before the intervention.
In defining infrainguinal anatomic stages (I-III), GLASS combines grades (0-4) for the FP (origin of the SFA to the
origin of the anterior tibial [AT] artery; Fig 5.2) and IP (origin of the tibioperoneal trunk and the AT artery to the
malleoli; Fig 5.3) segments in series. Stages were developed to correlate with estimated LBP, defined as maintenance of
in-line flow through the entire length of the TAP, from the SFA origin to the malleoli. LBP is considered to be lost when
any one of the following occurs:
1.
Anatomic failure: occlusion, critical stenosis, or reintervention affecting any portion of the defined TAP; or
2.
Hemodynamic failure: a significant drop in ABI (≥0.15) or TBI (≥0.10), or identification of ≥50% stenosis in the
TAP, in the presence of recurrent or unresolved clinical symptoms (eg, rest pain, worsening or persistent tissue
loss).
Fig 5.2
Femoropopliteal (FP) disease grading in Global Limb Anatomic Staging System (GLASS). Trifurcation is defined as the
termination of the popliteal artery at the confluence of the anterior tibial (AT) artery and tibioperoneal trunk. CFA,
Common femoral artery; CTO, chronic total occlusion; DFA, deep femoral artery; Pop, popliteal; SFA, superficial
femoral artery.
Fig 5.3
Infrapopliteal (IP) disease grading in Global Limb Anatomic Staging System (GLASS). AT, Anterior tibial; CTO, chronic
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total occlusion; TP, tibioperoneal.
LBP is an important new concept allowing more direct comparison between revascularization approaches in CLTI.
Estimating LBP after surgical or endovascular intervention is central to the development of EBR (Section 6). The writing
group defined three GLASS stages based on the likelihood of immediate technical failure (ITF)347 and 1-year LBP after
endovascular intervention of the selected TAP. GLASS stages for the limb thus reflect a gradient of infrainguinal disease
complexity:
•
Stage I: low-complexity disease: expected ITF < 10% and 1-year LBP > 70%
•
Stage II: intermediate-complexity disease: expected ITF < 20% and 1-year LBP 50% to 70%
•
Stage III: high-complexity disease: expected ITF > 20%; or 1-year LBP < 50%
Consensus process and assignment of limb stages
To assign GLASS stages (I-III) in the two-dimensional matrix shown in Table 5.3, a multinational, multispecialty group
of vascular specialists (GVG writing group and invited external experts) as well as evidence summaries7 and other
published material79,160,348-404 were surveyed. Representative examples of GLASS stage I to stage III disease are
illustrated in the angiograms depicted in Figs 5.4 to 5.6. Table 5.4 provides a descriptive summary of the three GLASS
stages.
Table 5.3
Assignment of Global Limb Anatomic Staging System (GLASS) Stage
Fig 5.4
Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage I disease patterns. The target
arterial path (TAP) is outlined in yellow. Left panel, TAP includes the anterior tibial (AT) artery. Femoropopliteal (FP)
grade is 0. Infrapopliteal (IP) grade is 2 (3-cm chronic total occlusion; chronic total occlusion of AT artery and total
length of disease <10 cm). Right panel, TAP includes the peroneal artery. FP grade is 2 (chronic total occlusion <10 cm;
total length of disease <⅔). IP grade is 0.
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Fig 5.5
Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage II disease patterns. The target
arterial path (TAP) is outlined in yellow. Left panel, TAP includes the anterior tibial (AT) artery. Femoropopliteal (FP)
grade is 1 (superficial femoral artery [SFA] occlusion <5 cm). Infrapopliteal (IP) grade is 2 (two focal stenoses of AT
artery, total length <10 cm). Right panel, TAP includes the peroneal artery. FP grade is 0 (no significant stenosis). IP
grade is 3 (chronic total occlusion of peroneal artery, 3-10 cm).
Fig 5.6
Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage III disease patterns. The target
arterial path (TAP) is outlined in yellow. Left panel, TAP includes the peroneal artery. Femoropopliteal (FP) grade is 4
(superficial femoral artery [SFA] disease length, 10-20 cm; popliteal stenosis <5 cm; heavily calcified). Infrapopliteal
(IP) grade is 2 (stenosis of tibioperoneal trunk and proximal peroneal <10 cm). Right panel, TAP includes the anterior
tibial (AT) artery. FP grade is 4 (popliteal chronic total occlusion extending into trifurcation). IP grade is 3 (chronic total
occlusion of target artery origin).
Table 5.4
Descriptive summary of Global Limb Anatomic Staging System (GLASS) stages of infrainguinal arterial disease
Managing CLTI with GLASS
Use of the GLASS system involves the following steps (Fig 5.7):
1.
Obtain high-quality angiographic imaging to include the ankle and foot (Section 3).
2.
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Identify the TAP.
3.
Determine the FP GLASS grade (0-4) (Fig 5.2).
4.
Determine the IP GLASS grade (0-4) (Fig 5.3).
5.
Decide whether there is severe calcification (eg, >50% of circumference; diffuse, bulky, or coral reef plaques
likely to compromise endovascular outcomes) within the FP and IP segments of the TAP. If present, increase the
segment grade by one.
6.
Combine FP and IP grades to determine the overall GLASS stage (Table 5.3).
7.
Use the pedal modifier (P0, P1, or P2) to describe the status of IM arteries.
For the individual patient with CLTI, an EBR strategy (Section 6) is based on the full integration of
1.
estimated patient risk and long-term survival;
2.
severity of limb threat (eg, using WIfI) (Sections 1 and 3); and
3.
anatomic pattern and severity of disease in the affected limb (eg, GLASS).
Fig 5.7
Flow chart illustrating application of Global Limb Anatomic Staging System (GLASS) to stage infrainguinal disease
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pattern in chronic limb-threatening ischemia (CLTI). FP, Femoropopliteal; IP, infrapopliteal; PLAN, patient risk
estimation, limb staging, anatomic pattern of disease; TAP, target arterial path; WIfI, Wound, Ischemia, and foot
Infection.
Limitations and future direction
The authors acknowledge the limitations of the available data in developing this initial version of GLASS. Severe
calcification, particularly in the tibial arteries, is a negative predictor of technical success for intervention and signifies a
higher risk for amputation.405,406 However, a simplified and validated scoring system for calcification that is associated
with procedural outcomes is still lacking.346 At the same time, pedal artery disease appears to be increasing in both
prevalence and importance, particularly in CLTI patients experiencing major tissue loss or infection (WIfI stage
4).407,408
Pedal interventions remain relatively uncommon, and data on outcomes are extremely limited. Patients with no IM
revascularization target are placed in a high-risk subgroup, although they are assigned a simplified modifier (P2) in the
current version of GLASS. In the future, it is anticipated that better data will allow a more sophisticated incorporation of
calcification and pedal disease. Other important issues, including the benefits of revascularizing multiple IP arteries, the
relative quality of runoff distal to the revascularization and extending to the wound-related artery or angiosome, and the
complex relationship between hemodynamic and clinical success, also require further study.
In assigning GLASS stages, the authors assume that preprocedural decision-making is frequently driven by the
estimation of the anticipated technical and clinical success after endovascular intervention. As a result, the preferred TAP
for endovascular intervention and bypass surgery may not always be the same. Thus, treatment outcomes for surgical
bypass should also be reported and analyzed on the basis of the actual procedure performed, including inflow artery,
outflow artery, and conduit used.
6 Strategies for EBR
Effective revascularization is the cornerstone of limb salvage in CLTI. Although multiple techniques are available, there
are limited high-quality data to support EBR. A new, systematic paradigm is required to improve decision-making,
clinical outcomes, and cost-effectiveness.
To aid clinical decision-making in everyday practice and to facilitate future EBR research in CLTI, the authors propose a
three-step integrated approach (PLAN; Figs 6.1 and 6.2) based on
•
Patient risk estimation
•
Limb staging
•
ANatomic pattern of disease
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Fig 6.1
Paradigm for evidence-based revascularization (EBR) in the treatment of chronic limb-threatening ischemia (CLTI).
Patient risk, Limb severity, and ANatomic stage are integrated in the PLAN approach. WIfI, Wound, Ischemia, and foot
Infection.
Fig 6.2
PLAN framework of clinical decision-making in chronic limb-threatening ischemia (CLTI); infrainguinal disease. Refer
to Fig 6.4 for preferred revascularization strategy in standard-risk patients with available vein conduit, based on limb
stage at presentation and anatomic complexity. Approaches for patients lacking suitable vein are reviewed in the text.
GLASS, Global Limb Anatomic Staging System; WIfI, Wound, Ischemia, and foot Infection.
PLAN: Patient risk estimation
The first step involves assessing the patient for candidacy for limb salvage, periprocedural risk, and life expectancy.
CLTI is associated with advanced age, multiple comorbidities, and frailty. The goals of treatment include relief of pain,
healing of wounds, and preservation of a functional limb. However, revascularization may incur significant morbidity
and mortality, requiring multiple hospitalizations, prolonged outpatient care, and thus considerable health and social care
costs. Whereas the majority of patients with CLTI should be considered candidates for limb salvage, some may be
appropriately treated with primary amputation or palliation after shared decision-making. Patients, families, and
caregivers should have access to appropriate expertise in making these challenging decisions. Although maintenance of
independent ambulatory status is an important goal, predicting functional outcomes after revascularization may be
challenging, particularly in patients who are severely deconditioned. Palliative care consultants, where available, may be
a valuable resource to optimize symptom management in patients with limited goals of care.
Palliative therapy should rarely include revascularization except in special circumstances, such as
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•
treatment of hemodynamically significant inflow disease, if needed to improve the likelihood of a successful
amputation at the most distal possible level; and
•
relief of intractable pain or to improve wound healing after shared decision-making with the patient, family, and
vascular treatment team.
Estimation of operative risk and life expectancy plays a critical role in EBR. Tradeoffs between risk, invasiveness,
hemodynamic gain, and anatomic durability of the vascular intervention are commonly made in everyday practice. Risk
stratification tools can assist by providing objective criteria for such decisions. Multiple tools have been developed and
applied to the CLTI population (Table 6.1).63-67,225,409-412 End points modeled have included all-cause mortality, major
amputation, AFS, and perioperative events. The list of predictors identified in these models includes advanced age (>75
or 80 years), CKD, CAD, congestive heart failure, DM, smoking, cerebrovascular disease, tissue loss, BMI, dementia,
and functional status. Frailty, a recently identified functional measure, is also of clear importance in the CLTI
population.413,414 Patients with ESRD are at the highest risk in many reports and yet have been specifically excluded in
some CLTI studies.415,416 All of these tools have been developed retrospectively using data from patients who have
undergone revascularization, thereby excluding those who were managed conservatively or selected for primary
amputation. Whereas some were validated in external data sets of similar patients, none has been prospectively tested
across the spectrum of CLTI presenting for initial evaluation and treatment. As such, no specific tool and model can be
recommended in preference to others.
Table 6.1
Comparison of risk stratification tools for the chronic limb-threatening ischemia (CLTI) population
Specific recommendations about preoperative cardiac and anesthetic evaluation before limb revascularization are beyond
the scope of this document. The reader is referred to Section 4 and to other published guidelines.417,418
PLAN: Limb staging
CLTI patients present with a broad spectrum of disease severity. Staging of the limb is central to EBR (Section 3), and
use of the SVS Threatened Limb Classification System (WIfI) is recommended (Section 1).10,68-72,171 This is the only
system that fully integrates wound severity, ischemia, and infection to stage CLTI.
The severity of ischemia and the benefits of revascularization do not map in an exclusively concordant fashion with
amputation risk across the spectrum of CLTI, as expressed in the original WIfI consensus document.10 Expert opinion,
now supported by reports from institutional series,69,70,72 suggests that the presumed benefit of revascularization in
CLTI is linked to both the severity of ischemia and the degree of limb threat (Fig 6.3). All symptomatic patients who
have severe (eg, WIfI grade 3) ischemia should undergo attempted revascularization, presuming they are appropriate
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candidates for limb salvage.5 In settings of advanced tissue loss or infection (eg, WIfI stage 4 limbs), revascularization
may also be of benefit in the presence of moderate ischemia (eg, WIfI ischemia grades 1 and 2). Conversely, patients
with lesser degrees of tissue loss or infection (eg, WIfI stages 1 to 3) and mild to moderate ischemia are often
successfully treated with infection control and wound and podiatric care. Revascularization may be considered
selectively in these patients if their wounds fail to progress (or regress) despite appropriate limb care after 4 to 6 weeks
or if they have signs or symptoms of clinical deterioration. In such cases, all elements of the initial staging and treatment
plan, including treatment of underlying moderate ischemia, should be re-evaluated. Whenever possible, the limb should
be restaged after surgical drainage or débridement and after the infective component is stabilized. During the course of
treatment, periodic restaging of the limb is important in guiding subsequent decisions, particularly when there is lack of
progress in healing or any deterioration of symptoms.
Fig 6.3
The benefit of performing revascularization in chronic limb-threatening ischemia (CLTI) increases with degree of
ischemia and with the severity of limb threat (Wound, Ischemia, and foot Infection [WIfI] stage). WIfI stage 1 limbs do
not have advanced ischemia grades, denoted as not applicable (N/A).
WIfI also provides a useful and necessary tool through which one can compare and contrast the quality of different
revascularization strategies in CLTI. This has become an issue of critical importance as an ever-increasing array of
technologies and treatment strategies are being used. The magnitude and durability of increased perfusion required to
resolve the clinical situation, and to maintain satisfactory limb health (eg, preservation of a functional foot, freedom from
recurrent CLTI), will vary considerably across the spectrum. The extent of benefit for revascularization (Fig 6.3) is also
linked to anatomic durability of the selected intervention. These concepts are central to PLAN and to the development of
EBR strategies in CLTI.
PLAN: Anatomic pattern of disease (and conduit availability)
Although secondary to the broader context of patient risk and limb threat severity, the anatomic pattern of arterial
occlusive disease is a dominant consideration in EBR. The overall pattern and severity of disease in the limb (eg, as
described by GLASS; Section 4) help define the optimal strategy for vascular intervention. Furthermore, the availability
and quality of autologous vein conduit (especially the great saphenous vein [GSV]) are key considerations for bypass
surgery and should be defined before revascularization decisions are taken in average-risk patients.13,77,79
“No-option” anatomy
The majority of CLTI patients are anatomically suitable for revascularization, and establishing direct in-line flow to the
foot is the primary technical goal. One important exception is ischemic rest pain, for which correction of inflow disease
alone or treatment of FP disease even without continuous tibial runoff to the foot may provide relief of symptoms. This
may also be the case in patients presenting with minor degrees of tissue loss (eg, WIfI stage 2). Thus, the definition of a
no-option anatomic pattern of disease is dependent on clinical context. Lack of a target artery crossing the ankle and
absence of a suitable pedal or plantar artery target (eg, GLASS P2 modifier) may be considered no-option disease
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patterns in patients with advanced CLTI (eg, WIfI stages 3 and 4). Angiography may occasionally fail to detect a patent
distal artery target, and there are reports of successful tibial and pedal bypass grafting based on exploration of an artery
identified on Doppler ultrasound examination that was not identified on contrast arteriography.419,420 Careful selection
and experienced surgical judgment are required before proceeding to surgery in such instances.
EBR strategies in CLTI
The technical options for treating complex patterns of disease in a minimally invasive fashion have increased markedly
in recent years and led some to advocate an “endovascular-first” approach for most or all patients with CLTI, reserving
bypass surgery as a secondary option. However, existing evidence argues strongly for a selective revascularization
algorithm based on specific clinical and anatomic scenarios, as described here. Currently enrolling RCTs are eagerly
awaited to provide higher quality data in support of EBR in patients with CLTI.13-15
The Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL) trial (now called BASIL-1) remains the only
multicenter RCT to have directly compared an endovascular-first with a bypass surgery-first strategy in limb-threatening
ischemia due to infrainguinal disease.159,421 BASIL was conducted across 27 hospitals in the United Kingdom and
enrolled 452 participants between 1999 and 2004. All but six patients in the endovascular arm received plain balloon
angioplasty (PBA) alone; approximately 25% of the bypasses were prosthetic; around one-third of the procedures were
IP; and just more than 50% of patients were observed for >5 years. Considering the follow-up period as a whole, an
intention-to-treat analysis showed no significant difference between the two arms in terms of AFS and overall survival.
However, for the approximately 70% of patients who lived for >2 years, HRs for overall survival (0.65; P = .009) and
AFS (0.85; P = .108) were better for those treated initially with bypass surgery. An analysis by treatment received
showed that prosthetic bypasses performed very poorly (worse than PBA) and that patients having bypass after failed
PBA had a highly significantly worse AFS and overall survival compared with those patients who received bypass as
their first allocated treatment.160
A systematic review comparing open and endovascular treatments for CLTI found only nine studies meeting standard
criteria, three of which were RCTs (among which only BASIL met all of the study quality benchmarks).6 Researchers
concluded that low-quality evidence (due to heterogeneity and imprecision) suggested similar mortality and amputation
outcomes but better expected patency for bypass surgery. Other comparative reviews have yielded broadly similar
conclusions.227,422-425 OPGs for endovascular interventions in CLTI based on open surgical data from high-quality
sources have been suggested and provide minimum standards of safety and efficacy until direct comparative data become
available.162
To obtain updated data on outcomes after endovascular and open bypass surgery in CLTI, a review was conducted of
comparative studies and noncomparative studies that met more inclusive criteria.7 These criteria included prospective
study design, 50 or more patients with critical or severe limb ischemia (Rutherford class 4-6 definition), infrainguinal
procedure, minimum follow-up of 1 year, at least 50 procedures of each subtype (endovascular or open), and adequate
anatomic description of lesion location and types of subinterventions (eg, percutaneous transluminal angioplasty, stent,
atherectomy) employed. In total, 44 studies enrolling 8602 patients were reviewed in detail and results tabulated to
display outcomes across anatomic subsets and from 30 days to 5-year follow-up intervals. Most of the studies were
assessed as having moderate to high risk of bias, and the study quality was variable.
Review of the attributes of these studies revealed several notable limitations: few studies of SFA intervention were
included because of inadequate numbers of CLTI patients (vs those with IC); the majority of FP bypass studies included
prosthetic grafts; and although a good number of studies (20) addressed endovascular intervention for IP disease, the
severity of disease was generally mild to moderate (GLASS IP grades 1 and 2), with no studies including GLASS IP
grade 4 disease. Thus, the current state of evidence in CLTI remains severely limited, particularly for assessing
endovascular outcomes in commonly encountered, complex (especially distal) disease patterns. Caveats aside, the
compendium of data suggests similar mortality, amputation, and AFS rates for endovascular and bypass surgery at 1
year, with improved patency for bypass using vein compared with endovascular interventions or prosthetic bypass grafts
at 1 year and beyond.
Additional evidence, including a larger body of retrospective studies and registries, provides further insights into specific
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factors associated with inferior outcomes for individual techniques and informs current vascular
practice.79,365,366,369,372,373,376,385,391,393,395,402,407,426-438 Surgical bypass with nonautologous conduits to IP targets in
CLTI performs poorly. Similarly, patency rates for endovascular intervention are poor in settings of diffuse tibial disease
and popliteal and trifurcation occlusions and are diminished in small, diffusely diseased or heavily calcified FP arteries.
Several studies suggest that endovascular outcomes for advanced tissue loss (eg, gangrene, WIfI stage 4, WIfI ischemia
grade 3, or foot infection grades 2 and 3) are inferior, with high early rates of major amputation.171,439 Patients with
ESRD experience higher rates of limb loss across all interventions. These factors must be carefully considered in each
individual case, evaluating the available treatment options against the patient risk, limb stage, functional status, and
presumptive importance of a hemodynamically durable intervention for resolving the clinical scenario at hand.
Finally, a nonselective endovascular-first approach carries some risk of both clinically ineffective and cost-ineffective
treatment and potential for harm. Whereas a significant percentage of CLTI patients are appropriate candidates for
endovascular intervention, those with severe anatomic patterns and higher stages of limb threat may not be well served
by a nonselective approach for several reasons. First, ineffective revascularization can lead to poor symptom relief,
limited durability of benefit, delayed wound healing, inadequate clearance of infection, or progression of tissue loss in
the foot. There are both patient and system costs to inadequately treated CLTI. Another important consideration is the
potential effect of endovascular failures on the outcomes of secondary bypass surgery in CLTI. Although data in this
regard are limited, several multicenter data sets including BASIL160 and large regional registries440,441 suggest that the
outcomes of bypass surgery in patients who have undergone failed endovascular interventions are significantly inferior to
those in patients who underwent primary bypass surgery. The inferior outcomes associated with “secondary bypass” are
similar whether the initial failure was percutaneous or a prior bypass graft. This may be a particularly high penalty to pay
if clinical success of the initial procedure was short-lived. These studies cannot establish causality vs association, but
they strongly suggest that the success of the initial vascular intervention is of importance in CLTI and that endovascular
failure, like open bypass failure, carries consequences. Thus, an important consideration is to avoid risking potential loss
of bypass targets in performing endovascular interventions. Conversely, surgical bypass may incur significant morbidity
and mortality despite the potential attractiveness of greater durability. Factors that may increase the risk of wound
complications, graft failure, or other major postoperative complications must be carefully weighed. These considerations
informed the consensus recommendations on specific EBR strategies.
EBR: Treatment of inflow disease
Inflow disease is defined here as proximal to the origin of the SFA and meeting one or more of the following criteria:
•
absent femoral pulse
•
blunted CFA waveform on Doppler ultrasound
•
>50% stenosis by angiography in the aorto-iliac arteries or CFA
•
aorta to CFA systolic pressure gradient >10 mm Hg at rest
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The decision to perform staged vs multilevel revascularization for patients with combined inflow and outflow disease is
individualized on the basis of severity of limb threat (especially presence of tissue loss), anatomic complexity, and
patient risk. In settings of rest pain and minor tissue loss, inflow correction alone may suffice to achieve the desired
clinical outcome. As procedural complexity increases, perioperative morbidity and mortality rise as well. Most patterns
of AI disease may be successfully treated using an endovascular approach, frequently employing bare-metal or covered
stents.82-84 Surgery is often reserved for extensive occlusions or after failure of endovascular procedures. The choice of
an open surgical inflow procedure should be based on patient risk, anatomic pattern of disease, and other clinical factors.
Direct anatomic bypass (eg, aortofemoral) grafting may be preferred to extra-anatomic reconstruction in average-risk
patients with severe ischemia (WIfI ischemia grades 2 and 3) because of greater anatomic and hemodynamic
durability.85-87
CFA endarterectomy can be performed with low morbidity and excellent long-term durability.88,89 It remains the optimal
approach to treatment of hemodynamically significant CFA disease, which often includes bulky calcific plaque. In some
cases, femoral interposition grafting may be preferred. In all cases, durable in-line PFA flow should be maximized. CFA
endarterectomy may be combined with proximal intervention to treat combined disease in a “hybrid” fashion.90
Although long-term outcome data are sparse, reports suggest that endovascular treatment of CFA disease may be a safe
alternative in selected patients (eg, high surgical risk, hostile groin anatomy).91-94
Surgical treatment (eg, profundaplasty or bypass grafting) of PFA disease is an important component of CLTI
revascularization with a major impact on the long-term prognosis for the limb. The indications for and optimal
approaches to treatment of nonorificial (ie, not in continuity with the CFA) or long-segment PFA disease are not
established. There is limited evidence regarding the use of endovascular interventions for PFA disease. However, it may
be considered a secondary approach in settings of hostile groin anatomy or in other high-risk circumstances.
EBR: Treatment of infrainguinal disease in average-risk patients
Outflow (infrainguinal) disease starts at the SFA origin (Section 5). An average-risk patient is defined as one in whom
the anticipated periprocedural mortality is <5% and the anticipated 2-year survival is >50% (Recommendation 6.4).
These patients are potential surgical or endovascular candidates, depending on individual clinical and anatomic factors.
Fig 6.4 provides a summary of preferred infrainguinal revascularization strategies for an average-risk patient with
available vein conduit based on the presenting combination of limb stage (WIfI) and anatomic pattern of disease
(GLASS). Open bypass surgery and endovascular therapy have complementary roles, with notable lack of consensus
across the intermediate ranges of clinical and anatomic complexity. Comparative effectiveness studies employing these
staging schemes are urgently needed to improve the quality of evidence for interventions in specific clinical scenarios.
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Fig 6.4
Preferred initial revascularization strategy for infrainguinal disease in average-risk patients with suitable autologous vein
conduit available for bypass. Revascularization is considered rarely indicated in limbs at low risk (Wound, Ischemia, and
foot Infection [WIfI] stage 1). Anatomic stage (y-axis) is determined by the Global Limb Anatomic Staging System
(GLASS); limb risk (x-axis) is determined by WIfI staging. The dark gray shading indicates scenarios with least
consensus (assumptions—inflow disease either is not significant or is corrected; absence of severe pedal disease, ie, no
GLASS P2 modifier).
Patients lacking adequate autologous (GSV) conduit must be considered separately as this is a critical factor in
determining the likely success and durability of bypass surgery. For those with no suitable venous conduit, prosthetic or
venous allografts are the only options. Given the inferior performance of these conduits in CLTI, endovascular
intervention is preferred when possible.160 Use of prosthetic or biologic conduits (eg, cryopreserved vein allografts) for
infrainguinal bypass in CLTI may be reasonable in highly selected cases, such as in patients with untreatable anatomy for
endovascular intervention or prior endovascular failure, with acceptable runoff, and in patients who are able to tolerate
aggressive antithrombotic therapy.
In many patients lacking GSV, arm/spliced vein bypass conduits may be an option. However, the results of arm/spliced
vein bypass are highly dependent on the operator’s training and experience. The determination of when and how to
employ these alternative vein conduits is surgeon specific. In general, large single-center and multicenter reports
demonstrate that arm and spliced vein bypasses perform better than nonautologous grafts to distal targets and are inferior
to autologous GSV conduits.7,79,442,443 However, these higher risk vein grafts require closer surveillance and more
reinterventions to maintain primary assisted patency.444
EBR: Treatment of infrainguinal disease in high-risk patients
A high-risk patient is defined as one in whom the anticipated perioperative mortality is >5% or the anticipated 2-year
survival is <50%. Because endovascular intervention can be performed with reduced morbidity, it may often be preferred
in high-risk patients who are otherwise candidates for functional limb salvage. Shared decision-making is of great
importance in high-risk patients to allow the patient, family, and other stakeholders to express value judgments on the
tradeoffs between risk and effectiveness in relation to the desired goals.
EBR: Infra-malleolar disease
Severe IM disease creates a major challenge to effective revascularization.407 The P2 modifier in GLASS describes the
circumstance in which no named artery crosses the ankle into the foot and there is no suitable target for bypass surgery.
Although technically successful endovascular interventions in the pedal arch have been reported, their durability and
hemodynamic and clinical effectiveness remain unknown.438 Diabetic patients often have a segment of preserved pedal
artery that may be a target for bypass. Open bypass surgery has also been successfully employed to tarsal and plantar
arteries, but again, techniques and outcomes are not established. Given the technical difficulty and the likely reduced
hemodynamic impact and durability, the appropriate role for interventions at this level is not determined. The impact of
IM disease on the success of proximal revascularization, whether open or endovascular, is likewise unknown. Although
the presence of an intact pedal arch appears important for both, clinical success may still be attained in the presence of
significant IM disease. The severity of limb threat (tissue loss or infection) is likely to be a critical modifier of the
relationship between IM disease severity and postprocedural clinical outcomes.
EBR: Role of angiosome-guided revascularization
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Whereas few would argue about the desirability of maximizing perfusion at the site of tissue loss, there is considerable
debate about the utility of angiosome-guided revascularization.445,446 First, unambiguous assignment of foot wounds to
an individual angiosome is possible in only a minority of cases.447 Toe lesions, which typically represent more than half
of the lesions encountered, have a dual blood supply (AT and PT), although for more proximal foot lesions, unique
angiosome assignment may be achieved in up to 75% to 80% of patients. Then there is the practical question of whether
the desired target artery for the angiosome is available and the comparative hemodynamic and clinical effectiveness of
“direct” vs “indirect” revascularization. Tibial and peroneal bypasses perform equally well for limb salvage, and DP
bypass can be effective for some hindfoot lesions.448 Systematic reviews have yielded conflicting results,96-99 and data
are inextricably confounded by the quality of the pedal arch and the nature of the revascularization performed.95,449
Whereas wound healing may be improved when direct revascularization is achievable, major amputation rates and
patency are not consistently different. To date, none of the analyses take into account the confounding effect of limb
staging, for example, using WIfI. In summary, angiosome-guided revascularization may be of importance in the setting
of endovascular intervention for midfoot and hindfoot lesions but is likely to be irrelevant for ischemic rest pain and of
marginal value for most forefoot lesions and minor ulcers. The role of multivessel (tibial) revascularization is also
currently unknown. However, it may be reasonable in selected patients with advanced limb threat (eg, WIfI stages 3 and
4) undergoing endovascular therapy if it can be safely accomplished without risking loss of a bypass target or
compromising runoff to the foot.
EBR: Preferred endovascular techniques for infrainguinal disease
PBA, drug-coated balloon (DCB) angioplasty, stent placement (bare-metal stent, drug-eluting stent [DES], or covered
stent), and atherectomy may all be reasonable options in specific circumstances and lesion anatomies. However,
unfortunately, there are few high-quality comparative data to guide the choice of a specific endovascular approach in
CLTI.7,380,387-389,396,450-455
PBA may be inferior to DCB angioplasty and stents for the treatment of intermediate-length SFA disease (FP grades 2-4)
in patients with IC and possibly rest pain.100-103 However, there are inadequate data to support a preferred endovascular
approach for FP disease in CLTI.
PBA remains a reasonable primary endovascular approach for anatomically suitable IP disease as current evidence is
inadequate to support other, more expensive techniques. Atherectomy is not superior to PBA and is associated with
greatly increased costs.453 Combination approaches, such as atherectomy followed by DCB angioplasty, add significant
cost and lack high-quality comparative data. Several modest-sized trials suggest potential short-term benefit for DESs in
short (ie, <3 cm) tibial lesions, but one cannot generalize these data to the population of CLTI patients as a whole, who
typically present with much more extensive disease.7,456 DES may be a preferred endovascular “bailout” after technical
complications (eg, dissection) or failed PBA for short, proximal IP lesions. Although early studies suggested a potential
advantage for DCBs in tibial arteries, an RCT showed no benefit of DCB angioplasty over PBA, with a nonsignificant
higher rate of amputations in the DCB angioplasty group.396 The results of further, ongoing studies are awaited. In
summary, PBA currently remains the standard of care for the endovascular treatment of IP disease in CLTI.
Technical advances in endovascular intervention include improved wires, low-profile catheters, and retrograde access to
allow treatment of complex disease patterns down to the distal calf and foot. Specialized catheters may facilitate crossing
of difficult chronic total occlusions and ensure re-entry into the true lumen. Retrograde access techniques using either
fluoroscopic or ultrasound guidance may increase the ability to cross chronic total occlusions at the IP and popliteal
levels. The “pedal loop technique” has been described to achieve complete arch reconstitution in the presence of IM
disease, and some reports suggest that it may be of value in highly selected patients.438,457 The clinical efficacy of these
techniques remains to be defined in CLTI as hemodynamic durability remains the primary limitation of endovascular
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interventions in high-complexity target path anatomy.
EBR: Preferred approaches for infrainguinal bypass
An acceptable target for bypass surgery in CLTI should provide adequate runoff to the lower limb and foot to resolve the
clinical situation. In the setting of WIfI stages 3 and 4, it is recommended that the selected target artery provide
continuous in-line flow to the ankle and foot.
Good-quality GSV is the optimal autologous conduit for infrainguinal bypass surgery. Alternative (small saphenous vein
or arm vein) or spliced veins are acceptable bypass conduits, although there is a higher frequency of reinterventions, and
durability is inferior to single-segment GSV grafts. There is no evidence to support a preferred configuration (reversed,
nonreversed translocated, in situ) for vein bypass grafting.
Prosthetic conduits may be useful in selected patients lacking other revascularization options. Heparin-bonded expanded
polytetrafluoroethylene grafts may be superior to standard expanded polytetrafluoroethylene grafts for below-knee
bypass.458,459 Other adjuncts, such as a distal vein cuff, may also improve patency of prosthetic bypass to tibial targets,
although the data are limited in scope and quality.460 In general, clinical outcomes of prosthetic grafting in CLTI are
highly sensitive to runoff and severity of limb presentation. Bypass using nonautologous conduit to poor-quality tibial or
pedal targets in CLTI is discouraged as patency rates are extremely poor. Defining the optimal approach for below-knee
bypass in patients lacking venous conduit remains a major challenge in the field; if these patients are not suitable for
endovascular intervention, the individual surgeon’s experience may dictate practice. Further advances in bioengineered
arterial conduits are needed to meet this clinical dilemma.
7 Nonrevascularization treatments of the limb
Although the optimal treatment of CLTI is undoubtedly revascularization, unfortunately, a significant proportion of
patients are not suitable for revascularization for anatomic or physiologic reasons. Whereas major amputation may be
suitable for some of these patients, there is clearly a significant number who might benefit from nonrevascularization-
based treatments.
There is, however, a paucity of strong evidence regarding these treatment options. The majority of studies are low quality
and uncontrolled, combined with considerable study heterogeneity, making systematic review and meta-analysis difficult
or even impossible. This heterogeneity is reflected by large variations in patient factors, lesions of interest, intervention
protocols, study designs, and end points (limb salvage, AFS, target lesion patency, pain relief, quality of life
determinants, ulcer healing, and evolution of tissue lesions).4
This section reviews nonrevascularization interventions, pharmacotherapy, and conservative management.
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Interventional nonrevascularization treatments
Spinal cord stimulation (SCS)
Mechanism of action
SCS, originally used to treat chronic pain, was first described by Cook et al461 in the treatment of PAD. In SCS,
electrodes are implanted in the lumbar epidural space and connected to a generator to stimulate sensory fibers.462 SCS
promotes activation of cell signaling pathways that cause the release of vasodilatory molecules, leading to a decrease in
vascular resistance and relaxation of smooth muscle cells.462 This improved peripheral microcirculatory status has been
shown to result in increased capillary flow and density of perfusing capillaries, higher skin temperature and local TcPo2,
normalization of pulse wave morphology, and improved skin nutrition.106 In addition, SCS suppresses sympathetic
vasoconstriction and pain transmission.462
Evidence
A 2013 Cochrane review analyzed data from 444 patients in six controlled studies investigating the use of SCS in
CLTI.106,463-468 The general quality of studies was good, and all studies used limb salvage as the primary end point
(major AFS at 12 months). When the results were pooled, limb salvage rates were found to be significantly higher in the
SCS group (RR for major amputation, 0.71; 95% CI, 0.56-0.90).106 Results were better when patients were selected on
the basis of their initial TcPo2. Significant pain relief was also found in both treatment groups, although the SCS group
required less analgesia. In addition, there was no significant effect on ulcer healing. Overall mortality was not evaluated,
but the overall complication rate was 17% (95% CI, 12-22%). Implantation problems occurred in 9% (95% CI,
4%-15%), reintervention for changes in stimulation occurred in 15% (95% CI, 10%-20%), and infection of a lead or
pulse generator pocket accounted for 3% (95% CI, 0%-6%).106
Researchers concluded that SCS offered a modest positive effect on pain relief and an 11% reduction in the amputation
rate compared with conservative management at 1 year.106 They stress, however, that the positive benefits should be
weighed against the high cost and possible complications. In fact, the Cochrane review found the cost to be significantly
higher in the SCS group by $8824. Klomp et al469 calculated the number needed to treat to save one limb as 13, at
$111,705 per limb saved and $312,754 per quality-adjusted life-year gained. They concluded that SCS is not a cost-
effective treatment of CLTI.
Lumbar sympathectomy (LS)
Mechanism of action
Sympathetic denervation of the lumbar sympathetic ganglia is performed either through open or laparoscopic
retroperitoneal access or through percutaneous chemical blockade. LS increases blood flow to the lower limb by
inducing vasodilation of the collateral circulation and shunting of blood through cutaneous arteriovenous anastomoses by
its reduction of sympathetic tone. This, in turn, improves tissue oxygenation and decreases tissue damage and pain. Pain
is also decreased by interruption of sympathetic nociceptive coupling and by a direct neurolytic action on nociceptive
fibers.470
Evidence
In their systematic review, Sanni et al470 reported that RCTs failed to identify any objective benefits for LS in patients
with CLTI. They concluded, however, that LS may be considered an alternative to amputation in patients with otherwise
viable limbs because it is minimally invasive and cost-effective, with a low complication rate.470 Chemical
sympathectomy and surgical sympathectomy also appear to perform equally well, with some suggestion that LS can
benefit diabetic patients.
Of the three RCTs that focus on LS in PAD, only two reported on its use in CLTI,471,472 with the third reporting on its
use in IC.473 Cross et al472 found that chemical sympathectomy provided relief of rest pain in 67% of patients
undergoing LS compared with 24% of controls at 6 months. However, in a contrasting study, Barnes et al471 found that
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LS combined with AI revascularization did not provide any additional benefits compared with revascularization alone. In
fact, the majority of cohort studies reporting LS in CLTI474-483 consistently demonstrate subjective improvements in
approximately 60% of patients with regard to pain relief and ulcer healing.470 Moreover, a Cochrane systematic review
was unable to find any RCTs that evaluated the effect of LS (open, laparoscopic, or chemical) compared with no
intervention in CLTI due to nonreconstructible PAD.107 Overall, data are limited, but there is no evidence to suggest that
LS reduces the risk of major amputation in patients with CLTI. It remains unclear whether any subgroup of CLTI patients
may have improved pain control or ulcer healing with LS.
Intermittent pneumatic compression (IPC)
Mechanism of action
In patients treated with IPC, arterial blood flow is increased in the distal limbs by an increase in the arteriovenous
pressure gradient, which stimulates the endothelial vasodilators, thus suspending the venoarteriolar reflex and
stimulating collateral artery growth.484 As a result, the arterial flow, peak systolic velocity (PSV), end-diastolic velocity,
and pulse volume are all increased.485
Several methods of lower limb IPC use various protocols. These include the ArtAssist (ACI Medical, San Marcos, Calif)
device, which provides sequential compression to the foot and calf; the Aircast ArterialFlow (DJO Global, Vista, Calif)
device, which compresses the calf; and devices that deliver leg compression synchronized with ventricular contraction of
the heart (Syncarbon [Contilabo, Saint Gobain, France] and Vascular Pump [Rheomedix, Philadelphia, Pa]).484
Evidence
Two controlled studies486,487 and several case series488-495 have been published regarding IPC, but there is no robust
evidence from high-quality trials. In one, investigators entered 171 patients with CLTI into a 3-month IPC program.494
They reported improved pain relief, increased TPs by a mean of 15 mm Hg, and increased popliteal artery flow by a
mean of 20 cm/s. The median AFS was 18 months, with 94% limb salvage at 3.5 years. They determined that IPC is a
cost-effective intervention at a cost of $4454 per patient.494 In a retrospective observational study involving 107 patients,
researchers from the Mayo Clinic found 40% wound healing at 6 months.493
In another study, a non-RCT involving 48 patients, investigators found that 58% of patients who underwent IPC
benefited from complete healing and limb salvage compared with 17% in the control group (OR, 7.00; 95% CI, 1.82-
26.89).486 In a prospective trial, changes in quality of life were reviewed before and after IPC treatment.495 Researchers
reported a significant improvement in pain, physical functioning, and general health perception. Another systematic
review found that IPC might be associated with improved limb salvage, wound healing, and pain management as well as
with a low risk of complications.484 However, this review also noted a high risk of bias in these studies, with large
variations in the type of compression and optimum parameters used.484
Wound healing varied considerably (4%-96% at 3 months) in studies that used the same IPC device. In contrast,
mortality rates were more consistent.484 It has been suggested that outcomes with IPC may be worse for patients with
renal failure, with the prognosis for this group being worse for both limb salvage and mortality.484
Guidelines on nonrevascularization interventions
The TransAtlantic Inter-Society Consensus II (TASC II) document on the management of PAD concluded that there is
low-level evidence available for the recommendation of SCS.156 Likewise, guidelines from the ESVS state that the
benefit of SCS is unproven, with insufficient evidence to recommend its use in the treatment of CLTI.496
Although the TASC II document did not include LS in the treatment of CLTI, it did mention its potential role in the
management of complex regional pain syndrome.156 The ESVS guidelines conclude that LS should not be considered an
option to prevent amputation but can be considered in patients who are not amenable to revascularization to relieve
symptoms.496 The American Heart Association’s guidelines on the management of PAD do not mention LS.496 Finally,
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the international guidelines make no reference to IPC at all.
Pharmacotherapy
Prostanoids
Mechanism of action
Prostanoids include a family of inflammatory mediators, mainly prostaglandin E1 (PGE1), prostacyclin (PGI2), and
iloprost. Prostanoids act by inhibiting the activation of platelets and leukocytes, by inhibiting the adhesion and
aggregation of platelets, and by promoting vasodilation and vascular endothelial cytoprotection through antithrombotic
and profibrinolytic activities.108,497,498
Evidence
A meta-analysis evaluating the use of PGE1 vs placebo in the treatment of 254 patients with CLTI demonstrated
favorable results at 6 months, with ulcer healing or pain reduction (47.8% vs 25.2% placebo) and reduction in major
amputation or death (22.6% vs 36.2% placebo) associated with PGE1 use.499 Subsequently, a 2018 Cochrane paper
reviewed 33 prostanoid studies with various formulations, doses, and administration routes.108 These included
intravenous (IV) administration of PGE1 (synthetic form, alprostadil) for 21 days and an intra-arterial administration; IV
administration of PGI2 for 4 to 7 days; IV administration of iloprost (synthetic analogue of PGI2) for 14 to 28 days, oral
administration for 28 days to 1 year, and low-dose infusion; IV administration of lipoecaprost for 50 days; and IV
administration of ciprostene (a PGI2 analogue) for 7 days.108,497 Compared with placebo, prostanoids appeared to have
some efficacy for treating rest pain (RR, 1.30; 95% CI 1.06 to 1.59) and ulcer healing (RR, 1.24; 95% CI 1.04 to 1.48).
As a group, however, prostanoids did not have a significant impact on amputations or mortality, although not all studies
defined major vs minor amputations.498 Prostanoids were associated with a statistically significant increase in side
effects (RR, 2.35; 95% CI, 1.99-2.78).498 The side effects were mostly minor, including headache, facial flushing,
nausea, vomiting, and diarrhea.
The authors of the Cochrane systematic review concluded that there is no strong evidence on the efficacy and safety of
prostanoids in patients with CLTI on the basis of a high-quality meta-analysis of homogeneous, long-term RCTs.497
They also called on the need for further high-quality trials.498 A subgroup analysis of the Cochrane meta-analysis,
however, suggested that iloprost appeared to reduce major amputation (RR, 0.69; 95% CI, 0.52-0.93) and fared better
with rest pain (RR, 1.54; 95% CI, 1.19-1.99) and ulcer healing (RR, 1.80; 95% CI, 1.29-2.50). The authors stated that
whereas previous meta-analyses of iloprost had been more positive,500 only a few of the studies used in those previous
meta-analyses could be included in the Cochrane review because of study methodology issues. In fact, in clinical
practice, iloprost appears to benefit approximately 40% of patients in whom revascularization is not possible.156,500
Since the Cochrane review was published, a newer RCT comparing a placebo with the use of PGI2 analogue taprostene
intravenously for 2 weeks failed to demonstrate any difference in pain relief, ulcer size improvement, or prevention of
amputation.501 There are no data to support the use of prostanoids to reduce the risk of major amputation in CLTI
patients in whom revascularization is not possible.
Vasoactive drugs
Naftidrofuryl
A Cochrane review of eight RCTs examined the IV administration of naftidrofuryl in 269 patients.109 The treatment
tended to reduce rest pain and to improve skin necrosis, but this was not statistically significant. The studies were found
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
Page 50 of 203
to be of low methodologic quality, with varying levels of severity of CLTI, varying lengths of duration of treatment
(from 3 to 42 days), and different measures of effect. This resulted in varying end points that precluded a meaningful
pooling of results.109 Thus, there is currently insufficient evidence to support the use of naftidrofuryl in the treatment of
CLTI.498
Pentoxifylline
This drug improves blood flow by increasing red blood cell deformity and decreasing viscosity. A European RCT
involving 314 patients found a significant reduction in rest pain, sleep disturbance, and analgesia requirements.502 In a
separate Norwegian study using the same dosing regimen, there was no statistically significant difference either in pain-
free levels or in absolute walking distance between the two groups.503 Researchers concluded that further investigation is
necessary to evaluate the role of pentoxifylline in the treatment of patients with CLTI. Thus, there is currently a lack of
consistent evidence to recommend the use of pentoxifylline in the treatment of CLTI.498
Cilostazol
This drug has been well studied in claudicants but not as much in CLTI. One small study demonstrated that cilostazol
improves microvascular circulation and skin perfusion pressure in ischemic limbs.504 Another uncontrolled study that
used cilostazol in conjunction with endovascular revascularization reported higher rates of AFS and limb salvage but not
higher rates of survival or freedom from further revascularization.505 In the absence of RCTs in patients with CLTI, there
is insufficient evidence that cilostazol improves clinical outcomes in patients with CLTI.504,505
Vasodilators
Because vasodilators can cause shunting of blood away from ischemic areas to nonischemic areas, they are of no value to
patients with CLTI.156
Defibrinating agents
Two small RCTs compared ancrod, a defibrinating agent, with placebo in CLTI.506,507 Although one study showed
positive changes in APs and TPs, both studies failed to demonstrate any improvements in clinical outcome.
Hyperbaric oxygen therapy (HBOT)
There are numerous plausible mechanisms for HBOT to have a therapeutic role in CLTI. These include increased oxygen
transport capacity of plasma (independent of red blood corpuscle number and function), improved function of the
leukocyte oxygen-dependent peroxidase system, reduced tissue edema due to the osmotic effect of oxygen, stimulation
of progenitor stem cell mobilization and angiogenesis, and improved fibroblast function.508 If there is superimposed
infection, HBOT also inhibits bacterial growth (particularly anaerobes), generates free radicals that destroy bacterial
cellular structures, and improves the oxygen-dependent transport of antibiotics.509
In 2015, a Cochrane review of the role of HBOT in healing of chronic wounds was published,110 involving 12 trials and
577 patients. Ten of the 12 trials studied the effect of HBOT on ulcer healing in patients with diabetes. The 2015 review
concluded that HBOT increased the rate of ulcer healing in DFUs at 6 weeks but not at longer term follow-up, with no
significant difference in the risk of major amputation.110
Three other studies involved patients with ischemic ulcers, but each study used varying definitions of ischemia.510-512
Abidia et al511 randomized 18 patients with an ABI of <0.8 or TBI of <0.7 and found improvement in wound healing in
the treatment group. Löndahl et al512 randomized 94 patients with adequate distal perfusion or nonreconstructible arterial
disease. They found that 57% of patients had a TP of <60 mm Hg (median, 52 mm Hg). Complete ulcer healing occurred
in 52% of the patients treated with HBOT compared with 29% of controls at 12 months (P < .02). Stratification based on
TPs did not appear to affect healing rates. A subsequent publication by this group demonstrated that preintervention
TcPo2 correlated with ulcer healing and that individuals with a TcPo2 of <25 mm Hg did not heal.513 There was no
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significant difference in major amputations between the two groups, with three amputations in the HBOT cohort and one
in the control cohort.
One study randomized 70 patients with DFUs to either HBOT or standard care.510 The mean ABI and TcPo2 were 0.65
and 23 mm Hg in the HBOT cohort and 0.64 and 21 mm Hg in the non-HBOT group. All patients with an ABI <0.9 or
TcPo2 <50 mm Hg were considered ischemic, underwent an iloprost infusion, and were examined for possible
revascularization. Thirteen patients in each group underwent a revascularization procedure. At the completion of the
therapy, resting TcPo2 increased by a mean of 12.1 in the HBOT group and 5.0 in the control group (P < .0002). There
was a significant reduction in major amputations in the HBOT group (P < .016).510
A large longitudinal cohort study using data from a wound healing group in the United States61 included patients with
DFUs and adequate foot perfusion as determined by clinicians. A total of 793 patients underwent HBOT. Propensity
scoring was used to compensate for the lack of randomization. The study found that individuals treated with HBOT were
less likely to have healing of ulcers (HR, 0.68; 95% CI, 0.63-0.73) and more likely to undergo lower limb amputation
(HR, 2.37; 95% CI, 1.84-3.04).514
A subsequent multicenter RCT (Does Applying More Oxygen Cure Lower Extremity Sores? [DAMO2CLES])
undertaken in 25 hospitals in the Netherlands and Belgium randomized 120 patients with an ischemic foot wound and
diabetes to standard care with or without a course of HBOT. Ischemia was defined as AP <70 mm Hg, TP <50 mm Hg,
or TcPo2 <40 mm Hg. All patients were assessed for revascularization, and when applicable, this was generally
performed before HBOT. Primary outcomes were limb salvage, wound healing at 12 months, and time to wound healing.
Mortality and AFS were also analyzed. Limb salvage (47/60 in the standard care cohort and 53/60 in the standard care
with HBOT cohort), index wound healing at 12 months (28/60 in the standard care cohort vs 30 in the standard care with
HBOT cohort), and AFS (41/60 in the standard care cohort vs 49 in the standard care with HBT cohort) were not
significantly different between the two groups. A high proportion (35%) of those allocated to HBOT were unable to
undergo HBOT or did not complete at least 30 treatments, mostly for medical comorbidities or logistical reasons,
reinforcing the significant medical comorbidities present in these patients.112
Overall, whereas controversy remains, there may be a role for the use of HBOT to accelerate ulcer healing in diabetic
patients with nonhealing neuropathic ulcers and low-grade ischemia who have failed to respond to conventional wound
care. However, HBOT does not prevent major limb amputation and should not be used as an alternative to
revascularization in patients with CLTI.
Guidelines on nonrevascularization pharmacotherapy
The TASC II document notes that although previous studies with prostanoids in CLTI suggested improved healing of
ischemic ulcers and reduction in amputation, trials do not demonstrate a benefit for prostanoids in promoting AFS.156
The current PAD guidelines and recommendations of the American College of Cardiology Foundation and the American
Heart Association state that parenteral administration of PGE1 or PGE2 may be considered to reduce pain and to
improve ulcer healing in CLI but that the beneficial effect is likely to occur only in a small subset of patients.515
Finally, international guidelines do not address vasoactive drugs, vasodilators, or defibrinating agents. However, the
TASC II guideline advocated for considering HBOT in selected patients who have not responded to revascularization.156
Conservative management
Wound care
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CLTI is associated with a markedly shortened life expectancy, and not surprisingly, patients with unreconstructed CLTI
experience poorer outcomes in terms of survival and limb salvage. In a retrospective study involving 105 patients with
unreconstructed CLTI, 46% of patients lost the limb and 54% died within 1 year.516 Of the patients with a nonamputated
leg, 72% were dead within 1 year. Thus, despite advances in revascularization techniques and anesthetics, endovascular
or surgical revascularization may not be appropriate in some patients, even if it is technically possible, because of
significant comorbidities and reduced life expectancy.
A group of 169 patients with stable tissue loss who were unsuitable for revascularization based on medical and anatomic
reasons were entered into a dedicated wound management program.290 At 1 year, 77% of patients remained amputation
free, 52% had ulcer healing, and only 28% required minor amputation. Investigators concluded that conservative
management might serve a subset of CLTI patients. In fact, circumstances other than revascularization have been
identified as important for conservative management, including adequate nutrition, absence of infection, removal of
mechanical features interfering with wound healing (by surgical débridement, hydrotherapy, or larvae therapy), negative
dressing therapy, and noncontact low-frequency ultrasound.517
More recently, a group of 602 diabetic patients with foot ulcers and low TPs or APs were observed.518 During the
variable follow-up period of 1 to 276 weeks, 38% of patients had healed primarily, 12% had minor amputation, 17%
healed after major amputation, and 33% died unhealed.
Conclusions
Despite the lack of evidence to support nonrevascularization methods in CLTI, they are still widely used in real-world
practice. In a mail-in questionnaire of vascular surgeons in the United Kingdom published in 2009, 75% believed that LS
had a role in clinical practice for inoperable PAD,519 although in current practice LS is rarely used for CLTI. Similarly, in
a report on outcomes in patients with nonreconstructible CLTI, 88% received prostanoid infusions, 14% low-molecular-
weight heparin or oral anticoagulants, 3% SCS, 17% HBOT, and 69% wound treatment. In addition, 13% of patients
underwent toe or other foot-sparing amputations; at 24 months, the major amputation rate was 9.3%, with a mortality
rate of 23.2%.520 It is possible that these examples of real-world nonevidence-based practice represent the desire to help
this challenging population of patients when traditional methods either are unsuitable or have failed. Still, these
treatments are mostly unsupported by evidence and should be considered alternatives only on an individual basis and
after careful consideration of benefit and risks.
8 Biologic and regenerative medicine approaches in CLTI
Biologic or regenerative medicine therapies include gene therapy and cellular therapy. These treatments offer the
potential to promote wound healing and to prevent amputation in patients who otherwise have no options for
revascularization.
Therapeutic angiogenesis is defined as the growth of new blood vessels from pre-existing blood vessels in response to
growth factor stimulation. This has been shown to occur in animal models of hind limb ischemia and can be induced
either by angiogenic proteins such as vascular endothelial growth factor or by cellular therapy using stem cells or bone
marrow aspirate. The concept of angiogenesis was introduced into the clinical realm by Jeffrey Isner in the early
1990s.521 Various growth factors, including vascular endothelial growth factor, hepatocyte growth factor (HGF), and
fibroblast growth factor (FGF), have been shown to promote angiogenesis in animal models. The short half-life of these
proteins has led to the use of gene therapy to maintain sustained expression in the ischemic limb. Most clinical trials to
date have used intramuscular injection of either a gene or cellular therapy. In the case of gene therapy, expression of the
protein is maintained for 2 to 6 weeks. Ongoing research in this arena includes alternative vectors to safely enhance long-
term gene expression.
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The putative mechanism of cellular therapy involves either the differentiation of stem cells into vascular cells, after
injection into the hypoxic extremity, or induction of angiogenic growth factor expression, again due to relative tissue
hypoxia in the ischemic extremity. General concerns about the safety of angiogenic therapy have been related to the
potential for “off-target” angiogenesis, which can result in promotion of occult tumor growth or accelerated progression
of diabetic proliferative retinopathy. To date, these concerns have not occurred in angiogenic clinical therapy trials that
have been completed.
Trials of gene and stem cell therapy in CLTI
Gene therapy
Fibroblast growth factor (FGF)
This has been extensively studied in the context of severe limb ischemia. The TALISMAN phase 2 trial (NCT00798005)
enrolled 125 patients and reported a significant improvement in AFS at 12 months of 73% in patients treated with FGF
plasmid compared with 48% in placebo-treated patients with no options for revascularization (P = .009).522 Complete
ulcer healing at 6 months occurred in 14% of the placebo group and 20% of the treatment group (not significant).522 In a
separate study, the investigators demonstrated proof of concept of gene therapy when they identified the FGF plasmid,
messenger RNA, and protein in the amputation specimens of patients with CLTI who received FGF plasmid injections
before amputation.523
These findings led to a phase 3 trial, the TAMARIS trial (NCT00566657).524 This trial enrolled 525 patients from 30
countries who had either an ischemic ulcer or minor gangrene. However, the TAMARIS trial failed to show a difference
in AFS compared with placebo in patients with CLTI (63% in the treatment group vs 67% in the placebo group).524 The
AFS for both groups was similar to that for the FGF-treated patients in the phase 2 TALISMAN trial (Table 8.1). The
likely explanation for the different results observed in the phase 2 TALISMAN and phase 3 TAMARIS trials is a type II
error in the earlier study.
Table 8.1
Major trials of gene therapy and cell therapy
Hepatocyte growth factor (HGF)
Several clinical trials have evaluated HGF plasmid in the treatment of patients with CLTI and no option for
revascularization. Early phase 2 trials (NCT00189540, NCT00060892) have shown that HGF plasmid gene therapy can
improve TcPo2 and pain scores in patients with CLTI compared with placebo, but this did not result in improved
AFS.525,526 A Japanese trial of 40 patients demonstrated a significant improvement in a composite end point of
improvement of rest pain in patients without ulcers or reduction in ulcer size in those with ulcers at 12 weeks (70.4% vs
30.8%; P = .014).527 The AFS at 12 months was not reported. There are currently no U.S. Food and Drug Administration
(FDA)-approved gene therapies for treatment of patients with CLTI.
Stem cell therapy
Preclinical studies using animal hind limb ischemia models have shown that stem cells injected intramuscularly into the
hind limb can promote improved blood flow through an angiogenic mechanism. Early studies in humans have similarly
shown improved vascularity in the treated extremity, as measured by ABI, although the mechanism by which this occurs
in humans is unknown. Cellular therapies can be divided into autologous and allogeneic. Several phase 1 and phase 2
trials have recently been completed, including ones from Harvest Technologies (NCT00498069) and Biomet
(NCT01049919).528,529 Both of these report promising early results of phase 1 trials using autologous bone marrow
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mononuclear cells (BMMNCs) in the treatment of CLTI.528,529 In addition, both companies have developed point-of-
care cell preparation systems. After bone marrow harvest, the BMMNCs are extracted for direct intramuscular injection
into the ischemic limb.
Iafrati et al528 reported the results of 97 patients. In patients treated with intramuscular bone marrow concentrate, there
was a 64% AFS at 6 months compared with 65% in the control group. The treated patients had a significant
improvement in pain relief and TBI.528,530 Another trial of 152 patients found little difference in AFS between the
treatment group and control group at 6 months (80% vs 69%; P = .224).529,531 Both of these phase 3 trials are being
conducted through investigator device exemptions from the Center for Devices and Radiological Health of the FDA.
Another trial, the RESTORE-CLI (phase 2) trial, used expanded autologous stem cell therapy, ixmyelocel-T, in the
treatment of CLTI patients for whom revascularization was not an option.532 Bone marrow aspirate (50 mL) was taken
from study patients and sent to the sponsor, where the cells were cultured in a bioreactor and expanded during a 2-week
period; when expanded, the cell population is enriched with mesenchymal precursors and alternatively activated
macrophages. It was then returned to the trial site for intramuscular injection into the ischemic limb of the patient. The
trial enrolled 72 patients with either ischemic rest pain or tissue loss. At 12 months, 40% of patients who were treated
with ixmyelocel-T experienced one or more treatment failure events (defined as death, major amputation, doubling of
wound size from baseline, or new-onset gangrene) compared with 67% of placebo-treated patients (P = .045, Fisher
exact test). There was no difference in AFS.532 Treatment failure events were particularly pronounced in patients who
presented with tissue loss at baseline. In the subgroup of patients presenting with wounds, 45% of patients treated with
ixmyelocel-T experienced a treatment failure event compared with 88% of control patients (P = .01).532
In a small study of 28 patients with CLTI, Losordo et al533 completed a placebo-controlled trial to compare CD34-
positive cells selected by leukopheresis after mobilization with granulocyte colony-stimulating factor. The investigators
showed a trend toward reduction in all amputations (both major and minor). At 12 months, 31% of treated patients
underwent amputation compared with 75% of placebo-treated patients (P = .058). There was no difference between the
two groups when only major amputation was evaluated, although the number of patients in the trial was small.533
In another small trial, the Bone Marrow Autograft in Limb Ischemia (BALI) study randomized 38 patients with CLI to
treatment with bone marrow-derived mononuclear cells vs placebo at seven centers in France.534 A single treatment
employing 30 separate intramuscular injections in the ischemic limb was performed. There was no statistical difference
in major amputation at 6 or 12 months or in ulcers or pain relief at 6 months. Interestingly, TcPo2 values increased in
both treated and placebo patients. Using a “jackknife” method of logistic regression, the authors suggest some benefit in
major amputation for the treated group. However, the total number of patients and events in this trial was small, and the
results can be considered only exploratory at best.
The Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial
randomized 160 patients with severe limb ischemia to three intra-arterial infusions of either BMMNCs or placebo, 3
weeks apart.535 No major differences were found in major amputations at 6 months (19% in patients receiving
BMMNCs vs 13% in the placebo cohort) or in AFS at 6 months (77% in patients receiving BMMNCs vs 84% in the
placebo group). No differences were found in the safety outcomes or secondary outcomes of the two groups.535
The recently completed phase 1 allogeneic cell therapy trial sponsored by Pluristem (NCT00951210) has shown
promising safety and potential efficacy (personal communication). This open label trial of allogeneic placental stem cells
(PLX-PAD cells) will be entering phase 2 placebo-controlled trials. The PLX-PAD cells are mesenchymal-like stromal
cells derived from the full-term placenta and are expanded using the sponsor’s proprietary bioreactor. The cells are
believed to be immune privileged and would potentially offer an “off-the-shelf” treatment option.
Finally, a meta-analysis of randomized placebo-controlled trials of stem cell therapy involved 499 patients in 10 trials.113
Follow-up in all of the included trials was <12 months, and only three studies observed patients for at least 6 months.
This meta-analysis demonstrated no improvement in major amputation rates or AFS associated with stem cell therapy.
Secondary outcomes (ABI, TcPo2, and pain scores) were significantly better in the treatment group.113
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Safety of therapeutic angiogenesis
Early concerns about off-target angiogenesis and the potential for progression of diabetic proliferative retinopathy or
occult tumor growth previously resulted in significant restrictions in the inclusion and exclusion criteria for entry into
these studies. As early studies demonstrated an acceptable safety record for this therapy and potential concerns about off-
target angiogenic complications lessened, these restrictions have since decreased.
Unanswered questions in the field
Trial design and completion hurdles
Trials involving CLTI patients face multiple hurdles that have resulted in delays in completion. The overall comorbid
burden of the population of CLTI patients results in a high incidence of adverse events throughout the length of the study.
Likewise, the heterogeneous nature of CLTI results in a highly variable natural history. Patients with ischemic tissue loss
have a major amputation rate at 1 year of up to 35% compared with <10% in patients with rest pain. In addition, the FDA
recommends that AFS should be the primary efficacy end point in a phase 3 CLTI trial. This has resulted in studies with
an expected enrollment requirement of at least 500 patients. The reason for these large numbers in a phase 3 trial is that
biologic treatment of CLTI is a limb-sparing procedure. As such, it is not expected to significantly influence mortality,
although mortality is a component of the primary end point. Consequently, because of the heterogeneous and frail nature
of the population of CLTI patients, larger numbers of patients are needed to complete a clinical trial that can detect any
potential efficacy on amputation at 1 year.
Selection of patients
Many trials have recruited individuals who are considered to have no option for revascularization. Unfortunately, there is
no consistent definition of no-option CLI. Published studies referred to in this section have broadly included individuals
who were considered poor candidates for surgical or endovascular revascularization. This was due to either technical
factors (inadequate venous conduit; unfavorable anatomy, such as absence of a patent artery in the calf that is in
continuity with the foot) or patient-related factors (poor operative risk, but pain or tissue loss was unlikely to require
amputation within 4 weeks). In several studies, imaging was assessed by an independent vascular specialist.
The development of advanced endovascular techniques gives many patients who were previously considered to have no
option for revascularization a new opportunity to be considered potentially suitable for endovascular intervention.
Nonetheless, there are few data supporting many of these techniques. Novel methods to measure circulating stem or
progenitor cells before therapy may prove helpful in serving as companion diagnostics to identify those individuals who
may or may not respond to angiogenic therapy.536
Conclusions
There have been promising early safety and efficacy trial data for both gene and cellular therapies in patients with CLTI.
Despite these early promising results, no phase 3 trials have shown this therapy to be effective. Still, current trial design
has improved, and there are multiple phase 3 clinical trials that either are actively enrolling or are in early stages of
development. These involve potentially disruptive technologies that, if proven effective, could dramatically alter how
patients with CLTI are cared for in the future. Until further evidence is available, these therapies should be considered
investigational.
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9 The role of minor and major amputations
CLTI is associated with a reduced life expectancy, a significant curtailment in ambulation, and a high likelihood of limb
loss. Preservation of a patient’s ability to walk is an important aspect of care in CLTI, and vascular reconstruction is the
most direct method for achieving functional limb salvage in these often critically ill patients. When properly applied,
open surgical and endovascular techniques have proved useful and successful for the preservation of limb function. A
successful limb salvage intervention is associated with low postprocedural morbidity and mortality, preservation or
restoration of independent ambulation, improved quality of life for the patient, and lower cost to the health care system.
Although most patients require a single procedure to accomplish this, many will need minor amputations to remove
distal necrotic or infected tissue to achieve a completely healed and functional extremity. This is especially true of
diabetics, who have a lifetime risk of foot ulceration of 25%, with 50% of ulcers becoming infected.154 Treatment of
these patients requires both in-line pulsatile flow to the foot and wound débridement or minor amputation.537
Minor amputations
Minor amputations of the foot include digital and ray amputation of the toe, transmetatarsal amputation of the forefoot,
and Lisfranc and Chopart amputations of the midfoot. Each of these can be useful to preserve foot function in
appropriately selected patients. Although there is a significant risk of need for reamputation at a higher level in diabetics,
the use of minor amputations, including single-digit and ray amputations, can preserve foot function in the majority of
patients.538-540 There are some instances in which transmetatarsal amputation may be a better first procedure, including
necrosis of the great toe requiring long ray amputation or ray amputation of the first and fifth toes, but ensuring adequate
distal perfusion and appropriate offloading of the forefoot are the major principles for preservation of foot
function.114,541
There are, however, situations in which an aggressive attempt at limb salvage would be unlikely to succeed, would pose
too great a physiologic stress on the patient, or would be of limited value because of other causes of limb dysfunction.
For these patients, major amputation may be considered a reasonable option. Because a well-planned primary amputation
can often result in a high likelihood of independent ambulation for many patients, this procedure should not be
considered a failure of vascular surgery. Rather, it should be viewed as another path to the goal of preserving the walking
ability in carefully selected patients or for resolution of ischemic pain, ulceration, and infection.
Primary amputation
Primary amputation in patients with CLTI is defined as lower extremity amputation without an antecedent open or
endovascular attempt at limb salvage. There are four major goals of primary amputation for patients with CLTI: (1) relief
of ischemic pain; (2) removal of all lower extremity diseased, necrotic, or grossly infected tissues; (3) achievement of
primary healing; and (4) preservation of independent ambulatory ability for patients who are capable. In addition, there
are five major indications for primary amputation.
1.
Nonreconstructible arterial disease, as confirmed by clear distal imaging studies that fail to identify patent distal
vessels needed for a successful intervention. In the setting of severe distal ischemia, in particular in association
with ischemic ulceration, gangrene, or infection, the inability to improve straight-line distal perfusion often results
in major amputation even with a patent bypass graft. Bypasses to arteries that do not have at least large,
angiographically apparent collateral vessel outflow provide little additional flow to the foot for distal limb
salvage.542 Patients without any appropriate targets for successful distal revascularization are frequently better
served with a primary major amputation.
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2.
Destruction of the major weight-bearing portions of the foot, rendering it incompatible with ambulation. The
weight-bearing portions of the foot consist of the calcaneus, the first and fifth metatarsal heads, and a functional
arch. Patients with gross destruction of the calcaneus and overlying skin should be considered for primary
amputation because a functional foot can infrequently be salvaged. After aggressive heel ulcer excision and
extensive calcanectomy, complete wound healing is infrequent and chronic pain is common.543,544
3.
Nonfunctional lower extremity due to paralysis or unremediable flexion contractures. These patients are unlikely
to benefit from attempts at revascularization, and there will be little change in quality of life despite a successful
intervention.
4.
Severe comorbid conditions or limited life expectancy due to a terminal illness. The goal of treatment for these
patients is relief from ischemic pain, if present, and an improvement in the remaining quality of life. Extensive
distal revascularization, prolonged hospitalization, and protracted recovery should be avoided. Assessment of the
patient’s frailty may be of value to determine whether primary major amputation is more appropriate than distal
revascularization.545,546
5.
Multiple surgical procedures needed to restore a viable lower extremity. As the technology and techniques of
vascular surgery have improved, surgeons have advanced beyond revascularization to complex vascular and soft
tissue reconstruction. This approach usually involves multiple surgical procedures to increase distal flow, removal
of all necrotic tissue, and reconstruction of these areas with free flaps. The course of treatment is prolonged,
involving multiple returns to the operating room, long periods of inactivity, and a difficult recovery. For these
patients, if multiple procedures with high morbidity are required, primary amputation should be strongly
considered to permit early ambulation. A detailed discussion with the patient to develop a comprehensive
treatment plan with shared decision-making is important for such advanced vascular disease.
For all patients considered for primary amputation, also consider revascularization to improve inflow in an attempt to
reduce the level of the amputation.118,119 For example, those patients with extensive infrainguinal arterial occlusion,
including the common and proximal PFA, might benefit from restoration of flow into the deep femoral system to reduce
the amputation level from the upper thigh to the level of the knee. In such cases, despite some additional risk, proximal
revascularization has the potential to offer a tangible and significant benefit to the patient.
Secondary amputation
For those in whom one or more attempts at revascularization have failed and the likelihood of a successful and durable
redo procedure is limited, major amputation with a goal of rehabilitation to independent ambulation should be
considered.
Level of amputation
Selecting the level of amputation that will heal primarily is critical to successful prosthetic rehabilitation and maximal
functional mobility. Thus, a great deal of consideration must go into selecting the initial level of amputation.
Preoperative tissue perfusion assessment can make it possible to lower the level of amputation, although there is no
accurate method to predict the optimal level of amputation.547 In addition, whereas assessment of preoperative tissue
perfusion can aid in decision-making, it still remains largely a clinical decision. Many techniques to evaluate tissue
perfusion have been tried, including laser Doppler flowmetry, thermography, skin perfusion pressure, fluorometric
quantification of a fluorescein dye, TcPo2, and indocyanine green fluorescence angiography. In particular, TcPo2 has
been extensively evaluated, and it has been shown that wound complications increase as TcPo2 levels fall below 40 mm
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
Page 58 of 203
Hg.547 Currently, there is still no single definitive method of evaluating tissue perfusion that can accurately predict the
wound healing potential or failure at the site of amputation.
Healing rates of amputations and reamputations
Achieving primary healing is challenging in ischemic lower limbs, and it is difficult to predict early failure (Table 9.1).
Multiple débridements and reamputations are required in 4% to 40% of patients, depending on the level of
amputation.548-550 Likewise, readmission rates of 20% have been reported even after minor amputations (toe and distal
forefoot), with the majority of reamputations occurring within 1 month.548-550 Reported long-term healing rates after
transmetatarsal amputations are approximately 53%.551 These amputations should not be offered to patients who have
poor rehabilitation potential.
Table 9.1
Major amputation of the lower extremity
The role of partial foot or midfoot (eg, Lisfranc, Chopart) amputations remains controversial. Prosthetic specialists
discourage the use of these procedures as they have higher rates of delayed healing, require more revisions, and develop
deformities and ulcers, and patients often struggle to achieve their full rehabilitation potential. Conversely, these
amputations preserve a weight-bearing heel and allow amputees the ability to mobilize for short distances without
prostheses.552
Transtibial amputation (below-knee amputation [BKA]) and transfemoral amputation (above-knee amputation [AKA])
are performed with an almost equal frequency in patients with CLTI. Reports have shown primary healing rates for BKA
of approximately 60%, with 15% leading to a transfemoral amputation.121,548 The transfemoral amputation has the
highest probability of successful primary healing and therefore has been the amputation of choice in individuals who are
less likely to ambulate with a prosthesis.
Recent data from the American College of Surgeons National Surgical Quality Improvement Program show improved
results with a 12.6% early failure rate for BKA compared with 8.1% for AKA.553 A similar trend is found in data from
the National Vascular Registry of the United Kingdom, which show that one in eight AKAs and one in six BKAs remain
unhealed at 30 days.554
Knee disarticulation
The biomechanical advantages of a knee disarticulation or through-knee amputation (TKA) compared with an AKA are
well recognized, although it remains an infrequently performed amputation. A well-performed TKA offers healing rates
that are comparable to those of AKA and provides bedridden and wheelchair-bound patients with a higher level of
mobilization and transfer, counterbalance, and reduced potential for contractures. Even in patients who have
rehabilitation potential, the current prosthetic technology permits excellent functional mobility, making TKA a good
amputation choice when a BKA is unlikely to heal. The aesthetic disadvantage of a TKA is that the prosthetic knee will
be marginally distal to the normal contralateral knee in a sitting position.
Mortality
Survival after major lower limb amputation is poor, as seen in a systematic review that reported 30-day postoperative
mortality rates of 4% to 22%.555 Even after minor amputations, the 1-year and 5-year mortality rates are reported to be
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16% and 25%, respectively, for those with limb ischemia.556 Mortality rates for minor amputations are higher in
diabetics, with type 2 diabetics having a 5-year mortality of >50%.557 The 5-year mortality after major amputations
varies from 30% to 70% and is significantly worse for AKA than for BKA.558,559 The mortality is even higher in
bilateral lower limb amputees, with a 5-year survival rate of <40%.560 These mortality rates demonstrate the high rate of
comorbidities and the frailty of this group of patients.
In patients with diabetes who have had major amputations, survival is often worse than in some malignant diseases.
Survival rates have been reported as 78% at 1 year, 61% at 3 years, 44% at 5 years, and 19% at 10 years.561
In 2010, recognizing the need to do more to reduce perioperative mortality, the Vascular Society of Great Britain and
Ireland introduced a quality improvement framework to reduce mortality from amputation surgery to <5% by 2015,
which was later revised to <10% in 2016.562 Recent data from the United Kingdom’s National Vascular Registry showed
mortality rates of 11.6% for AKA and 6.1% for BKA by establishment of dedicated multidisciplinary amputation
services that provided expeditious and comprehensive preoperative and postoperative care.550 These rates are similar to
results from the American College of Surgeons National Surgical Quality Improvement Program of 12.7% for AKA and
6.5% for BKA, with an overall 9.1% mortality of 6389 patients studied.563
Fate of contralateral limb after lower extremity amputation
Published reports of the risk of contralateral amputation vary from 2.2% to 44%, with a lower risk if the index
amputation is a minor amputation.124 In most patients, the reason for contralateral amputation is disease progression,
although the medical management of unilateral amputees can also be suboptimal, with one-third of patients not
prescribed a statin and an antiplatelet agent.123 Continued follow-up of these patients at least yearly after
amputation with attention to the contralateral limb is important.124
Prosthetic rehabilitation, mobility, and quality of life
When an amputation is inevitable, and whenever possible, a prosthetic specialist should be involved in decision-making
with the surgical team regarding the optimal level of amputation that will ensure the best opportunity for healing,
survival, and maximum functional mobility. Advances in prosthetics have resulted in a prosthesis for every stump.
However, to use the prosthesis effectively, the stump must be created to truly function as a dynamic sensorimotor end
organ and not simply as an inert filler in the socket.
Muscle-stabilizing procedures can help create a stump with its proprioception intact and any of the procedures can be
used, including myoplasty, myodesis, and osteomyoplasty. The stump evolves with time, and the prosthetic requirements
continue to change. The patient requires regular adjustments in the prosthesis and often complete revisions. A poorly
fitting prosthesis can be as disabling as the actual amputation.
The quality of life after amputation is significantly influenced by pain, social isolation, depression, and the patient’s
lifestyle before amputation. Mobility has a direct effect on quality of life. It is a key determinant to the social
reintegration of the amputee and has a beneficial effect on late mortality.
Energy expenditures of ambulation increase with ascending levels of amputation. Energy consumption during
ambulation is increased by 10% to 40% after BKA and by 50% to 70% after AKA.564 The potential for rehabilitation is
better with BKA than with AKA. Therefore, it is worthwhile to try to salvage a BKA in a patient who has the potential to
ambulate fully. In studies involving >100 patients, ambulatory status at 6 to 12 months after amputation varies from 16%
to 74%.551 At 2 years, only 40% of BKA patients achieve full mobility.121
Maintaining ambulation is one of the most important factors in preserving independence. A significant amount of
evidence is available to suggest that early postsurgical prosthetic fitting leads to early mobility.565 However, to achieve
and to maintain daily functional ambulation, multidisciplinary inputs are needed from physiotherapists, occupational
therapists, prosthetists, social workers, recreational therapist nurses, psychologists, and the surgeon. Despite initial
successful prosthetic rehabilitation, prosthetic use deteriorates over time, and most patients eventually become household
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walkers only.566
Delivery of amputation service
Based on current international practice,562,566 the following best practice recommendations will help decrease mortality
and improve functional outcomes:
1.
The indication for any nonurgent amputation should be discussed at a multidisciplinary team meeting after a full
functional and vascular assessment.
2.
Patients should be informed as to the rationale of any amputation as well as the postamputation care pathway.
3.
Patients should have access to a second opinion (by a vascular specialist from another institution).
4.
A preoperative assessment by a rehabilitation and occupational physiotherapist as well as by a prosthetic specialist
should be organized.
5.
Procedures should be performed on an elective list (within 48 hours of the decision).
6.
Amputations should be performed by or in the presence of a board-certified consultant surgeon.
7.
A named discharge coordinator should ensure that there is a defined postamputation care pathway.
10 Postprocedural care and surveillance after infrainguinal revascularization for CLTI
This section reviews evidence for adjunctive medical therapies, surveillance, reintervention, and postprocedural care
after infrainguinal revascularization for CLTI.
Medical therapies
All patients who have undergone revascularization for CLTI should continue with best medical therapies to slow the
progression of atherosclerosis and mitigate the adverse impact of risk factors as recommended in Section 4. In addition,
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the role of specific pharmacotherapy for maintaining the benefits of revascularization has been the subject of a number of
studies.
Endovascular interventions
Long-term antiplatelet therapy remains a cornerstone to reduce atherothrombotic events and to improve patency and limb
salvage rates after peripheral interventions.35,135 Contemporary management involves the choice between single
antiplatelet therapy and DAPT. Aspirin has been a mainstay of treatment because it is efficacious and cost-effective.
Clopidogrel is also effective as a single agent.35,567 Use of DAPT after intervention has become standard in the treatment
of CAD134,568 and has migrated to other arenas of vascular intervention. Clopidogrel is a prodrug requiring conversion
by cytochrome P450 enzymes, the activity of which may be affected by genetic polymorphisms or drug-drug
interactions. It has been estimated that between 4% and 30% of individuals treated with conventional doses of
clopidogrel do not attain the full antiplatelet response.569 Of note, it has been reported that patients with PAD may have a
higher prevalence of resistance to clopidogrel than coronary intervention patients.136
Despite an absence of level 1 evidence, DAPT is frequently employed for 1 to 6 months after peripheral
interventions.134,136 The Clopidogrel and Aspirin in the Management of Peripheral Endovascular Revascularization
(CAMPER) study was designed to compare aspirin with DAPT but was stopped because of poor enrollment.137,570 The
MIRROR trial was a double-blind RCT comparing clinical outcomes of aspirin and placebo vs aspirin and clopidogrel
for 6 months after FP intervention. Of the 80 patients who were randomized, 42% had CLTI.136 Decreased target lesion
revascularization was observed in patients randomized to the DAPT arm, although there was no significant difference in
patency rate. A meta-analysis suggested that DAPT might be associated with a reduced risk of major amputations after
revascularization, with increased bleeding risk vs monotherapy.297 A propensity-adjusted analysis from the Vascular
Quality Initiative associated DAPT use with improved survival after revascularization for CLTI.571 The efficacy of
DAPT may depend on multiple factors, including procedure-related, anatomic, and patient factors. Subgroups of patients
who may derive more benefit from DAPT include those with complex disease patterns, those with prior failed
interventions, and those at lower risk of bleeding complications (eg, younger patients). Adequately powered RCTs are
needed to better define the risks and benefits of DAPT after peripheral intervention as well as optimal dosing and
duration of treatment.
The phosphodiesterase inhibitor cilostazol has antiplatelet and antiproliferative properties, and several studies have
suggested that it may reduce the incidence of restenosis after catheter interventions. Iida et al572 reported that cilostazol
treatment reduced angiographic restenosis after FP intervention (angioplasty with provisional stenting) in an open label
randomized trial of 200 patients, of whom 90% had intermittent claudication. A meta-analysis suggested an association
between cilostazol use and reduced rates of in-stent restenosis after FP stenting in “high-risk” patients, pooling studies
that included 75% claudicants.573 Conversely, an open label RCT found no effect of cilostazol treatment in reducing
restenosis after IP interventions for severe limb ischemia.574 No clear recommendation can be made at present regarding
the potential benefit of cilostazol after endovascular interventions for CLTI.
Vein and prosthetic bypass grafts
After vein graft implantation, patency of the graft is likely to be enhanced by lifestyle modifications and medical therapy.
Most studies of vein graft patency include patients with both CLTI and claudication. Meta-analyses from prospective
studies130,131 along with multiple case series demonstrate a consistent association between the avoidance of smoking and
enhanced vein graft patency. Statin medications have not been evaluated in randomized trials for enhancement of vein
graft patency, although some retrospective studies suggest that they may be of benefit.125,126 In a cohort study, statin use
was not associated with better limb outcomes, although overall survival was improved.129
Although antiplatelet agents are commonly used, there is inconclusive evidence that they specifically enhance lower
extremity vein graft patency. A Dutch trial of 2690 patients randomized to oral anticoagulants (target international
normalized ratio of 3-4.5) or 80 mg of aspirin per day after lower extremity bypass found better vein graft patency at 12
and 24 months for the oral anticoagulants on subgroup analysis.575 However, there were twice as many bleeding
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complications in the anticoagulant-treated patients. In contrast, a multicenter U.S. trial comparing warfarin plus aspirin
with aspirin alone found no improvement in vein graft patency and a higher rate of bleeding in the combined treatment
arm.576 A study of 56 patients with poor-quality venous conduits compared aspirin alone with a combination of aspirin
and warfarin and found improved patency in the aspirin plus warfarin group.577 Finally, a systematic review found no
effect of aspirin or dipyridamole compared with placebo on vein graft patency at 1 year.127,128 Vein graft patients
receiving aspirin or aspirin plus clopidogrel have similar patency, and there is a higher rate of mild to moderate bleeding
with DAPT.132 A more recent systematic review concluded that antiplatelet therapy has a beneficial effect on primary
patency of peripheral bypass grafts compared with placebo or no treatment.128 It appears, then, that there is limited
evidence to support a specific antithrombotic regimen in patients after vein bypass grafting for CLTI. Single antiplatelet
therapy, recommended as standard for long-term PAD management, should be continued in these patients. Treatment
with warfarin may be considered in patients with high-risk vein grafts (eg, spliced vein conduit, poor runoff) who are not
at increased risk for bleeding.
In contrast, there is consistent evidence supporting the use of antiplatelet therapy in patients who have undergone
prosthetic bypass grafting. Two Cochrane reviews have supported the use of aspirin and other antiplatelets in maintaining
lower extremity bypass graft patency, and greater benefits have been seen with prosthetic grafts.127,128 Other studies
have demonstrated similar findings.133 In particular, one randomized trial (Clopidogrel and Acetylsalicylic Acid in
Bypass Surgery for Peripheral Arterial Disease [CASPAR]) showed that DAPT with clopidogrel and aspirin led to
significantly improved patency in prosthetic grafts but not in venous grafts.132 However, this was accompanied by an
increased risk of mild to moderate bleeding. Another study demonstrated that the use of anticoagulants such as vitamin K
antagonists did not improve the prosthetic graft patency, although they were beneficial in venous conduits.575,578 In a
single-center study, investigators suggested the use of therapeutic vitamin K antagonists to prolong the patency of
prosthetic grafts with low velocities.579
Surveillance and reintervention
After endovascular treatment
Despite the high initial technical success rates of endovascular interventions, early failure of these minimally invasive
procedures is common.100,365,580-583 This has led to high rates of secondary interventions and questions of clinical
efficacy to support them.
Currently, guidelines support DUS surveillance and prophylactic reintervention for asymptomatic vein graft stenosis to
promote long-term patency.138,584-589 Conversely, strategies for surveillance and guidelines for reintervention after
angioplasty have primarily been left up to the individual practitioner. There are many determinants of failure after
angioplasty, including indication (claudication vs CLTI), lesion length, lesion severity (occlusion vs stenosis),
calcification, location, concomitant inflow and outflow vessel disease, use of stents, and residual stenosis or recoil at the
time of the initial procedure. As a result, predicting which interventions are more prone to failure has proved challenging,
and there is scarce evidence to support indications for repeated interventions in CLTI.
Modalities for surveillance include clinical follow-up visits (assessment of symptoms, inspection of the extremity, pulse
examination), ABI measurements, and DUS scan (PSV measurement and velocity ratio). Other imaging modalities, such
as DSA, CTA, and MRA, are not reasonable for surveillance because of invasiveness, cost, and limited access as well as
exposure to ionizing radiation and contrast dye and potential risks from the procedure itself.
Surveillance by clinical follow-up alone may be insufficient to detect restenosis as patients may remain asymptomatic
until the target artery has occluded, akin to bypass grafts. Likewise, ABI measurement alone has limited value, given the
difficulty in determining the level of restenosis, the limitation in diabetics with calcified vessels, and the variability of
correlation when there is a drop in ABI (>0.15) with lesion severity.590,591 The addition of DUS provides anatomic
information using direct visualization of the vessel as well as physiologic information based on spectral waveforms,
pressure, and velocity measurements. The combination of PSV and velocity ratio measurements offers high positive
predictive value for identifying moderate and severe restenosis when it is correlated with angiography.592,593
The value of DUS in a postprocedural surveillance program needs to be balanced by the potential harm associated with
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performing unnecessary procedures on asymptomatic restenotic lesions that may have an otherwise benign natural
history. The cost associated with maintaining such a program should also be considered. One strategy is to pursue DUS
surveillance at regular intervals (3-6 months) and to consider reintervention for severe recurrent asymptomatic lesions
(>70%) before they progress to complete occlusion. This approach is supported by data suggesting that restenotic lesions
are markers of subsequent failure.142,594,595
Several studies have shown that reintervention on occluded lesions brings higher rates of distal embolization and
subsequent reocclusion in comparison to intervening on restenotic but patent vessels.596,597 Although these seem to be
reasonable incentives for surveillance, DUS may not identify all of these lesions before failure; for example, not all
angioplasty site reocclusions are preceded by severe restenotic lesions.141,598,599 To date, there are inadequate data
demonstrating clinical benefit of a DUS surveillance program after endovascular intervention for CLTI. Still, there are
likely to be subgroups of patients who may benefit more than others from close surveillance and early reintervention.
These may include patients who have experienced multiple failed angioplasties; patients who have previously undergone
failed bypasses or for whom conduits are unavailable; patients who had presented with severe ischemia (eg, WIfI grade
3), unresolved tissue loss, or appearance of new inflow lesions; and patients with known poor runoff or long target vessel
occlusions that are prone to failure.
Vein and prosthetic bypass grafts
Vein grafts primarily fail when stenotic lesions develop within the venous conduit or at anastomotic sites of the conduit
to the inflow and outflow arteries. Stenotic lesions can also develop in the outflow artery remote from the distal
anastomotic site. Approximately one-third of lower extremity vein grafts develop lesions that threaten graft patency, and
most occur within 2 years of graft placement. Vein grafts are never entirely free of the risk for development of intragraft
or anastomotic stenosis. The risk of vein graft stenosis is greater with smaller caliber conduits, with nonsaphenous or
spliced venous conduits, and in grafts with anastomosis to more distal (tibial or pedal) arteries. Surveillance of lower
extremity autologous vein grafts is based on this natural history and assumes that a patent, hemodynamically
uncompromised reconstruction is optimal for wound healing and limb viability. Secondary reconstructions for
thrombosed lower extremity vein grafts are technically more complex and less durable than revision of a failing but
patent bypass.
Vein graft surveillance programs may be solely clinical or clinical and vascular laboratory based. The TASC II working
group recommended that patients treated with lower extremity vein grafts be observed for at least 2 years with a
surveillance program consisting of an interval history to detect new symptoms, pulse examination, and measurement of
resting and postexercise ABI, when possible.156 Most vascular laboratory-based surveillance programs focus on DUS
detection of stenotic lesions within the graft or at the anastomotic sites. Although there is considerable information on
DUS surveillance of lower extremity vein grafts for CLTI, there are few prospective data.
The Vein Graft Surveillance Randomised Trial (VGST), a prospective trial from the United Kingdom, randomized 594
patients with patent vein grafts 30 days after surgery to either clinical surveillance or combined DUS surveillance and
clinical surveillance. The majority of operations (two-thirds) were femoral-popliteal bypasses for CLTI. Conduits were
ipsilateral reversed saphenous vein in >90%. Thus, technical complexity of surgery in the VGST may not reflect that of
open reconstructions performed for CLTI in the modern endovascular era. At 18 months, the investigators found no
differences in primary, primary assisted, or secondary patency between the two surveillance strategies.589 A smaller
study from Sweden randomized 156 patients with lower extremity arterial reconstructions to intensive surveillance,
including DUS scanning (n = 79), or routine clinical surveillance (n = 77). There were 40 polytetrafluoroethylene grafts,
equally distributed between the two groups. Only two grafts in each group were performed for claudication, and two-
thirds were to the popliteal artery. Among the vein grafts in the study, there was improved assisted primary and
secondary patency in the intensive surveillance group that had DUS scanning.585
The benefit of a vein graft surveillance program with DUS scanning is suggested in large single-institution case series as
well as in one large multi-institution prospective study.79,138,140,600,601 These studies and others have demonstrated large
differences between primary patency and assisted primary patency of vein grafts monitored with a DUS-based
surveillance program.139 They also demonstrate that electively revised vein grafts have excellent long-term patency,
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even comparable to that of grafts that have never undergone revision. In contrast, salvage of vein grafts that have already
thrombosed is associated with markedly reduced secondary patency. Improved quality of life has been associated with
maintained patency of vein grafts performed for CLTI.233 Despite these observations, it must be acknowledged that the
clinical benefit of DUS-based surveillance after vein bypass for CLTI is still unclear. A systematic review found low-
quality evidence for DUS surveillance of infrainguinal vein grafts.602
The underlying principle of clinical surveillance of vein grafts is that recurrence of symptoms, change in pulse status, or
decrease in ABI >0.15 indicates an at-risk graft that should be considered for revision. It is also suggested that vein grafts
with >70% stenosis identified by DUS scanning be considered for revision as such lesions are unlikely to improve and
associated grafts have an adverse natural history.138,600 These lesions are defined by an associated PSV of >300 cm/s, a
PSV ratio (defined as PSV at the lesion divided by PSV in a proximal segment) of >3.5, or a midgraft PSV <45 cm/s.
Vein graft stenoses treated with open surgical techniques (patch angioplasty or interposition grafting) have excellent
long-term patency and associated limb salvage.139 The technical success and short-term patency of surveillance-detected
lesions treated with catheter-based techniques are high, although long-term data are lacking. In general, longer lesions
and lesions detected within 3 months of graft implantation are best treated surgically. Short lesions and those treated after
3 months of graft implantation may be treated either surgically or with catheter-based techniques, primarily balloon
angioplasty, and possibly with drug-coated balloons.603,604 With either mode of treatment, recurrence of stenosis within
the vein graft or its anastomoses is possible. Thus, continued surveillance after reintervention is indicated to detect
recurrent and new stenotic lesions. After treatment of a vein graft stenosis, the treated graft should undergo surveillance
at intervals similar to those for primarily placed grafts.139 Treatment of recurrent lesions in previously revised vein grafts
can also provide continued long-term patency and limb salvage.139
Long-term patency of infrainguinal prosthetic bypass grafts is inferior to that of venous bypass grafts. Evidence as to the
efficacy of prosthetic graft surveillance programs is more inconclusive. In one study, 69 patients with infrainguinal
prosthetic bypasses were assessed by ultrasound after 4 weeks and every 3 months thereafter (total follow-up was 3
years).605 The ultrasound examination appeared to be of limited value, with 12 of 14 failing grafts not correctly
predicted. In a retrospective analysis of 118 above-knee prosthetic grafts, most bypass occlusions again occurred without
previously detected lesions.606 A quarter of patients developed a graft-related stenosis detected by ultrasound. Successful
intervention of the stenotic lesions was associated with a lower bypass occlusion rate of 21% at 2 years (vs 41% for the
entire series). Hence, in the authors’ opinion, ultrasound surveillance was justified. In another study of 89 grafts in 66
patients (FP and femorotibial), specific criteria for DUS proved predictive for patency of prosthetic tibial bypasses but
not of popliteal bypasses.607 These criteria included PSV >300 cm/s at graft anastomoses, adjacent PSV ratio >3.0,
uniform PSVs <45 cm/s, and monophasic flow throughout the graft.
One study sought to describe modes of failure and associated limb loss after infrainguinal polytetrafluoroethylene bypass
grafting as well as benefits of warfarin on graft patency.579 The study involved 121 patients (86% with CLTI) with 131
infrainguinal (above-knee and below-knee) bypasses. Of these, 77% of the below-knee bypasses had anastomotic
adjuncts (vein cuff or patch). Postoperative DUS was performed at 1 month, 4 months, and 7 months and then twice
yearly. Multivariate analysis showed that low graft flow (midgraft velocity <45 cm/s) was more commonly associated
with graft failure than stenosis detected by DUS. Therapeutic anticoagulation with warfarin increased patency in patients
with low-flow grafts but not in patients with high-flow grafts.579
A consensus document from Mohler et al608 supports surveillance of prosthetic reconstructions at baseline and at 6-
month intervals, similar to vein reconstructions. DUS imaging criteria were recommended for patients after femoral-
femoral bypass grafting, particularly for those with a PSV >300 cm/s in the inflow iliac artery and a midgraft
velocity <60 cm/s predictive of graft failure.609 When DUS-directed intervention was performed, patency at 5 years
(assisted patency) was 88%. Patency appeared to be improved in comparison to most reports in the literature of patency
without surveillance. DUS surveillance of prosthetic grafts does not reliably detect correctable lesions that precede
failure as it does in vein bypass grafts. Instead, surveillance may serve as a predictor of graft thrombosis by the detection
of midgraft velocities below 45 cm/s. Prosthetic grafts with low velocity may benefit from warfarin to improve patency,
which may justify surveillance. The use of warfarin was recommended if the mean graft velocity was below 60 cm/s to
reduce the incidence of expanded polytetrafluoroethylene bypass graft thrombosis.579 No specific recommendations can
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be made, however, regarding surveillance and reintervention for prosthetic grafts, and this information can only serve as
a guideline.
Management of the limb after revascularization
Treatment of lower extremity tissue loss both acutely and in the longer term is complex and mandates a team approach.
Physicians, surgeons, and nurses must work collaboratively rather than in individual silos of care.610-612 In these cases,
wound healing is protracted, with the median time to healing ranging from 147 days for forefoot wounds to 188 days for
midfoot wounds and 237 days for hindfoot wounds.613 The likelihood and duration of healing are also determined by the
presence of concomitant infection and ischemia.192
The Threatened Limb Classification System from the SVS has been validated in several studies.68-70,164,166 It is a
promising, pragmatic means to assess the likelihood of morbidity for at-risk legs and to communicate severity. The
structure of the WIfI system is designed using a scale of none (0), mild (1), moderate (2), or severe (3), similar to the
TNM system in cancer assessment.10,68,69,164 The system can be visualized as three intersecting rings of risk, enabling
the team to collectively identify which risk is more dominant at any given time.
Tissue loss-dominant conditions
The primary issue after revascularization in CLTI is often management of tissue loss (wound healing). Therapy is based
primarily on appropriate débridement, offloading, and a simple moisture-retentive dressing strategy.233 Pressure
offloading is one of the single most important and yet neglected aspects of therapy. Whereas the total contact cast
remains the gold standard for offloading noninfected, nonischemic wounds, other techniques may also be considered,
depending on available resources.614,615
More significant degrees of tissue loss may require a strategy of filling the defect followed by skin grafting.616,617 Once
the wound heals and the patient is no longer “tissue loss dominant,” care then shifts to maximizing ulcer-free and
activity-rich days in diabetic foot remission.618 This may include protecting the tissue by external (shoes, insoles, and
inflammation monitoring) and internal (reconstructive surgery, physical therapy, and rehabilitation) means.619-622 The
role and timing of foot amputations (eg, digital, forefoot, or midfoot) are discussed in Section 9.
Ischemia-dominant conditions
The management and monitoring of ischemia play a central role in healing as well as in recurrence and involve regular
vascular assessment and monitoring for potential intervention.
Infection-dominant conditions
Infection is often the primary factor leading to amputation, accentuated by tissue loss and ischemia. Addressing this triad
involves surgical and medical therapy based on established criteria. Each member of the wound care team must work to
categorize, stage, and grade the severity of each component of the “wound triad” initially and at all follow-up encounters.
Appropriate and regular documentation of the wound status is crucial, including diagrams and photographs to document
progress. Often, one or more of these conditions can be found to be more “dominant” and can then be targeted for care.
These conditions are dynamic and will change over time. During follow-up, recurrence may be related to tissue loss
(deformity, inappropriate shoes, or change in activity). As a result, nonhealing may be due to ongoing or recurrent
ischemia, and intervening in the development of an infection may require additional surgical or medical intervention.
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11. Study designs and trial end points in CLTI
IDEAL: A framework for research
The evidence base underpinning the surgical and endovascular management of CLTI is weak compared with that
available for coronary interventions and pharmacologic cardiovascular risk reduction. In addition, methodologies (phase
1 to 4 trials) that have been successfully used by the pharmaceutical industry to generate level 1 evidence cannot be
easily transferred to the evaluation of revascularization strategies for CLTI, and so different approaches are required. The
Idea, Development, Exploration, Assessment, and Long-term study (IDEAL) framework provides a system for
evaluating new surgical and interventional therapies that can be adapted for use in CLTI (Table 11.1).623-627
Table 11.1
IDEAL: Stages of surgical and endovascular innovation for chronic limb-threatening ischemia (CLTI)
Depending on the stage of surgical innovation, the IDEAL framework describes a wide range of different methodologies
that can be used to provide varying levels of evidence that serve different purposes. However, once the assessment stage
has been reached, RCTs remain by far the most reliable means of comparing the clinical effectiveness and cost-
effectiveness of alternative treatment strategies and should be the method of choice whenever it is practically and
financially feasible. Funding of such trials by governmental or professional organizations to assess existing or new
technologies further enhances the value of the resulting data by avoiding actual or perceived commercial sponsor bias.
Still, RCTs have limitations, including cost, long completion times, potentially incomplete applicability to populations of
patients outside the defined inclusion criteria, and restricted ability to address epidemiologic study questions.
As a result, a number of alternative methodologic approaches are available and can be employed in certain
circumstances.628 For example, large administrative databases and prospective registries (particularly population-based
ones) have the benefit of relative low cost, simplicity, and improved external validity, although they can carry a
substantial risk of treatment bias and confounding. Given that the observed treatments are typically not randomly
assigned but rather chosen on the basis of a mix of the patient’s characteristics and the provider’s inclination, reliable
comparisons between dissimilar groups can be a problem. Additional risks include important sampling errors and
improper or imprecise assignment of causality to a particular observed end point, although some of these limitations can
be mitigated by employing multivariate analysis. Still, the increasing use of registries designed to capture the outcomes
of patients with vascular disease reflects their value in identifying trends in practice patterns. Added value can be found
in capturing the experience of particular subsets of patients undergoing defined treatments or techniques. However,
because registries are highly dependent on robust follow-up and capture of detailed information of the patient on a
consistent basis, they are also susceptible to reporting and attrition bias that can paint an unreliable picture with regard to
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the clinical effectiveness and cost-effectiveness of a particular treatment strategy.
Objective performance goals OPGs
The SVS Critical Limb Ischemia Working Group developed a standardized set of outcome measurements, OPGs, derived
from CLTI patients undergoing open bypass in several RCTs.162 The OPGs include major adverse limb events (MALE)
and postoperative death as a measure of early safety and AFS to define longer term clinical effectiveness. Additional
safety and efficacy OPGs were created for specific outcome variables of interest, and risk-stratified guidelines based on
clinical, anatomic, and conduit criteria were identified for defined subgroups. The main aim of the OPG initiative was to
establish benchmark values against which novel endovascular therapies could be initially evaluated without undertaking
full RCTs. However, without good-quality RCTs, OPGs cannot be refreshed and, over time, will increasingly come to
rely on historical controls. As such, RCTs are still required to determine both the clinical effectiveness and cost-
effectiveness once safety and efficacy OPGs have been met.
RCTs
An appropriately designed RCT remains the optimal means of providing critical confirmatory evidence before the
widespread adoption of novel interventions.629-631 The paucity of such studies in CLTI,13-15,632 however, underscores
the many challenges that aspiring investigators face, particularly in trying to complete trials on time and on budget.
Trial design
The adaptive features of a pragmatic trial design allow investigators greater flexibility with regard to specific treatment
decisions. They will also generally lead to results that are more universally applicable, particularly in time-intensive and
laborious studies that unfold during a period of potentially changing treatment paradigms. Conversely, a nonpragmatic
design can more definitively generate supportive evidence for a particular technology or treatment scheme. It can also
facilitate direct comparisons within a given revascularization strategy. One should determine to what degree a particular
study is targeting real-world applicability and balance the theoretical, statistical, and practical impact of choosing one
design over another.
Inclusion and exclusion criteria
Therapeutic goals can differ according to whether the CLTI patient presents with ischemic rest pain only or with minor or
major tissue loss. More important, the goals in all CLTI patients differ significantly from those in patients presenting
with IC. Therefore, it should be clear that it is rarely if ever appropriate to combine IC patients and CLTI patients in the
same study. Similarly, it is clearly inappropriate to extrapolate data gathered in patients with IC to those with CLTI and
vice versa.
Because CLTI represents a wide spectrum of disease, it is important that trials describe patients who are enrolled in terms
of limb threat (Sections 1 and 3) and anatomic burden of disease (Section 5). Amputation rates are significantly higher in
patients with tissue loss than in those with rest pain. This makes the group of patients with tissue loss a potentially more
attractive one for a study in terms of being able to demonstrate the clinical effectiveness and cost-effectiveness of a new
intervention with an achievable sample size and within a realistic time. However, as the severity of tissue loss progresses,
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opportunities to detect therapeutic benefit may begin to decrease as some patients with advanced disease will inevitably
progress to amputation or death regardless of the intervention provided. As such, the CLTI patient group, in which there
is a real prospect of showing true benefit for a new intervention, may be more limited than is often initially appreciated.
Outcomes
Efficacy vs effectiveness
It is important to distinguish between clinical efficacy and clinical effectiveness. Clinical efficacy is the patient benefit
observed under ideal circumstances. Does the procedure work in a selected group of homogeneous patients when it is
performed by a selected group of clinicians? This is best demonstrated by an explanatory trial. Clinical effectiveness is
the patient benefit observed from a procedure in the real world. It is best demonstrated by a pragmatic trial. With regard
to CLTI, although the majority of published (usually industry-funded) trials fall into the clinical efficacy category, the
results are often presented and overinterpreted as if they represent clinical effectiveness. This has incorrectly led to new
treatments being adopted as the standard of care solely on the basis of limited evidence gathered in highly selected
patients and centers.
Types of end points
Most CLTI trial end points can be broadly divided into the following categories:
1.
Objective clinical: AFS, MALEs
2.
Subjective clinical: patient-reported outcomes measures (PROMs), including generic and disease-specific HRQL
instruments633
3.
Hemodynamic: ankle and toe pressures and indices
4.
Anatomic: patency; target lesion, vessel, and limb revascularization
To describe the overall quality of revascularization for CLTI, RCTs should use a menu of outcomes derived from all four
of the categories (Table 11.2).
Table 11.2
Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL-2), Balloon vs Stenting in Severe Ischaemia of the Leg
(BASIL-3), and Best Endovascular vs Best Surgical Therapy for Patients with Critical Limb Ischemia (BEST-CLI) trial
end points
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It is also important for RCTs to include a full health economic analysis for the cost-effectiveness of the comparator
interventions to be determined. This is preferably based on quality-adjusted life-years. It is then up to each health care
system to determine whether and how such data should be used in relation to individual “willingness to pay” thresholds,
which are typically based on economic, societal, and political considerations. For example, in the United Kingdom,
bearing in mind the proportion of gross domestic product that the country has decided to spend on health care and the
Department of Health’s agreed social value judgments, the National Health Service will not usually fund interventions
that are associated with an incremental cost-effectiveness ratio in excess of £20,000 per quality-adjusted life-year. This
figure represents the United Kingdom’s willingness to pay threshold.
Objective clinical outcomes
AFS has been recommended as a suitable primary CLTI efficacy end point by TASC II, the U.S. FDA, the UK National
Institute for Health and Care Excellence, and the SVS Critical Limb Ischemia Working Group. It has been used in a
number of CLTI RCTs, including Project of Ex-vivo Vein graft Engineering via Transfection III (PREVENT III),634 all
three BASIL trials, and BEST-CLI. As with most end points, however, AFS has its limitations. For example, AFS does
not distinguish between transfemoral and transtibial amputation, and because the performance and timing of amputation
can be discretionary and not easily blinded, AFS does not necessarily capture the full clinical impact of particular
revascularization strategies. Thus, the severity of pain and use of analgesia, the success of healing of minor amputations
and tissue loss, and the requirement for reintervention are all important clinical parameters not characterized by AFS. In
addition, its appropriateness in patients with rest pain only has been questioned, and as a composite, AFS life tables do
not distinguish between effect of the intervention on limb salvage and overall mortality. Therefore, whereas it is
reasonable to use AFS and other related composite end points, such as MALEs, as the determinants of sample size
calculations, they should be accompanied by a range of single, composite, objective, and subjective clinical end points.
Subjective outcomes
Given the growing appreciation of the importance of the patients’ perception of their treatment experience, incorporating
HRQL and PROMs into trial designs is strongly recommended. A number of well-validated generic HRQL instruments
are now available in a range of languages. These include the 12-Item Short-Form Health Survey and the EuroQol-5
Dimension questionnaire as well as more disease-specific instruments, such as the Vascular Quality of Life tool. Some
researchers have advocated that future RCTs be based on anticipated PROMs and HRQL benefits.
Hemodynamic outcomes
Measuring hemodynamic parameters in CLTI patients can be challenging because CLTI is defined in part by the
hemodynamic consequences of the disease (Section 1). Thus, it is important to attempt to describe the outcome of
various interventions for CLTI in terms of their impact on hemodynamic measures, including ankle and toe pressures and
indices.
Anatomic outcomes
Anatomic outcomes such as patency have been widely used in regulatory trials designed to obtain premarketing
authorizations despite the well-recognized problematic relationship between these outcomes and clinical success. The
related outcome measures of clinically driven target lesion and target vessel revascularization are inappropriate in the
context of CLTI, given the frequency of complex multilevel disease and the high degree of subjectivity surrounding
decisions to reintervene. Patency as an outcome metric is further limited by the lack of consensus with regard to
definitions after endovascular interventions. The role of patency and other anatomic end points within CLTI trial
methodology needs to be better defined.
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Follow-up
Determining the end points as well as the frequency and time during which they will be collected will depend on the
study aims, design, and budget. Given the importance of evaluating the impact of comparator interventions on the natural
history of CLTI, a follow-up period of at least 2 to 3 years is strongly recommended as it is unlikely that 6-month or 12-
month follow-up periods will provide adequate assessment of clinical durability.
Clinical outcomes can be measured either in absolute proportions or by cumulative outcome estimates using the Kaplan-
Meier analysis. Absolute proportions provide the most transparent and reliable outcome measure. Unfortunately, because
they evaluate identical follow-up periods in all participants, they also limit follow-up to the observation period of the last
included patient. In contrast, cumulative estimates can integrate variable follow-up periods, thereby avoiding loss of
available information. These estimates, however, are based on specific assumptions and are therefore vulnerable to
attrition bias.635,636 Consequently, incomplete follow-up might lead to relevant but easily missed false outcome
estimates that can affect study groups differently.637 To evaluate the risk of attrition bias, completion of follow-up should
be measured independently of the study design and systematically declared against a predefined study end date using the
follow-up index or the C index.
Time-to-event analysis
Given the chronic and recurrent nature of CLTI, there is a compelling need to develop end points that move beyond the
historical paradigm of a simple time-to-first-event analysis. End points such as AFS can reliably capture the centrally
important end-stage events of limb amputation and death. Likewise, MALE and other end points focused on
reintervention or other patient-related outcomes can capture the early clinical impact of treatment failure. Unfortunately,
these and other time-to-first-event end points collectively may present an incomplete assessment of the total impact
various CLTI treatment strategies over time.
The primary goal of a time-integrated measure for CLTI disease severity should be to more accurately assess long-term
relief from commonly occurring multiple events in a manner that is analogous to disease-free survival after cancer
treatment. Without such a time-integrated approach, even an otherwise well designed CLTI trial may prove to be an
incomplete and potentially misleading assessment of overall clinical effectiveness and cost-effectiveness. As an example,
consider two CLTI patients with ulceration.
•
Patient 1 has an endovascular intervention that heals his wound but after 2 months has recurrent symptoms and
restenosis with a second intervention at 4 months. He develops another recurrence with pain and two gangrenous
digits at 6 months. The patient subsequently requires a bypass graft at 7 months and a transmetatarsal amputation
of the foot, resulting in clinical stabilization for 2 years. Outcomes: no death; no major amputation; time to first
reintervention, 4 months; time to initial healing, 2 months; time to MALE, 7 months.
•
Patient 2 receives a bypass graft that heals his wound by 3 months. At 7 months, he presents with an asymptomatic
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graft stenosis and undergoes a surgical revision (3-cm interposition graft). He remains clinically stable for 2 years.
Outcomes: no death; no major amputation; time to first reintervention/MALE, 7 months; time to initial healing, 3
months.
Patient 1 had clinical recurrences and two reinterventions and spent most of the year with symptoms. Patient 2 had a
prophylactic reintervention and spent most of the year symptom free. A CLTI trial using only AFS and MALE as end
points would have failed to differentiate these two notably different clinical experiences.
Sample and effect size
CLTI patients who are entered into the “nonactive treatment” (placebo) group in RCTs often have outcomes that are
better than expected compared with similar patients who are treated outside of research conditions. This makes it more
difficult to demonstrate differences in clinical effectiveness and cost-effectiveness among the comparator interventions
for CLTI. As a result, researchers must avoid the potential pitfall of basing the power calculation for their trial on an
unrealistically large effect size. It is widely agreed that it is poor science and unethical to embark on a trial when there is
no realistic prospect of answering the question being posed. An overpowered trial is equally undesirable as it is a misuse
of resources, and patients may be disadvantaged by continuing to receive a treatment that is likely of little or no value or
even potentially harmful to them. Despite this understanding, the CLTI literature is characterized by studies that present
highly questionable, post hoc, subgroup analyses. To guard against this, all CLTI protocols along with full statistical
analysis plans should be published in peer-reviewed journals to allow independent, public, and transparent scrutiny.
Beyond the pivotal RCT
Given the challenges inherent in evaluating the wide array of novel endovascular modalities for CLTI, comparative trials
of varying size and scope can be effective in establishing the utility of a particular technique, device, or overall
revascularization strategy. As described within the OPGs, focused superiority or noninferiority RCTs can also be used to
test a novel intervention against more established alternatives, and the safety and efficacy of new technologies can be
effectively studied in a timely fashion. However, once the pivotal RCTs have been successfully completed, it is important
that ongoing surveillance be rigorously undertaken with the use of well-designed, large, prospective, observational
studies, including disease- or procedure-based national registries. Of note, some countries require manufacturers and
importers to submit reports of device-related deaths, serious injuries, or malfunctions to the appropriate regulatory
bodies.
Also important is cooperation among publicly and industry-funded investigators in designing and performing RCTs.
Currently, this is happening with the BASIL and BEST-CLI trials, which will serve to facilitate subsequent individual
patient data analyses, meta-analyses, and subgroup analyses. Ultimately, this type of data sharing will provide a powerful
framework for refining OPGs and validating the use of tools to better define patient, limb, lesion, and anatomic risk in
CLTI patients, such as WIfI and GLASS.
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Strength of recommendation and level of evidence
Multiple methods to systematically assess the quality of research have been proposed and used by various bodies.
Whereas each method has its advantages and disadvantages, the continued use of multiple methodologies that each
produces slightly different strengths of recommendation on any given topic leads to inconsistency and confusion. As a
result, there is a strong movement globally to use the GRADE system as a means of rating the level of evidence and
thereby defining the appropriate strength of resulting recommendations.638 The GVG on CLTI also endorse the use of
GRADE. Thus, it is in the best interests of public and commercial researchers who want their research to have maximum
impact on practice to ensure that their studies are designed in such a way as to score well using the GRADE criteria.
12 Creating a center of excellence for amputation prevention
The major causes of amputation are related to diabetes and CLTI. Of the 200 million people worldwide with PAD, CLTI
affects at least 2% to 3%.1 Whereas revascularization is the treatment of choice in preventing limb loss, procedure bias,
lack of specialty training, market forces, and lack of consensus definitions remain major obstacles in achieving the best
possible outcomes for CLTI care.639
The CLTI patient is particularly complex. Patients with PAD have an increased risk of CAD and cerebrovascular disease
and an elevated risk of 5-year mortality.640 Historically, CLTI was primarily sequalee of smoking and a diet high in
saturated fats. However, in the last few decades, the rise in CLTI has followed the global epidemic of diabetes. Because
of this changing epidemiology, this section focuses mainly on establishing and monitoring teams for the patient with
diabetes-related CLTI, but the concepts presented herein can be applied to all CLTI teams.
Diabetes-related CLTI is only one part of diabetic foot syndrome, which is a common but complex group of
complications from diabetes. These include neuropathy, ulceration, Charcot foot, soft tissue and bone infection, and PAD
including CLTI and gangrene. It is well known that diabetes increases the risk of myocardial infarction by 50% and
stroke by 25%; however, the greatest increased risk is for a foot or leg amputation.618 Diabetic foot syndrome is also a
costly comorbidity representing approximately one-third of the total cost of diabetes.641 One study found the mean 1-
year cost from a public payer perspective in the United States to be $44,200.642 Roughly 75% of the cost was due to
inpatient hospitalizations, for which the average length of stay for DFU and lower extremity amputation exceeded that
of myocardial infarction, stroke, and diabetic ketoacidosis.643-645
The patient with diabetic foot syndrome has a poor prognosis. It is frequently associated with loss of quality of life,
work, independence, and income for both the patient and the primary caregiver. The relative 5-year mortality rate after a
lower extremity amputation is a staggering 70%.646 For patients with DFU, it is 55%; and for patients with PAD alone,
the 5-year relative mortality rate is 32%.647 Thus, although diabetes is an endocrine disease, common complications of
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diabetes are related to microvascular or macrovascular disease. For this reason, diabetic foot syndrome should be more
appropriately thought of as part of the cardiovascular complications of diabetes.
Many institutions and government agencies have responded to the growing complexity, options, and subspecialization of
treating medical conditions by creating disease-specific Centers of Excellence. A Center of Excellence is a virtual or
physical location with a team of highly skilled experts who are often involved in research and innovation to advance their
field.648 Whereas there have been experts in the field of PAD who have opined on what a Center of Excellence for CLTI,
diabetic foot care, or amputation prevention might encompass, there are currently no governmental agencies or
professional societies that have established such guidelines.
Center of Excellence
In 2010, building on the work of the International Working Group on the Diabetic Foot, three tiers of care were proposed
for an amputation prevention team—basic, intermediate, and Center of Excellence (Table 12.1).649 The basic model of
care is performed in an office setting with a general practitioner, internist, or endocrinologist and a specialist nurse. An
intermediate model of care is set in a hospital or multidisciplinary clinic and consists of various specialists to heal
wounds and to prevent limb loss. This model is similar to a wound care center in the United States or a diabetic foot
clinic in Europe. A Center of Excellence model is typically found in a tertiary care hospital with a predetermined team of
specialists operating under clinical practice pathways, policies, and procedures. The Center of Excellence has advanced
diagnostics and can intervene rapidly to prevent limb loss.
Table 12.1
The three tiers of care for amputation prevention and diabetic foot care centers
Currently, in many countries, there are no criteria required to designate oneself a Center of Excellence for health care.
Anyone or any institution can use the terminology, and doing so does not guarantee that excellent care is being delivered.
Based on experience in creating Centers of Excellence, a set of criteria are proposed to determine Center of Excellence
designation in CLTI and amputation prevention, as outlined in Table 12.2.
Table 12.2
Criteria for Center of Excellence designation in chronic limb-threatening ischemia (CLTI) or amputation prevention
Team setting, components, and function
No single specialist possesses all the necessary skills to manage diabetic foot syndrome. Therefore, it is important to
create a team of specialists with the required skills. Whereas some of the services required to treat CLTI and to prevent
amputation can be performed in the outpatient setting, many needed services are intensive and require access to an acute
care hospital.
An understanding of the natural history of amputation in diabetes can assist in determining how to build an effective
team (Fig 12.1).650 Diabetes leads to peripheral neuropathy, although the timing of its onset is related to long-term
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control of blood glucose level. Peripheral neuropathy leads to unfelt repetitive trauma and in combination with foot
deformity causes DFU.651 Approximately half of these patients have significant PAD with their DFU. Still, more often
than not, infection serves as the final event leading up to the amputation.652
Fig 12.1
The elevating risk of the “stairway to an amputation” or the natural history of diabetes-related amputations.
Fitzgerald et al610 described the seven essential skills for limb salvage teams. These were modified to identify nine skills
needed for the comprehensive management of diabetic foot. Table 12.3 lists the essentials skills as well as the type of
specialist who should be added to the team to complete a given task. The simplest method to construct a team for a
Center of Excellence is to ensure that each of these skills is covered by an expert on the team. In addition, several authors
have described an irreducible minimum to the team that includes vascular surgery and surgical podiatry. These two
specialties have been nicknamed the “toe and flow” team.610,649
Table 12.3
The nine essential skills to prevent amputations in diabetes and the possible specialty responsible
Team-driven protocols
It is simply not enough to have a designated team. The team must be used in an effective manner, and outcomes should
be monitored in a structured fashion. Fig 12.2 illustrates a useful pathway in setting up the structure of the team,
establishing goals, and ensuring that the goals are met. Published CPGs from medical and surgical societies establish best
practices, but they are not always feasible for practice in all settings. Current CPGs exist for PAD in diabetes, diabetic
foot infections, DFUs, offloading of DFUs, inpatient management of the diabetic foot and the Charcot foot, and
prevention of diabetic foot problems.158,653-658 Whereas these CPGs can serve as a template, localities are encouraged to
create their own clinical practice pathways specific to the facility or system in which they practice.
Fig 12.2
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A schematic on how to organize the diabetic foot care within a multidisciplinary team.
The clinical practice pathways are used to identify the team structure and patient flow, when to engage various members,
and what to do if the patient is not improving as expected. Policies and procedures are then created to assist providers
and staff in complying with the pathway. Quality assurance goals are also created for measurable policies and
procedures. Certain outcomes are self-explanatory, such as limb salvage rate, whereas others should be followed to
ensure the quality of care delivered by the Center of Excellence. These can include the high-low amputation ratio,659
median days to heal for foot wounds, healing percentage, and quality of life measures. Table 12.4 lists the most important
measurable outcomes for limb salvage and their calculation. These data may not always be easy to track. Existing
electronic health record systems are lacking in their ability to track and to report most of these or other custom measures.
Centers of Excellence often resort to developing their own software or keeping track of data manually in spreadsheets.
Table 12.4
Major outcome measures for chronic limb-threatening ischemia (CLTI) and amputation prevention
Finally, performance improvement plans must be drafted and initiated when the quality assurance goals are not met.
Fig 12.3 shows an example of how this system would be applied to vascular disease screening in DFUs.
Fig 12.3
An example of using the organized care model for peripheral artery disease (PAD) screening in diabetic foot ulcers
(DFUs). CPG, Clinical practice guideline; CPP, clinical practice pathway; P&P, policies and procedures; PI,
performance improvement; QA, quality assurance.
Team impact
In 2005, the World Health Organization and the International Diabetes Federation declared that up to 80% of diabetes-
related amputations are preventable.660,661 Currently, the only intervention to address this has been the formation of
multidisciplinary teams to prevent unnecessary amputations. In fact, the multidisciplinary team to prevent diabetes-
related amputations dates back to at least 1934, when Elliott P. Joslin, an endocrinologist in Boston, established his team
to treat diabetic gangrene.662
In the United States, an organized team in a public hospital reduced lower extremity amputations 72% during 2 years. In
the Veterans Affairs medical centers, several factors were significant in the reduction of lower extremity amputations,
including use of a specialized team and establishment of a high-risk foot clinic.663,664 In a military medical center,
amputations were reduced by 82% as a result of a specialized limb preservation service.665 Another report showed a
reduction improvement in diabetes-related foot outcomes with an integrated interdisciplinary team in a large academic
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medical center.666 In several other studies, adding podiatry to the team was found to be helpful in reducing amputations
and significantly reducing the cost associated with diabetic foot.641,663,667,668
The impact of a limb salvage team is not limited to any geographic area. In The Netherlands, investigators reported a
34% nationwide reduction in amputations after setting up multidisciplinary teams.669 In Brazil, the establishment of >20
interdisciplinary foot clinics nationwide is leading to improved care.670 In Italy, investigators reported a reduction in
hospitalizations and amputations in the diabetic foot after implementing a multidisciplinary referral team.670,671 In
Spain, a multidisciplinary foot team reduced amputations during 3 years compared with the previous 6 years.672 The
United Kingdom has also seen reduced amputations secondary to better-organized diabetic foot care with specialized
clinics that follow multidisciplinary care pathways and protocols.673,674 Lastly, in Finland, a decrease in major
amputations was correlated with rising interest in limb salvage and an increase in distal vascular procedures.675 In a
subsequent study, researchers reported a reduction in amputations and length of stay when inpatient care was
reorganized.676
Summary
Centers of Excellence can be implemented with a well-organized team approach to diabetic foot syndrome and, in
particular, the foot with CLI. Creating an integrated team whose primary focus is limb salvage and that receives all
referrals for suspected CLTI is key. Teams can improve processes, time to intervention, and outcomes. The setting and
structure of the team will ultimately depend on the availability and local need. However, to be most successful, Centers
of Excellence should have team members who are capable of performing the nine essential skills as outlined in
Table 12.3.
Centers of Excellence have published pathways and policies and procedures to determine the function and involvement
of various members. Equally important to setting up the team is measuring the Center’s performance. This is best
accomplished with concrete quality assurance goals and the implementation of a performance improvement plan to be
used when these goals are not met.
13. Global perspectives in CLTI
The preceding sections of this guideline make recommendations regarding the diagnosis and treatment of CLTI based on
data published in peer-reviewed journals and, where such data are lacking, consensus expert opinion. Vascular specialists
managing CLTI across the globe serve the needs of diverse communities and cultures, working within a wide range of
health care environments. Most vascular specialists will strive to keep up to date with the published evidence base and
are greatly facilitated in doing so through the use of modern information technology systems. However, the reality is that
most publications on CLTI are written in English, and the data contained therein overwhelmingly derive from relatively
few countries, mainly HICs (western Europe, North America, Japan), that have mature, well-resourced health and social
care systems as well as clinical research infrastructure. Most vascular specialists treating patients with CLTI do not, of
course, work in such favorable environments. As such, they often have to adapt foreign “evidence-based
recommendations” to their own particular situation to provide the best possible care to their patients with the resources
available. The GVG authors recognize this and, specifically, that some of the recommendations contained within this
guideline are likely to remain aspirational for many vascular specialists working in diverse health care settings across the
globe. The authors therefore thought it important to examine the state of CLTI care from a broader perspective. To that
end, a questionnaire enquiring about the presentation, diagnosis, and management of CLTI was sent to vascular
specialists (n = 50) working in a range of lower, middle, and higher income countries. This section primarily comprises a
description of the responses received (n = 22), supported by published locoregional data where available. The authors
and the Steering Committee of the GVG appreciate and recognize these contributors for providing survey responses for
this Section (Table 13.1).
Table 13.1
Contributors
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Whereas the information provided may not be considered the highest quality from an epidemiologic perspective, a
number of important global issues emerged from the responses. This brief overview highlights the urgent need for better
data on the impact of CLTI and how it is managed around the world. The majority of responses derive from a few key
opinion leaders from Latin America, Asia, and Africa; thus, the following discussion may not reflect concerns of other
populations, providers, and nations.
Definition and classification
Clinical criteria, history, and examination are the mainstays of CLTI diagnosis across the world, with the use of
adjunctive hemodynamic and perfusion measurements appearing to be highly variable. ABI testing was used by all
except one respondent. However, although all respondents regularly dealt with diabetic vascular disease and the
acknowledged limitations of APs in that setting, only two used TPs; none used TcPo2 routinely. All (except one who
exclusively used WIfI) used either the Fontaine or Rutherford classification for staging, approximately in equal numbers.
About one-third of respondents described employing WIfI in addition to another clinical classification system. In
summary, therefore, across most of the world, there appears to be limited adherence to any one published definition or
staging system for CLTI.
Epidemiology and risk factors
Although accurate country-specific epidemiologic data are sparse, there seems little doubt that the increasing prevalence
of DM (Fig 13.1) together with the growing use of tobacco and population aging is resulting in a significant increase in
CLTI and amputations across much of the world, especially in LMICs.677
Fig 13.1
International Diabetes Federation global diabetes projections.
In 2013, Fowkes et al1 undertook a meta-analysis of 34 studies to compare the prevalence and risk factors between HICs
and LMICs. This is well outlined in Section 2 of this document, but it is worth recalling some of the key presented data.
They concluded, “Globally, 202 million people were living with peripheral artery disease in 2010, 69.7% of them in
LMIC, including 54.8 million in Southeast Asia and 45.9 million in the western Pacific Region. During the preceding
decade, the number of individuals with peripheral artery disease increased by 28.7% in LMIC and 13.1% in HIC. Also of
note is the percentage of increase of PAD is higher in women than men in LMIC which is opposite of HIC.” The increase
in PAD burden observed in women and in the younger, economically productive age groups is especially worrisome
(Table 13.2).
Table 13.2
Estimated number of people living with peripheral artery disease (PAD)
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The data on country-specific incidence of PAD and CLTI are sparse in these LMICs, unlike in HICs. There are no
relevant epidemiologic data from large regions, but the updated data from Abbas are tabulated for perspective, reflecting
PAD in diabetics in sub-Saharan Africa (Table 13.3).
Table 13.3
Prevalence (%) of peripheral artery disease (PAD) in diabetics
Lacking firm epidemiologic data, recent estimates of CLTI prevalence have used extrapolations from demographic and
other available disease prevalence data, yielding global estimates of between 20 and 40 million individuals afflicted.
About two-thirds of these are projected to be in LMICs. Unfortunately, documented data to support this are difficult to
find in any indexed, peer-reviewed journals.
According to the survey respondents, the risk factors for CLTI in their regions are largely as expected, but DM is a
predominant cause, more than in HICs. The prevalence reported by respondents varied from 40% to 90%. Interestingly, a
cultural preference for walking barefoot or a lack of appropriate footwear is a significant problem in some countries.
Approximately 60% to 80% of all the PAD patients seen by the respondents present with CLTI. The average age was
around 65 years, and about 70% were men. Most respondents reported that 70% to 100% of CLTI patients presented with
tissue loss; in three countries, it was <50%. Primary amputation was performed in 10% to 40% of CLTI patients, this
being mainly (25%-90%) because of delayed presentation or referral. Only two countries reported a primary amputation
rate of <10%. Postprocedural amputation rates were reported at around 5% to 10%, although two countries reported
much higher rates (60%-70%) because of late presentation or aggressive disease patterns encountered.
Diagnostic evaluation
DUS appears to be used almost universally, although three respondents preferred to proceed directly to other imaging
modalities. Only five respondents performed DSA as their primary imaging modality. The remainder opted for MRA and
CTA in about equal numbers. In patients with renal impairment, DSA was preferred by most, with half opting for
iodinated contrast agents with appropriate renal protection measures and the other half favoring CO2 angiography. Two
respondents performed only noninvasive testing in such patients before intervention.
Medical and noninterventional management (with or without revascularization)
Respondents reported widespread routine use of antiplatelet and lipid-lowering agents. ACEIs, vasoactive drugs (such as
cilostazol and pentoxifylline), and anticoagulants were used selectively. IV prostanoids and vasodilators were used by
some as adjuncts to revascularization and in those with nonreconstructible disease. Use of arterial assist devices
(compression pump), HBOT, and SCS was uncommon. Lumbar sympathectomy was performed by a third of
respondents, possible in patients with Buerger's disease (not specified).
Anatomic classification, risk stratification, and predictors of limb salvage
The almost uniform answer to the question How satisfied are you with present systems? was “somewhat satisfied.”
Interestingly, only six respondents used TASC to inform decisions about revascularization strategies and procedures in
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patients with CLTI. There was strong support for a new approach to patient and limb risk stratification and for a new
anatomic classification system.
Revascularization
Although, overall, there has been a shift toward endovascular intervention, there is considerable variation in practice
across the respondents—varying from 5% to 80% for both endovascular and “open” procedures! All stated that the
preferred conduit for both above-knee and below-knee bypass continues to be autogenous vein. Prosthetic grafts are used
selectively above the knee, but none advocate their use for distal bypass. None of the respondents endorsed “routine
stenting” in the femoral-popliteal region, and all endovascular options (balloon angioplasty, DCB, stenting) are used
selectively. Balloon angioplasty is preferred for endovascular intervention in infrapopliteal vessels; four respondents
selectively use DCB, but none were in favor of stents below the knee.
Postprocedural surveillance and follow-up
All the respondents said they had defined follow-up protocols for patients undergoing infrainguinal revascularization. All
patients (surgical and endovascular) are observed at least every 3 months for a year and then at variable intervals
thereafter. Clinical evaluation and ABI are the mainstays of surveillance. Use of other noninvasive methods (PVR, DUS)
is variable. Specific protocols for vein and prosthetic bypass grafts seem to be standardized per available data in a
minority of centers. Approach to surveillance-detected lesions is similarly variable but mostly dictated by the patient’s
symptoms rather than by the result of physiologic testing. Arteriography is reserved for clinically significant lesions.
Postprocedural drug therapy, for example, with antiplatelet and lipid-lowering agents, appears concordant with current
published recommendations. Because most CLTI patients had tissue loss, almost all the centers provided intensive
wound services within their department as part of a multidisciplinary team approach. Nearly all agreed that wound
infection is a significant determinant of outcome after revascularization and possible cause of amputation even after
successful revascularization.
Health economics
CLTI has a serious adverse economic impact on patients, their families, and wider communities right across the world
but especially so in LMICs. Although these countries are often grouped together, the division between middle income
and lower income is variable and imprecise. Furthermore, there is often considerable inequality within each LMIC, and
respondents reported that most patients with CLTI (30%-90%) appear to come from the poor socioeconomic
backgrounds. The following data from the Indian National Sample Survey Office could represent the situation in many
LMICs678:
1.
Only 18% of the urban population and 14% the of rural population are covered by some form of health insurance.
2.
Governmental health expenditure is <2% of gross domestic product overall.
3.
People in villages mainly depend on “household income or savings” (68%) and “borrowings” (25%) to fund
hospitalization expenses.
4.
Around 1% of the poor in rural areas have to sell their physical assets to meet health expenditure, and >5% seek
help of friends and relatives. This is also in line with earlier studies showing that millions are pushed into poverty
each year by medical expenditure and that such expenses are among the leading causes of indebtedness among the
poor.
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5.
In cities, people rely much more on their income or savings (75%) than on borrowings (18%) to fund
their treatment. Previous studies have repeatedly shown that India has one of the most privatized health care
systems in the world, with out-of-pocket expenses accounting for the bulk of medical spending.
In India, the cost of IP bypass is U.S. $1500 to $3000, and costs of balloon angioplasty are similar. The use of a stent or
DCB would add another U.S. $500 to $1000, and wound care adds at least U.S. $500. Such out-of-pocket expenses are
probably unaffordable for most CLTI patients. Importantly, these costs depend on recycling of single-use devices like
sheaths, angioplasty balloons, and guidewires. Without such practice, the cost would increase by at least 50%, and far
fewer patients, especially poorer ones, would have access to treatment, resulting in much greater loss of life and limb.
Recycling of single-use devices (not just vascular devices) is common in Asia, Africa, Latin America, and eastern
Europe, and proper regulation of the practice, including appropriate consent procedures, is important to mitigate patient
harm.679
Summary of global perspectives
Based on the responses to the questionnaire and the limited published and unpublished data at times, we can draw the
following conclusions.
1.
CLTI is a significant and increasing global problem, especially in LMICs, where the incidence in women appears
to be rising more quickly than in men.
2.
Diabetes and unabated smoking are the major causes of CLTI globally.
3.
Although vascular specialists try to follow the published evidence base, economic and social constraints mean that
the approach to CLTI must to tailored to the working environment.
4.
CLTI and diabetic foot problems are associated with high amputation rates in LMICs because of delayed
presentation and referral and limited access to affordable care.
5.
Economic constraints are an important limitation in the adoption of advanced vascular technologies, and practical
issues such as recycling of single-use devices require oversight from a public health perspective.
6.
Few countries maintain national registries or other CLTI data sets.
7.
Most countries do not have a standardized approach to CLTI, with considerable locoregional variation in practice.
8.
Most countries do not have well-organized and supported vascular societies where best practice and research can
be shared and disseminated.
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Dissemination and implementation
A large number of vascular specialists from around the world have contributed to the GVG, and that global involvement
sets the present guideline document apart from all previous consensus statements. The paradigms and tools, such as
WIfI, PLAN, and GLASS, set out in the GVG will, it is hoped, meet the needs of the global vascular community as
expressed by our questionnaire respondents. However, some guideline recommendations will not be achievable by
vascular specialists working in LMICs. The GVG recommendations should not, therefore, be viewed as an inflexible
global “standard of care.” Following publication, it will be important to disseminate the GVG as quickly and widely as
possible, simultaneously through a range of different channels, and to obtain validation and feedback from the global
community. Dissemination will be assisted by publication of the full GVG as a supplement to the Journal of Vascular
Surgery and European Journal of Vascular and Endovascular Surgery, publication of an executive summary with the
recommendations in a range of other journals in a number of different languages, presentations at conferences, and free
online access to the documents linked from societies’ web pages.
Addendum
As this guideline goes to press (April, 2019), the safety of paclitaxel-eluting devices for the treatment of peripheral
arterial disease has come under intense scrutiny. The GVG Steering Committee, recognizing the importance of this issue
to the vascular community, has unanimously approved the statement below. Given time constraints, this statement was
not reviewed by the entire GVG Writing Group. This statement was approved by the three major sponsoring societies
(ESVS, SVS, WFVS).
Statement on the Safety of Paclitaxel-eluting devices for the treatment of CLTI
Recently the safety of paclitaxel (PTX)-eluting devices for the treatment of patients with peripheral arterial disease
(PAD) has come into question. A meta-analysis of randomized controlled trials investigating these devices in the femoral
and/or popliteal arteries identified an increased mortality at two years and beyond in patients treated with the PTX
devices versus controls.680 These trials largely enrolled patients with intermittent claudication, with a small minority
(11%) being within the spectrum of CLTI. Ongoing efforts from regulatory bodies and other independent groups seek to
further clarify the validity of these observations. In the interim the US Food and Drug Administration has urged caution
in the use of PTX devices for treatment of PAD.
The GVG Steering Committee believes that the risks and benefits of treatments for CLTI, including drug-eluting devices,
need to be examined with appropriately controlled, prospective studies that are specific to the CLTI population. In this
regard, the execution of randomized controlled-trials involving PTX-eluting devices in CLTI, with appropriate safety
monitoring and regulatory oversight, are important to the vascular community. Such trials should incorporate appropriate
informed consent discussions with subjects, including the potential increased risk of mortality, and should mandate long-
term follow-up for at least 2 years. Outside of such trials, given the indeterminate risk and efficacy of these devices in
patients with CLTI, and the availability of alternative modalities, we believe appropriate caution should be exercised.
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Editorial
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The Global Vascular Guidelines (GVGs) published in this month’s supplement of the Journal of Vascular Surgery1
are the most comprehensive clinical practice guidelines ever published on the management of patients with critical
limb-threatening ischemia (CLTI). Combined with a new systematic review and meta-analysis,2 these documents
represent 5 years of work by an international team of vascular specialists, each with recognized expertise in
peripheral arterial disease (PAD). The guidelines considered evidence on all therapies currently available
throughout the world to treat this important global problem and the end result is a monumental work of exceptional
quality.
Clinical research studies
Thoracoabdominal and complex aortic aneurysms
The “bare branch” for safe spinal cord ischemia prevention after total endovascular repair
of thoracoabdominal aneurysms
Matteo Orrico, MD et al.
Staged endovascular treatment of thoracoabdominal aortic aneurysms (TAAAs) with temporary perfusion of the
sac through a branch left unstented or a dedicated branch is a strategy intended to reduce the risk of postoperative
spinal cord ischemia (SCI). However, potential complications of this approach are aneurysm sac progression
between stages, visceral embolism, and occlusion or displacement of components. We here present the “bare
branch” technique, a safe adjunct to TAAA repair in terms of interstage complications.
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Midterm results of laser generated in situ fenestration of the left subclavian artery during
thoracic endovascular aneurysm repair
Björn Sonesson, MD, PhD et al.
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To analyze the midterm result of in situ fenestration (ISF) of the left subclavian artery (LSA) during thoracic
endovascular aneurysm repair (TEVAR).
Fenestrated endovascular aneurysm repair is associated with lower perioperative
morbidity and mortality compared with open repair for complex abdominal aortic
aneurysms
Rens R.B. Varkevisser, BS et al.
The Zenith Fenestrated Endovascular Graft (ZFEN; Cook Medical, Bloomington, Ind) has expanded the anatomic
eligibility of endovascular aneurysm repair (EVAR) for complex abdominal aortic aneurysms (AAAs). Current
data on ZFEN mainly consist of single-institution experiences and show conflicting results. Therefore, we
compared perioperative outcomes after repair using ZFEN with open complex AAA repair and infrarenal EVAR in
a nationwide multicenter registry.
Fenestrated endovascular aneurysm repair-induced acute kidney injury does not result in
chronic renal dysfunction
S. Keisin Wang, MD et al.
Acute kidney injury (AKI) is a common physiologic complication after fenestrated endovascular aneurysm repair
(FEVAR). This investigation was initiated to determine the unknown impact of post-FEVAR AKI on long-term
renal function after index hospital discharge.
Thoracic aortic dissections
Thoracic endovascular aortic repair for retrograde type A aortic dissection
Takatoshi Higashigawa, MD et al.
The efficacy of thoracic endovascular aortic repair (TEVAR) for retrograde type A aortic dissection (r-TAAD) with
the entry tear in the descending aorta has not been clarified.
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Fig 2.1
Prevalence of peripheral artery disease (PAD; ankle-brachial index [ABI] <0.9) by age and sex in high-
income countries (HICs) and in low- and middle-income countries (LMICs).1
Fig 2.2
Odds ratios (ORs) for peripheral artery disease (PAD) in high-income countries (HICs) and low- and
middle-income countries (LMICs). BMI, Body mass index; CRP, C-reactive protein; CVD, cardiovascular
disease; HDL, high-density lipoprotein.
Fig 2.3
Association of risk factors with the level of atherosclerotic target lesions. The red overlay on the anatomic
cartoon illustrates the association of risk factor with patterns of atherosclerotic disease.217
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Fig 3.1
Flow diagram for the investigation of patients presenting with suspected chronic limb-threatening ischemia
(CLTI). ABI, Ankle-brachial index; PAD, peripheral artery disease; TBI, toe-brachial index; WIfI, Wound,
Ischemia, and foot Infection.
Fig 3.2
Suggested algorithm for anatomic imaging in patients with chronic limb-threatening ischemia (CLTI) who
are candidates for revascularization. In some cases, it may be appropriate to proceed directly to
angiographic imaging (computed tomography angiography [CTA], magnetic resonance angiography [MRA],
or catheter) rather than to duplex ultrasound (DUS) imaging.
Fig 5.1
Inframalleolar (IM)/pedal disease descriptor in Global Limb Anatomic Staging System (GLASS).
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Fig 5.2
Femoropopliteal (FP) disease grading in Global Limb Anatomic Staging System (GLASS). Trifurcation is
defined as the termination of the popliteal artery at the confluence of the anterior tibial (AT) artery and
tibioperoneal trunk. CFA, Common femoral artery; CTO, chronic total occlusion; DFA, deep femoral
artery; Pop, popliteal; SFA, superficial femoral artery.
Fig 5.3
Infrapopliteal (IP) disease grading in Global Limb Anatomic Staging System (GLASS). AT, Anterior tibial;
CTO, chronic total occlusion; TP, tibioperoneal.
Fig 5.4
Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage I disease patterns. The
target arterial path (TAP) is outlined in yellow. Left panel, TAP includes the anterior tibial (AT) artery.
Femoropopliteal (FP) grade is 0. Infrapopliteal (IP) grade is 2 (3-cm chronic total occlusion; chronic total
occlusion of AT artery and total length of disease <10 cm). Right panel, TAP includes the peroneal artery. FP
grade is 2 (chronic total occlusion <10 cm; total length of disease <⅔). IP grade is 0.
Fig 5.5
Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage II disease patterns.
The target arterial path (TAP) is outlined in yellow. Left panel, TAP includes the anterior tibial (AT) artery.
Femoropopliteal (FP) grade is 1 (superficial femoral artery [SFA] occlusion <5 cm). Infrapopliteal (IP)
grade is 2 (two focal stenoses of AT artery, total length <10 cm). Right panel, TAP includes the peroneal
https://www.jvascsurg.org/article/S0741-5214(19)30321-0/fulltext#/article/S0741-5214(19)30321-0/fulltext 08/06/2019, 07G06
Page 177 of 203
artery. FP grade is 0 (no significant stenosis). IP grade is 3 (chronic total occlusion of peroneal artery, 3-10
cm).
Fig 5.6
Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage III disease patterns.
The target arterial path (TAP) is outlined in yellow. Left panel, TAP includes the peroneal artery.
Femoropopliteal (FP) grade is 4 (superficial femoral artery [SFA] disease length, 10-20 cm; popliteal
stenosis <5 cm; heavily calcified). Infrapopliteal (IP) grade is 2 (stenosis of tibioperoneal trunk and
proximal peroneal <10 cm). Right panel, TAP includes the anterior tibial (AT) artery. FP grade is 4
(popliteal chronic total occlusion extending into trifurcation). IP grade is 3 (chronic total occlusion of target
artery origin).
Fig 5.7
Flow chart illustrating application of Global Limb Anatomic Staging System (GLASS) to stage infrainguinal
disease pattern in chronic limb-threatening ischemia (CLTI). FP, Femoropopliteal; IP, infrapopliteal; PLAN,
patient risk estimation, limb staging, anatomic pattern of disease; TAP, target arterial path; WIfI, Wound,
Ischemia, and foot Infection.
Fig 6.1
Paradigm for evidence-based revascularization (EBR) in the treatment of chronic limb-threatening ischemia
(CLTI). Patient risk, Limb severity, and ANatomic stage are integrated in the PLAN approach. WIfI,
Wound, Ischemia, and foot Infection.
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Fig 6.2
PLAN framework of clinical decision-making in chronic limb-threatening ischemia (CLTI); infrainguinal
disease. Refer to Fig 6.4 for preferred revascularization strategy in standard-risk patients with available
vein conduit, based on limb stage at presentation and anatomic complexity. Approaches for patients lacking
suitable vein are reviewed in the text. GLASS, Global Limb Anatomic Staging System; WIfI, Wound,
Ischemia, and foot Infection.
Fig 6.3
The benefit of performing revascularization in chronic limb-threatening ischemia (CLTI) increases with
degree of ischemia and with the severity of limb threat (Wound, Ischemia, and foot Infection [WIfI] stage).
WIfI stage 1 limbs do not have advanced ischemia grades, denoted as not applicable (N/A).
Fig 6.4
Preferred initial revascularization strategy for infrainguinal disease in average-risk patients with suitable
autologous vein conduit available for bypass. Revascularization is considered rarely indicated in limbs at
low risk (Wound, Ischemia, and foot Infection [WIfI] stage 1). Anatomic stage (y-axis) is determined by the
Global Limb Anatomic Staging System (GLASS); limb risk (x-axis) is determined by WIfI staging. The dark
gray shading indicates scenarios with least consensus (assumptions—inflow disease either is not significant
or is corrected; absence of severe pedal disease, ie, no GLASS P2 modifier).
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Fig 12.1
The elevating risk of the “stairway to an amputation” or the natural history of diabetes-related
amputations.
Fig 12.2
A schematic on how to organize the diabetic foot care within a multidisciplinary team.
Fig 12.3
An example of using the organized care model for peripheral artery disease (PAD) screening in diabetic foot
ulcers (DFUs). CPG, Clinical practice guideline; CPP, clinical practice pathway; P&P, policies and
procedures; PI, performance improvement; QA, quality assurance.
Fig 13.1
International Diabetes Federation global diabetes projections.
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The Global Vascular Guidelines (GVGs) published in this month’s supplement of the Journal of Vascular Surgery1 are
the most comprehensive clinical practice guidelines ever published on the management of patients with critical limb-
threatening ischemia (CLTI). Combined with a new systematic review and meta-analysis,2 these documents represent 5
years of work by an international team of vascular specialists, each with recognized expertise in peripheral arterial
disease (PAD). The guidelines considered evidence on all therapies currently available throughout the world to treat this
important global problem and the end result is a monumental work of exceptional quality.
CLTI, a new term used in the guidelines instead of critical limb ischemia, is defined as advanced PAD with rest pain,
gangrene, or ulceration of >2 weeks duration. The methodology used by the writing group is critical to its acceptance--
the authors met strict standards for conflict of interest and used relevant data from peer-reviewed journals, without
industry involvement, to write the recommendations. The guidelines are evidence-based, many supported by systematic
reviews and meta-analyses, and represent the research and consensus of all important specialties: vascular surgery;
interventional radiology; vascular medicine; interventional cardiology; and angiology, who treat patients with CLTI. As
such, in 2019, these guidelines are the gold standard document for the management of CLTI.
Edited by Michael S. Conte, Andrew W. Bradbury, and Philippe Kolh and authored by 48 experts, this all-inclusive, 123-
page document is based on data from 676 references and includes 114 recommendations on definition, risk factors,
diagnosis, staging, strategies for revascularization, medical, endovascular, and surgical management,
nonrevascularization treatments, amputations, postprocedural care, and surveillance of patients with CLTI. Since
important studies expected to provide level 1 evidence on management of CLTI are still being conducted in the U.S.3 and
in England,4 only nine recommendations are strong (Grade I), supported by a high level (A) of evidence. Still, the
guidelines include important recommendations for all physicians, health care professionals, and third-party payors who
are involved with the care of patients with CLTI.
What did we learn that should now be the standard of care for CLTI?
First, we learned that the diagnosis of CLTI requires a thorough history and physical examination by an experienced
vascular physician, as well as combination of tests, including noninvasive physiologic studies, followed by either duplex
imaging or cross-sectional imaging using computed tomography angiography or magnetic resonance angiography.
Catheter angiography and intravascular ultrasound, in most cases, should be reserved to document anatomy before
treatment and should not be used for making the diagnosis. There are many patients with noncritical PAD and coexisting
diabetes, vasculitis, or degenerative arthritis that masquerade as CLTI; therefore, the initial evaluation should be
performed in an accredited vascular laboratory equipped with objective hemodynamic tests to establish the diagnosis
using segmental limb and toe pressures and ankle-brachial indices. Once the initial assessment is completed, the
guidelines endorse the Society for Vascular Surgery Threatened Limb Classification system that is based on grading of
Wound, Ischemia, and foot Infection (WIfI); it provides the most accurate staging of CLTI.5
Second, we learned that all patients with CLTI should receive best medical therapy, including antithrombotic, lipid-
lowering, antihypertensive and glycemic control medications, preventive foot care and counseling on smoking cessation,
a low-fat and low-sodium diet, and appropriate exercise.
Third, we learned that Evidence-Based Revascularization (EBR) depends on Patient risk, Limb severity, and ANatomic
complexity (PLAN). The proposed new Global Anatomic Staging System (GLASS) replaces previously used
classifications; it defines a preferred target artery path (TAP), estimates limb-based patency (LBP), and establishes stages
of complexity for interventions. GLASS is used to determine the likelihood of limb salvage and the best route to achieve
it.
Fourth, we learned that access to perform both invasive treatments, endovascular procedures and open surgery, is
required to appropriately treat these patients. The old adage “when your only tool is a hammer, the whole world looks
like a nail” certainly applies to the management of CLTI. Considering only one approach may reduce the likelihood of
successful treatment and it may even expose patients to ineffective or inappropriately invasive procedures. Having an
autogenous saphenous vein available favors surgical bypass in advanced CLTI, while endovascular interventions are
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preferred for high-risk patients with less complex anatomy. Long-term limb surveillance after any revascularization is
strongly recommended.
Fifth, the guidelines address the current lack of evidence supporting nonrevascularization therapies, including cell-based
and gene therapies, spinal cord stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen treatment.
Finally, since most patients with CLTI have tissue loss, either from an ischemic ulcer or gangrene, many patients are not
fully ambulatory and are deconditioned. They often require wound care, amputations, and rehabilitation after
revascularization. Consequently, vascular specialists who manage CLTI must have an understanding of wound care and
amputations and either be able to perform these procedures or have immediate access to them.
The authors of this study, representing the Society for Vascular Surgery, the European Society for Vascular Surgery, and
the World Federation of Vascular Societies, are to be congratulated for conducting a comprehensive review of the
literature, adhering to established principles of writing evidence-based recommendations, and providing a document that
should be used by all vascular specialists who treat patients with CLTI, irrespective of their specialty. The authors and all
sponsoring societies need to be committed to revising and updating the document as new procedures and information
become available, particularly after the multidisciplinary prospective randomized trials that are in progress are
completed.
Author conflict of interest: none.
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